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ABSTRACT 
 
 
 The Hedgehog (Hh) signal transduction pathway functions as one of the key 
developmental pathways and deranged Hh signalling is associated with numerous cancer 
and tumor conditions. The Smoothened (Smo) G protein coupled receptor (GPCR) 
functions as the signal transducer of the Hh pathway and is the most attractive drug target 
of the pathway. The structure of the Smo receptor includes seven membrane spanning 
domains, extracellular and intracellular loops connecting the membranous domains and 
the extracellular cysteine rich domain (CRD). The extracellular CRD of the Smo receptor 
is homologous to the Frizzled (FzD) CRD. The FzD CRD interacts with the physiological 
ligand of the FzD receptor: Wnt, but the function of the Smo CRD is not clearly 
elucidated.  
 
In the present dissertation we determined the first structure of the Drosophila Smo 
CRD by solution Nuclear Magnetic Resonance (NMR) spectroscopy. The structure of the 
Smo CRD comprises primarily of four helices and is stabilized by disulfide bonds 
between the conserved cysteine residues. The tertiary structure of the Smo CRD is similar 
to the structure of the FzD CRD. 
 
Additionally, we showed that both the Drosophila and the human Smo CRD 
interact with the glucocorticoid: Budesonide (Bud), albeit with different binding 
affinities. We identified the key residues in both species that are important for this 
interaction and generated the complex structure of the Drosophila Smo CRD with Bud 
using computational methodologies. The binding pocket in the Smo CRD can be targeted 
for the development of novel anti-cancer therapeutics. 
 
The Smo receptor possesses a binding cavity located in the transmembrane 
domains and we determined that the Smo CRD also possesses ligand binding capabilities. 
This finding enabled us to propose a novel mechanism of Hh signalling. We speculate 
that certain Smo ligands bind to the Smo CRD and membrane spanning domains 
simultaneously to regulate intracellular signalling. Phosphatidylinositol-4-phosphate 
(PI(4)P) has been shown to regulate Smo activation. We determined that the fatty-acid 
side chains of the phosphatidylinositols interact with Smo CRD, and PI(4)P specifically 
enhances activator induced Hh signalling.  Therefore, we speculated that PI(4)P may 
function to bridge the Smo extracellular and the membrane spanning domains, wherein 
the fatty-acid side chains of PI(4)P docks in the Smo CRD and the inositol head with the 
fourth position phosphate is necessary for anchoring in the cavity in the transmembrane 
domains; however, PI(4)P may not necessarily function as endogenous Smo ligand 
because in the cell-based luciferase reporter assays PI(4)P could only enhance signalling 
in the presence of an activator of Hh signalling. This suggests that PI(4)P binding to Smo 
is either a prerequisite and renders Smo active to further induce downstream signalling or 
PI(4)P acts as an allosteric activator of Hh signalling. 
 
 
  
 vi 
TABLE OF CONTENTS 
CHAPTER 1. INTRODUCTION .....................................................................................1?
1.1. An Overview of the Components of the Hedgehog Signal Transduction 
Machinery ................................................................................................................1?
1.1.1. Hedgehog ...........................................................................................................1?
1.1.2. Patched ...............................................................................................................2?
1.1.3. Hedgehog Co-receptors .....................................................................................2?
1.1.4. Smoothened ........................................................................................................5?
1.1.5. Hedgehog Signalling Complex ..........................................................................5?
1.1.6. Ci/Gli Transcription Factors ..............................................................................6?
1.2. The Smoothened Receptor ........................................................................................6?
1.2.1. Smoothened Structure and Post-translational Modifications .............................6?
1.2.2. Smoothened as a G Protein Coupled Receptor ..................................................9?
1.2.3. Smoothened Signalling and Regulation by Small Molecules ..........................10?
1.3. The Hedgehog Signal Transduction Cascade .........................................................13?
1.4. Implications of the Hedgehog Pathway in Cancer ..................................................15?
1.4.1. Basal Cell Carcinoma.......................................................................................15?
1.4.2. Medulloblastoma ..............................................................................................16?
1.4.3. Rhabdomyosarcoma .........................................................................................16?
1.4.4. Targeting the Hedgehog Pathway to Treat Cancers.........................................16?
1.4.5. Promoting the Smoothened Cysteine Rich Domain as a Novel Target for 
Drug Development ...........................................................................................17?
CHAPTER 2. METHODS ..............................................................................................18?
2.1. Introduction .............................................................................................................18?
2.2. The Physics and Mathematics behind Nuclear Magnetic Resonance .....................19?
2.3. The Nuclear Magnetic Resonance Instrumentation ................................................23?
2.3.1. Magnet .............................................................................................................23?
2.3.2. Lock System .....................................................................................................25?
2.3.3. Shim Coils ........................................................................................................25?
2.3.4. Sample Probe ...................................................................................................25?
2.3.5. Control Console and the Terminal Computer ..................................................26?
2.4. Setting up a Nuclear Magnetic Resonance Experiment ..........................................26?
2.5. Protein Structure Determination by Nuclear Magnetic Resonance ........................28?
2.5.1. Synopsis ...........................................................................................................28?
2.5.2. Nuclear Magnetic Resonance Experiments .....................................................29?
2.5.3. Heteronuclear Backbone Assignment ..............................................................30?
2.5.4. Amino Acid Side Chain Assignment Strategy .................................................31?
2.5.5. Nuclear Overhauser Effect Correlation Spectroscopy Assignments and 
Distance Constraints ........................................................................................33?
2.5.6. Structure Calculation and Refinement .............................................................35?
2.5.7. Structure Validation .........................................................................................36?
2.6. Nuclear Magnetic Resonance as a Tool to Study Protein-ligand Interactions .......38?
 vii 
2.6.1. 1D Nuclear Magnetic Resonance Experiments to Screen and Identify 
Potential Ligands for Proteins ..........................................................................38?
2.6.2. Chemical Shift Mapping to Determine the Ligand Binding Surface on the 
Protein ..............................................................................................................40?
2.6.3. Binding Kinetics to Determine the Dynamics of Protein-ligand Interaction ...41?
2.6.4. Dissociation Constant to Determine the Binding Affinity ...............................41?
2.6.5. Protein-ligand Complex Structure Determination by Nuclear Magnetic 
Resonance ........................................................................................................44?
CHAPTER 3. NUCLEAR MAGNETIC RESONANCE ASSIGNMENTS AND 
SOLUTION STRUCTURE OF THE SMOOTHENED CYSTEINE RICH 
DOMAIN ..........................................................................................................................46?
3.1. Introduction .............................................................................................................46?
3.2. Experimental Procedures ........................................................................................48?
3.2.1. Vector Construction .........................................................................................48?
3.2.2. Protein Expression and Purification .................................................................48?
3.2.3. Circular Dichroism Spectroscopy ....................................................................48?
3.2.4. NMR Spectroscopy ..........................................................................................49?
3.3. Results and Discussion ...........................................................................................49?
3.3.1. Circular Dichroism Spectra ..............................................................................49?
3.3.2. One Dimensional Proton NMR Spectra ...........................................................49?
3.3.3. Two Dimensional 1H-15N and 1H-13C Heteronuclear Single Quantum 
Coherence Spectra and Nuclear Magnetic Resonance Assignments ...............52?
3.3.4. Nuclear Overhauser Effect Assignments Structure Calculation and 
Refinement .......................................................................................................52?
3.3.5. Solution Structure of the Drosophila Smo CRD .............................................56?
3.4. Discussion ...............................................................................................................61?
CHAPTER 4. GLUCOCORTICOIDS MODULATE HEDGEHOG 
SIGNALLING ..................................................................................................................63?
4.1. Introduction .............................................................................................................63?
4.2. Experimental Procedures ........................................................................................64?
4.2.1. Protein Expression and Purification .................................................................64?
4.2.2. Nuclear Magnetic Resonance Chemical Shift Perturbation Analysis ..............64?
4.2.3. Structural Modelling of Drosophila Smoothened Cysteine Rich Domain in 
Complex with Budesonide ...............................................................................65?
4.2.4. Bio-Layer Interferometry Assay ......................................................................65?
4.2.5. Cell-based Luciferase Reporter Assays ...........................................................66?
4.3. Results and Discussion ...........................................................................................66?
4.3.1. Drosophila Smo CRD Binds to the Synthetic Glucocorticoid Budesonide.....66?
4.3.2. High Ambiguity Driven Biomolecular Docking of the Drosophila 
Smoothened Cysteine Rich Domain in Complex with Budesonide ................68?
4.3.3. Human Smoothened Cysteine Rich Domain Binds to the Synthetic 
Glucocorticoid Budesonide ..............................................................................71?
4.3.4. Binding Affinity of the Glucocorticoid Budesonide for Smoothened 
Cysteine Rich Domain .....................................................................................71?
 viii 
4.3.5. Effect of Budesonide on in-vitro Hh Signalling ..............................................75?
4.4. Discussion ...............................................................................................................79?
4.4.1. Cysteine Rich Domains and Hydrophobic Ligands .........................................79?
4.4.2. Same yet Different Drosophila and Human Smoothened Cysteine Rich 
Domain .............................................................................................................79?
4.4.3. Ligand Binding Provides a Novel Insight into Hedgehog Signalling ..............81?
CHAPTER 5. PHOSPHOLIPIDS AND HEDGEHOG SIGNALLING .....................82?
5.1. Introduction .............................................................................................................82?
5.2. Experimental Procedures ........................................................................................83?
5.2.1. Protein Expression and Purification .................................................................83?
5.2.2. NMR Experiments ...........................................................................................83?
5.2.3. Cell-based Reporter Assays .............................................................................84?
5.3. Results and Discussion ...........................................................................................84?
5.3.1. Phosphatidylinositols Bind to the Human Smoothened Cysteine Rich 
Domain .............................................................................................................84?
5.3.2. The Phosphatidylinositol-4-phosphate Induces Backbone Chemical Shift 
Perturbations in Human Smoothened Cysteine Rich Domain .........................85?
5.3.3. Phosphatidylinositols Exert Varied Effects on in-vitro Hedgehog 
Signalling .........................................................................................................90?
5.4. Discussion ...............................................................................................................90?
CHAPTER 6. IMPLICATIONS AND FUTURE DIRECTIONS ...............................95?
6.1. The Structures of the Smoothened G Protein Coupled Receptor (Structure 
Determination Strategies follow the Rule of Divide and Conquer) .......................95?
6.2.  Multiple Ligand Binding Sites on Smoothened Receptor Help Propose a 
Novel Mechanism for Hedgehog Signalling ..........................................................97?
6.3. The Unanswered Question: Does Smoothened Really Have an Endogenous 
Ligand? ................................................................................................................100?
6.4. Smoothened as a Template for Drug Discovery ...................................................101?
LIST OF REFERENCES ..............................................................................................105?
APPENDIX A. DROSOPHILA SMO CRD ATOM ASSIGNMENTS ......................116?
APPENDIX B. HUMAN SMO CRD ATOM ASSIGNMENTS ................................151?
VITA................................................................................................................................161?
 
 
  
 ix 
LIST OF TABLES 
Table 3-1. NMR and refinement statistics used for calculating the structure of 
Drosophila Smo CRD. .....................................................................................59?
Table 4-1. The HADDOCK input and output parameters for docking Bud on 
Drosophila Smo CRD. .....................................................................................70?
  
 x 
LIST OF FIGURES 
Figure 1-1. Schematic representation of the post-translational modifications of the Hh 
ligand. ...............................................................................................................3?
Figure 1-2. Schematic representation of the Hh receptors. ..................................................4?
Figure 1-3. Schematics of the Hedgehog Signalling Complex (HSC) and the domain 
architecture of the Gli transcription factor. ......................................................7?
Figure 1-4. The structural domains of the Smo receptor and the disulfide bonds 
stabilizing the Smo extracellular linker and the extracellular loops. ................8?
Figure 1-5. Chemical structure of selected Smo modulators. ............................................12?
Figure 1-6. The Hedgehog Signal Transduction Cascade. ................................................14?
Figure 2-1. Behavior of nuclear spins in the absence and presence of an external 
magnetic field. ................................................................................................21?
Figure 2-2. Magnetic field strength and NMR sensitivity. ................................................22?
Figure 2-3. Components of an NMR spectrometer. ...........................................................24?
Figure 2-4. Visualizing three dimensional NMR spectrum and generation of strips. .......32?
Figure 2-5. Flowchart for NMR based protein structure determination. ...........................37?
Figure 2-6. Transferred NOE experiments to determine protein-ligand interactions. .......39?
Figure 2-7. Representation of the different binding kinetics. ............................................42?
Figure 2-8. Example of chemical shift perturbation plot. ..................................................43?
Figure 3-1. Primary sequence alignment of Smo CRD. ....................................................47?
Figure 3-2. The CD spectra of the Smo CRD. ...................................................................50?
Figure 3-3. The 1D proton spectrum of Drosophila Smo CRD. .......................................51?
Figure 3-4. The 2D spectra of the Drosophila Smo CRD. ................................................53?
Figure 3-5. The NOE strip plot representing helical region of Drosophila Smo CRD. ....54?
Figure 3-6. Chemical structure depicting the atoms in an amino acid. ..............................55?
Figure 3-7. Structure refinement of the Drosophila Smo CRD. ........................................57?
 xi 
Figure 3-8. Solution structure of the Drosophila Smo CRD. ............................................58?
Figure 3-9. Structure of the Drosophila Smo CRD and comparison with the mouse 
FzD8 CRD. .....................................................................................................60?
Figure 4-1. The Drosophila Smo CRD binds to the inhibitory glucocorticoid Bud..........67?
Figure 4-2. The complex structure of Drosophila Smo CRD and the glucocorticoid 
Bud. ................................................................................................................69?
Figure 4-3. The human Smo CRD binds to the inhibitory glucocorticoid Bud. ................72?
Figure 4-4. Binding affinity measurement of Drosophila Smo CRD and Bud for 
residues F187, F188 and F191. ......................................................................73?
Figure 4-5. Binding affinity measurement of Drosophila Smo CRD and Bud for 
residues L127 and A132. ................................................................................74?
Figure 4-6. Binding affinity measurement of human Smo CRD and Bud. ........................76?
Figure 4-7. BLI binding assays show that Bud binds to Drosophila Smo CRD with a 
lower affinity than human Smo CRD. ............................................................77?
Figure 4-8. Bud attenuates SAG induced reporter gene activity. ......................................78?
Figure 5-1. The phosphatidylinositols with a single phosphate group bind to human 
Smo CRD. ......................................................................................................86?
Figure 5-2. The phosphatidylinositols with two phosphate groups bind to human Smo 
CRD. ...............................................................................................................87?
Figure 5-3. The fatty-acid side chain of the phosphatidylinositols is essential for 
interaction with the human Smo CRD. ..........................................................88?
Figure 5-4. The phosphatidylinositol: PI(4)P, interacts with the human Smo CRD. ........89?
Figure 5-5. The effect of the phosphatidylinositols with one phosphate group on Hh 
signalling. .......................................................................................................91?
Figure 5-6. The effect of the phosphatidylinositols with two phosphate groups on Hh 
signalling. .......................................................................................................92?
Figure 5-7. The effect of the phosphatidylinositols with three phosphate groups on Hh 
signalling. .......................................................................................................93?
Figure 6-1. Superimposed structures of the Drosophila and the zebrafish Smo CRD. .....96?
Figure 6-2. A novel model for Smo allosteric regulation. .................................................99?
 xii 
Figure 6-3. Design of Smoothened inhibitors. .................................................................103?
Figure 6-4. Design of Smo inhibitors. .............................................................................104?
 
  
 xiii 
LIST OF ABBREVIATIONS 
 
 
ADC Analog Digital Converter  
AIR Ambiguous Interaction Restraints 
BCC Basal Cell Carcinoma 
BLI Bio-Layer Interferometry 
Boc Brother of Cdo 
Boi Brother of Ihog 
Bud Budesonide 
cAMP cyclic Adenosine Mono Phosphate 
CARA Computer Aided Resonance Assignment 
CD Circular Dichroism 
Cdo Cell adhesion molecules Downregulated by Oncogenes 
Ci Cubitus interruptus 
Cic Ciclesonide 
CK1 Casein Kinase 1 
Cos2 Costal 2 
COSY Correlation Spectroscopy 
CRD Cysteine Rich Domain 
CSP Chemical Shift Perturbation 
DHh Desert Hedgehog 
Disp Dispatched 
ECD Extra Cellular Domain 
ECL Extra Cellular Loop 
ECLD Extra Cellular Linker Domain 
FA Fluocinolone Acetonide 
FDA Food and Drug Administration 
FID Free Induction Decay 
FT Fourier Transform 
Fu Fused 
FzD Frizzled 
Gas Growth Arrest Specific  
Gli Glioma associated genes 
GPCR G Protein Coupled Receptor 
GRK G Protein Coupled Receptor Kinase 
GSK Glycogen Synthase Kinase  
HADDOCK High Ambiguity Driven Biomolecular Docking 
Hh Hedgehog 
HHIP Hedgehog Interacting Protein 
HSC Hedgehog Signalling Complex 
HSQC Heteronuclear Single Quantum Coherence 
ICL Intra Cellular Loop 
Ihh Indian Hedgehog 
IP3 Inositol-3,4,5- triphosphate 
ITC Isothermal Calorimetry 
 xiv 
MB Medulloblastoma 
MRI Magnetic Resonance Imaging 
NMR Nuclear Magnetic Resonance 
NOESY Nuclear Overhauser Effect correlation Spectroscopy 
PDB Protein Data Bank 
PI(3,4)P2 Phosphatidyl Inositol-3,4-bisphosphate 
PI(3,4,5)P3 Phosphatidyl Inositol-3,4,5-triphosphate 
PI(3,5)P2 Phosphatidyl Inositol-3,5-bisphosphate 
PI(4)P Phosphatidyl inositol-4-phosphate 
PI(4,5)P2 Phosphatidyl inositol-4,5-bisphosphate 
PI3P Phosphatidylinositol-3-phosphate 
PKA Protein Kinase A 
PPM Parts Per Million
Ptc Patched Drosophila 
Ptch Patched vertebrates 
RCSB Research Collaborator for Structural Bioinformatics 
RDC Residual Dipolar Coupling 
RF Radio Frequency 
RMS Rhabdomyosarcoma 
RND Resistance Nodulation cell Division 
SHh Sonic Hedgehog 
SLMB Slimb 
Smo Smoothened 
SPR Surface Plasmon Resonance 
SSA Super Streptavidin 
SSD Sterol Sensing Domain 
STD Saturation Transfer Difference 
SuFu Suppressor of Fused 
TA Triamcinolone Acetonide 
TOCSY Total Correlation Spectroscopy 
Water-LOGSY Water-ligand Observation with Gradient Spectroscopy 
7TM Seven Transmembrane Domains 
 
 
 
 
 1 
CHAPTER 1. INTRODUCTION
 
 
1.1. An Overview of the Components of the Hedgehog Signal Transduction 
Machinery 
 
The Hedgehog (Hh) signal transduction pathway plays an important role during 
embryogenesis controlling cell growth, proliferation and differentiation[1-3]. In adult 
tissues Hh signalling has been proposed to play a role in the proliferation and 
differentiation of adult stem cells[4]. Disruption of Hh signalling during development and 
the postnatal period leads to a plethora of developmental anomalies such as 
holoprosencephaly and Pallister-Hall Syndrome[5, 6]. Malfunctioning of the Hh pathway 
in adult life leads to tumor development and progression specifically in a subset of 
medulloblastoma (MB), basal cell carcinoma (BCC) and rhabdomyosarcoma (RMS)[7-
10]. The core components of the Hh signal transduction cascade have been well 
conserved from Drosophila to humans, although some differences do exist[11, 12]. The 
G protein coupled receptor (GPCR), Smoothened (Smo), functions as the signal 
transducer of the Hh pathway and is the primary focus of the present dissertation[13-16]. 
This section will briefly describe the individual components of the Hh signal transduction 
cascade. 
1.1.1. Hedgehog
 
The Hh pathway gets its name from the endogenous ligand of the pathway, Hh. 
The Hh gene was first identified as a segment polarity gene in Drosophila
melanogaster[1]. The Hh mutations resulted in shorter embryos when compared to the 
wild-type embryos and exhibited a range of embryonic cuticular defects[1, 17]. The 
appearance of denticular or hairy larvae inspired the name hedgehog (Hh)[1]. The Hh 
gene is equally important in vertebrates wherein it has been described to play an 
important role in regulating cell fate and number in brain and spinal cord which in turn 
controls the patterning of limbs and internal organs[2, 11]. 
 
Hh binds to the Patched (Ptch) receptor and may act as a morphogen, a mitogen or 
a survival factor[2, 18]. Although the mechanism of action of Hh is conserved from 
Drosophila to vertebrates, Drosophila has only one type of Hh whereas vertebrates have 
three distinct types of Hh: Sonic Hedgehog (SHh), Indian Hedgehog (IHh) and Desert 
Hedgehog (DHh)[11, 19]. DHh is closely related to the fly Hh, and SHh and IHh are 
related to each other[20]. 
 
The Hh protein is synthesized as a precursor protein and undergoes significant 
post-translational modifications[11]. It has an amino (N) terminal signalling unit and a 
carboxyl (C) terminal protease domain[11]. The C-terminal region of the precursor 
protein is cleaved to release the signalling Hh protein (HhN) which in turn is dual-lipid 
modified[11]. One of the lipid modifications is palmitoylation and the other is the 
addition of cholesterol[21-23]. The palmitate modification is on a cysteine residue at the 
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N-terminus of the protein that is exposed after the signal peptide is cleaved off. The 
cholesterol modification is on the C-terminus of HhN following autocatalytic 
cleavage[11]. The schematics depicting the sequential lipid modifications on the Hh 
protein are shown in Figure 1-1. Lipid modifications of Hh have been suggested to aid in 
Hh oligomerization and form soluble protein complexes responsible for signalling[20, 
24-26]  Hh is released from the producing cell by the twelve transmembrane protein 
Dispatched (Disp)[27]. 
 
 
1.1.2. Patched 
The patched (ptc) gene was also identified in Drosophila as a segment polarity 
gene[28]. In Drosophila there is only one type of Ptc whereas in zebrafish, mice and 
humans two homologs of Patched; Ptch1 and Ptch2 have been reported[2, 29]. Ptch 
functions as the receptor for the Hh ligand[28, 30, 31]. Unlike other signalling pathways 
in which receptors act as positive modulators of the pathway, Ptch acts as a negative 
regulator and inhibits signalling in the absence of the Hh ligand[32]. The binding affinity 
of Ptch for the Hh ligand is in the low nanomolar range[30, 33].
 
The Ptch receptor is predicted to possess twelve membrane spanning domains and 
is structurally related to the bacterial resistance-nodulation-cell division (RND) 
transporters[28, 30, 31]. Both the N- and C-terminus of the Ptch receptor are located in 
the cytoplasm. It has two large extracellular loops which bind to the Hh ligand[33]. The 
Ptch receptor structure also includes a sterol sensing domain (SSD) comprised of 180 
amino acids and correspond to five consecutive transmembrane helical domains[34]. 
Figure 1-2A illustrates the different domains of the Ptch receptor.  
 
In the absence of the Hh ligand, Ptch inhibits Smoothened (Smo) from 
functioning and transducing downstream signalling[2, 3]; however the functional details 
of how Ptch inhibits Smo are still subject to debate. Ptch does not inhibit Smo 
stoichiometrically because even in the excess of Smo, Ptch can inhibit Smo function[35]. 
Additionally, coimmunoprecipitation and cell imaging experiments have confirmed that 
Ptch does not physically associate or colocalize with Smo[36]. Ptch is known to control 
the subcellular distribution of Smo and thereby control its activity[36, 37]. When Hh 
binds to Ptch, it loses its constitutive repression on Smo, facilitating Smo translocation to 
the cell membrane in Drosophila and primary cilium in vertebrates to transduce 
signalling[36, 38]. 
1.1.3. Hedgehog Co-receptors  
 
The Hh ligand has been reported to bind to other proteins which function as Hh 
co-receptors. Ihog and brother of Ihog (Boi) were amongst the first identified Hh co-
receptors in Drosophila[39, 40]. Ihog receptors bind to the ligand Hh and the receptor 
Ptch[11, 18]. Ihog receptors possess a single transmembrane domain, an N-terminal 
extracellular and a C-terminal intracellular domain as shown in Figure 1-2B[41].  
 3 
 
Figure 1-1. Schematic representation of the post-translational modifications of the 
Hh ligand.  
The Hh ligand is secreted as an inactive precursor protein. The N-terminal signal 
sequence is cleaved following the addition of the palmitate moiety to the N-terminus and 
the cholesterol moiety to the C-terminus to produce the active Hh ligand.  Source: Heal 
WP, Jovanovic B, Bessin S, Wright MH, Magee AI, Tate EW. Bioorthogonal chemical 
tagging of protein cholesterylation in living cells. Chemical Communications 
2011,47:4081-4083. 
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Figure 1-2. Schematic representation of the Hh receptors. 
(A) The Ptch receptor possesses twelve membrane spanning domains. The first and the 
fourth extracellular loops are large and serve as the Hh binding site. Ptch also maintains a 
sterol sensing domain (SSD) formed by the transmembrane helices two through six. (B)
The Hh co-receptors such as Ihog are a single-pass membrane protein. The extra-cellular 
domain is characterized by four immunoglobulin folds (Ig) and two or three fibronectin 
domains (Fn3). The first Fn3 domain binds to the Hh ligand and the second Fn3 domain 
binds to the Ptch receptor.
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The extracellular domain (ECD) is characterized by four immunoglobulin (Ig) 
like domains and two fibronectin type III (FN3) domains in Drosophila and three FN3 
domains in vertebrates[41]. The domain architecture of the Ihog receptor is shown in 
Figure 1-2B. The first FN3 domain binds to Hh and the second FN3 domain binds to 
Ptch[41, 42].  The vertebrate orthologs of Ihog are cell adhesion molecules down-
regulated by oncogenes (Cdo) and brother of Cdo (Boc)[43].  
 
Heparin in flies and calcium in vertebrates play an important role in stabilizing 
the interaction between Hh co-receptors and the ligand Hh[44]. Growth arrest specific 
gene 1 (Gas1) has also been reported to function as an Hh co-receptor in vertebrates[18, 
45]. The physiological significance of the Hh co-receptors is underscored by the fact that 
missense mutations in these receptors were identified in patients suffering from 
holoprosencephaly[46]. 
1.1.4. Smoothened
 
The Smoothened (Smo) receptor is encoded by the smo gene which was first 
identified as a segment polarity gene in Drosophila[1]. The Smo receptor is a member of 
the Frizzled (FzD) class of G protein coupled receptors (GPCR) and functions as the 
signal transducer of the Hh pathway[13-15]. The aims of this dissertation have been to 
study the structural and functional significance of the Smo receptor and are discussed 
elaborately in the subsequent chapters. A brief introduction to some of the intricate 
details of the Smo receptor will be described in section 1.2. 
 
 
1.1.5. Hedgehog Signalling Complex
Downstream of Smo, Hh signal is transduced by the Hedgehog Signalling 
Complex (HSC) which is comprised of the kinesin-like protein Costal2 (Cos2) in 
Drosophila / Kif 7 in vertebrates, the serine/threonine kinase Fused (Fu), Suppressor of 
Fused (SuFu) and the transcription factor Cubitus interruptus (Ci) in Drosophila and 
Glioma associated genes (Gli) in vertebrates[11, 47, 48]. The HSC binds microtubules in 
an Hh-dependent manner, probably aided by Cos2. Cos2 is a scaffold protein which also 
recruits other serine/threonine kinases like protein kinase A (PKA), glycogen synthase 
kinase 3 (GSK3) and casein kinase 1 (CK1)[47, 49]. Sequential phosphorylation of the 
transcription factor by the above mentioned kinases triggers its ubiquitination and 
proteolysis to generate a transcriptional repressor[50]. Thus Cos2 functions as a negative 
regulator of the pathway[11, 47, 49, 50]. 
 
On the other hand Fu functions as a positive modulator of the pathway[49]. 
Translocation of the HSC to the plasma membrane in response to the Hh ligand induces 
phosphorylation of Cos2 by Fu[11, 18, 51]. Consequently, Cos2 dissociates from the 
HSC, leading to the accumulation of the active transcription factor[11, 18].  
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The activity of the transcription factor Ci, is further inhibited by SuFu which is 
the primary mode of restricting Ci activation when Ci proteolysis is blocked[18, 52, 53]. 
In Drosophila loss of SuFu does not lead to ectopic Hh signalling, suggesting that there 
are other Ci inhibitory mechanisms present in Drosophila[18]. In vertebrates loss of SuFu 
leads to ectopic Hh signalling suggesting that SuFu is the primary inhibitor of Gli[18, 53, 
54]. Figure 1-3A summarizes the components constituting the HSC. 
 
 
1.1.6. Ci/Gli Transcription Factors 
 
The expression of the Hh target genes are controlled by the zinc finger 
transcription factors Ci and Gli in Drosophila and vertebrates respectively[11, 55-57]. In 
vertebrates there are three different forms of Gli: Gli 1, Gli 2 and Gli 3[57]. The Ci 
protein is related to the Gli 2 and Gli 3 proteins[11, 58].  
 
The Gli transcription factors share five highly conserved tandem C2H2 zinc 
fingers and a conserved His-Cys linker between the zinc fingers[18, 59]. The Ci, Gli 2 
and Gli 3 proteins include an N-terminal transcription repressor domain and a C-terminal 
transcription activator domain as shown in Figure 1-3B[56, 60, 61]. The full length Ci, 
Gli 2 and Gli 3 proteins function as transcription activators, but proteolytic degradation of 
the C-terminus allows these transcription factors to function as transcription 
repressors[11, 56, 61]. Gli 1 lacks the N-terminal repressor domain and functions only as 
a transcription activator[11, 18]. 
1.2. The Smoothened Receptor 
 
The Smo receptor functions as the signal transducer in the Hh pathway[2, 11, 13, 
14]. This section will elaborate on the structural and functional intricacies of the Smo 
receptor.  
1.2.1. Smoothened Structure and Post-translational Modifications 
 
Smo is a member of the FzD class of G protein coupled receptors (GPCRs) and 
functions as the signal transducer of the Hh pathway[15, 16, 62, 63]. Recently, the 
structure of the Smo seven transmembrane domains (7TM) and the extracellular linker 
domain (ECLD) were elucidated by X-ray crystallographic methods[64]. The structure 
showed that Smo possesses seven membrane spanning helical domains and a short eighth 
helix packed parallel to the membrane as shown in Figure 1-4A. The 7TM domains are 
connected by three intracellular loops (ICL) and three extracellular loops (ECL). The 
third extracellular loop (ECL3) is large and extends into the extracellular space[64]. Smo 
also possesses an N-terminal extracellular cysteine-rich domain (CRD) and a C-terminal 
intracellular domain that was not included in the crystal structure.  
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Figure 1-3. Schematics of the Hedgehog Signalling Complex (HSC) and the domain 
architecture of the Gli transcription factor. 
(A) The key components of the HSC include the microtubule-associated protein Costal2 
(Cos2), Fused (Fu), Suppressor of Fused (SuFu), the protein kinases: protein kinase A 
(PKA), casein kinase 1 (CK1), glycogen synthase kinase 3 (GSK3), and the transcription 
factor Ci/ Gli. (B) Domain architecture of the Gli transcription factor highlighting the 
main structural features. Source: Briscoe J, Therond PP. The mechanisms of Hedgehog 
signalling and its roles in development and disease. Nature Reviews Molecular Cell 
Biology 2013,14:416-429 
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Figure 1-4. The structural domains of the Smo receptor and the disulfide bonds 
stabilizing the Smo extracellular linker and the extracellular loops.  
(A) The structure of the seven transmembrane domains of the Smo receptor (pdb code 
4JKV)[64]. The position of the extracellular cysteine rich domain (CRD) and the 
intracellular cytoplasmic domain (CTD) not included in the crystal structure are 
indicated. (B) Sequence alignment of the Drosophila (D) Smo extracellular linker domain 
(ECLD) and the extracellular loop 1 (ECL1) with the human (H) Smo ECLD and ECL1. 
The cysteines engaged in disulfide bond formation in human Smo are conserved in 
Drosophila. The red lines indicate the disulfide bond pattern. 
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The Smo N-terminal CRD is similar to the CRD of the FzD receptors and is 
connected to the first transmembrane domain by the ECLD[16, 65, 66]. The ECLD has 
three conserved cysteines; the first two cysteines form a disulfide bond within the ECLD 
and the third cysteine forms a disulfide bond with a conserved cysteine in the first 
extracellular loop as shown in Figure 1-4B[64]. These disulfide bonds stabilize the Smo 
extracellular structures close to the 7TM bundles. Additionally the residues in the first 
extracellular loop form hydrogen bonds with residues in the extracellular linker, further 
stabilizing the extracellular linker and the extracellular loops in proximity to one 
another[64]. 
 
The Smo cytoplasmic domain is about 241 amino acids longer in Drosophila than 
humans. Both Drosophila and vertebrate Smo C-termini contain putative phosphorylation 
sites and conserved clusters of basic amino acids[67, 68]. Phosphorylation neutralizes the 
charge on the basic residues and leads to a conformational switch which brings the 
cytoplasmic loop of the adjacent Smo receptor in close proximity and facilitates 
downstream signalling[68]. In the presence of Hh, Drosophila Smo is phosphorylated by 
PKA, CK1, CK2 and the G protein coupled receptor kinase (GRK2)[69-72]. The 
vertebrate protein kinases include CK1? and GRK2[73].  
 
On the intracellular surface the Smo receptor also possesses conserved tryptophan 
residues. Tryptophan 535 and W545 are of potential interest.  Tryptophan 535 is 
conserved in the Smo family and is superimposable with the NPXXY motif of class A 
GPCRs[64]. Mutation of  W535L leads to a constitutively active Smo receptor[74]. The 
W545 is homologous to the tryptophan of the KTXXXW motif of the FzD receptors[64]. 
In the FzD receptors the conserved KTXXXW motif of helix VIII is essential for the 
interaction of the FzD receptor and the Dishevelled protein[75]. This interaction is 
essential for the activation of the Wnt/beta catenin pathway[75, 76]. In Smo the 
conserved sequence is KATXXXW[64]. The hydroxyl group of the threonine and the 
indole nitrogen of the tryptophan form a hydrogen bond with residues from the 
intracellular tip of helix VII and the first intracellular loop respectively[64].  Thus the 
KATXXXW motif in Smo is essential for maintaining the tertiary fold of the protein; 
however, like the KTXXXW motif of the FzD receptor, the KATXXXW motif of the 
Smo receptor may directly bind to a downstream signalling protein or molecule to 
regulate signalling. 
 
 
1.2.2. Smoothened as a G Protein Coupled Receptor 
 
The Smo receptor has been classified as a member of the FzD class of GPCRs and 
shares less than 10% primary sequence identity with class A GPCRs[15, 16, 62, 63]. Smo 
retains the canonical 7TM helices characteristic of GPCRs and also shares some of the 
intracellular structural features with class A GPCRs such as the helical turn in the first 
intracellular loop and an intracellular helix VIII parallel to the cell membrane[62, 64]. On 
the extracellular surface the beta hairpin structure of the ECL2 is common for Smo and 
class A GPCRs. The canonical GPCR disulfide linkage between conserved cysteines in 
the ECL2 and TM3 is also found in Smo receptors[64, 77]. Furthermore Smo can be 
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phosphorylated by a GPCR kinase (GRK2) and is known to recruit ?-arrestin[78]. 
Additionally, Smo has been shown to recruit G-proteins mainly G?i further justifying the 
classification of Smo as a GPCR[15, 79]. 
 
Smo lacks some of the canonical class A GPCR features, such as the D/ERY 
motif in helix III[62, 64]. Conserved prolines which play an important role in receptor 
activation in helix V, VI, VII of class A GPCRs are absent in Smo. The Smo receptor has 
conserved glycines in helices V, VI and VII which may provide flexibility to the receptor 
allowing it to carry out structural rearrangements during receptor activation and 
signalling[64]. The extracellular loops of Smo are long compared to class A GPCRS and 
the extracellular CRD is unique to the FzD group of GPCRs[62, 64].  
 
1.2.3. Smoothened Signalling and Regulation by Small Molecules 
 
Smoothened activation is controlled by Ptch and involves three distinct 
phenomena: stabilization, conformational change and membrane localization[80, 81]. 
When Hh binds to Ptch it is internalized and degraded, leading to Smo stabilization and 
translocation from the endocytic vesicles to the cell membrane in Drosophila and primary 
cilium in vertebrates to activate downstream signalling[38, 68]. Thus Smo functions as 
the obligatory signal transducer of the Hh pathway located at the junction of the 
extracellular and intracellular events. Despite the central role played by Smo in mediating 
Hh signalling, the mechanism by which Smo activation is regulated and coupled to 
downstream signalling remains elusive. It has been suggested that Smo regulation may 
involve endogenous small molecules[80]. 
 
Various reports have shown that Smo activity can be regulated by a wide variety 
of small molecules[82, 83]. Cyclopamine, a plant alkaloid was the first described Smo 
inhibitor known to bind in the cavity of the 7TM domains. It is a natural product that can 
be isolated from corn lily and has anti-cancer effects[84-86]. Since the identification of 
cyclopamine, cell-based screens directed towards the Hh pathway have identified small 
molecules that directly bind Smo. The identified small molecules include agonists like 3-
chloro-N-[4-(methylamino) cyclohexyl]-N-[3-(pyridin-4-yl) benzyl] benzo[b] thiopene-2-
carboxamide (SAG) and purmorphamine and antagonists such as N-[(1E)-(3,5-dimethyl-
1-phenyl-1H-pyrazol-4-yl) methylidene]-4-(phenylmethyl)-1-piperazinamine (SANT) 
and GDC-0449 molecules[83, 87-89]. All of these small molecules have been described 
to bind in the same site as cyclopamine[83, 85, 87, 90].  Presently, the only Food and 
Drug Administration (FDA)-approved Smo inhibitor is GDC-0449 which also docks in 
the 7TM domains[64, 91]. The recently elucidated crystal structure of the Smo 7TM 
domains in complex with an anti-tumor agent showed that the antitumor molecule docks 
in the long and narrow cavity within the 7TM helices making contacts with residues of 
helix I, II, V and VII[64]. The ECLD and the ECL form the orifice of the cavity and 
contact the antitumor agent[64].  
 
In recent times oxysterols and glucocorticoids have been identified as two major 
groups of small molecules which bind to a site distinct from the cyclopamine binding site 
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in the cavity of the 7TM domains[92-94]. Pharmacological and biochemical studies have 
shown that 20 (S)-hydroxyl cholesterol (20(S)-OHC) acts as an allosteric activator of 
vertebrate Hh signalling, functioning at the level of Smo[92]. Additional cholesterol 
derivatives like 7-keto-25-OHC and 7-keto-27-OHC have also been reported to regulate 
Smo activity[95]. The length of the carbon chain attached to the steroid moiety is 
reported to be six or eight carbon atoms long for maximal Hh pathway activation by 
oxysterols[92, 96]. Mutation experiments have suggested that an intact extracellular Smo 
CRD is required for oxysterols to bind to Smo[92, 95]. 
 
Glucocorticoids were identified as Smo modulators in high-content cell-based 
screening experiments[93]. They could be categorized into two groups: the activatory 
glucocorticoids and the inhibitory glucocorticoids. As the name suggests activatory 
glucocorticoids like fluocinolone acetonide (FA) and triamcinolone acetonide (TA) 
promoted Smo ciliary translocation and downstream Hh signalling[93]. The inhibitory 
glucocorticoids such as Budesonide (Bud) repressed Smo ciliary translocation and 
downstream Hh signalling[93]. Interestingly, although the activatory glucocorticoids 
were shown to bind in the cavity of the Smo 7TM domains by cyclopamine binding 
competition assays, the inhibitory glucocorticoids were suggested to bind to a site distinct 
from the cyclopamine binding site in the 7TM domains[93].  
 
Most importantly the inhibitory glucocorticoid Bud acted on wild-type as well 
drug resistant Smo: SmoM2 and Smo D473H[93]. SmoM2 is a constitutively active form 
of Smo isolated from BCC patients[74]. There is a mutation, W535L, in the seventh 
transmembrane domain which may interfere with the interaction between the Smo 
receptor and the G-proteins. Smo D473H was isolated from MB patients treated with the 
FDA-approved drug GDC-0049[97]. This mutation is localized in the sixth 
transmembrane domain towards the extracellular surface and may play a role in small 
molecule binding. The occurrence of this mutation was accompanied by resistance to the 
drug[97]. Thus these Smo mutants were not responsive to previously identified Smo 
antagonists.  
 
Most of the current literature asserts that mammalian Smo is responsive to 20-
OHC and glucocorticoids whereas Drosophila Smo is cited as nonresponsive to these 
small molecules[92, 95, 96];  however, in Drosophila, the phospholipid, 
phosphatidylinositol-4 phosphate (PI4P), has been reported to regulate Smo activity[98].  
The loss of the kinase (STT4) responsible for the synthesis of PI4P results in the Hh loss-
of-function phenotypes. The loss of the phosphatase (Sac1) responsible for the 
degradation of PI4P results in the Hh gain-of-function phenotypes[98]. PI4P kinase 
depletion in a mouse fibroblast cell line also impairs activation of the Gli-luciferase 
reporter gene by SHh, implying that phospholipids play a role in regulating vertebrate Hh 
signalling[98]. 
 
Clearly Smo activity is susceptible to regulation by more than one distinct class of 
molecules as shown in Figure 1-5. These small molecules may bind in the same or 
different site on Smo to regulate Hh signalling. 
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Figure 1-5. Chemical structure of selected Smo modulators.  
Smo activity is regulated by small molecules such as cyclopamine, GDC-0449, SAG, 
cholesterol derivatives, glucocorticoids and phospholipids. 
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1.3. The Hedgehog Signal Transduction Cascade 
The Hh signal transduction cascade is switched on when the endogenous Hh 
ligand binds to the large extracellular loops of the receptor protein Ptch assisted by the 
Hh co-receptors[28, 30, 33]. Hh binding to Ptch renders Ptch inactive and trapped in 
endocytic vesicles. Consequently Ptch loses its housekeeping inhibition on the Smo 
receptor[36].  The Smo receptor then translocates from the endocytic vesicles to the 
primary cilium in vertebrates or the cell membrane in Drosophila[36, 38, 99]. Thus Smo 
functions as the signal transducer of the pathway located at the nexus of the extracellular 
and intracellular events.  
 
Smoothened in the plasma membrane is phosphorylated by the protein kinases 
PKA, CK1 and GPRK2[69-72]. Phosphorylation triggers a conformational switch in the 
cytoplasmic domains of the Smo receptor triggering downstream Hh signalling[68]. The 
Smo protein interacts with the kinesin-like protein Cos2[100, 101]. The Cos2 protein is 
one of the components of the HSC; the other members of the HSC include the 
serine/threonine kinase Fu and the transcription factor Ci/Gli[47-49]. The HSC is a 
cytoplasmic multi-protein complex responsible for transmitting the Hh signal from the 
Smo receptor to the Ci/Gli transcription factors[11, 18, 57]. The vertebrate analogue of 
Cos2 is Kif7[11, 12].  The Cos2 protein in turn is phosphorylated by the serine/threonine 
kinase Fu causing the release of the Ci/Gli transcription factor from the HSC[51, 102]. 
The Ci/Gli transcription factor accumulates in its full length form, and translocates to the 
nucleus to activate the transcription of the Hh target genes[11, 18]. Some of the Hh target 
genes include Cyclin D, Cyclin E, n-myc and patched[11, 55]. 
 
The Hh signal transduction is switched off in the absence of the Hh ligand as 
shown in Figure 1-6A and switched on in the presence of the Hh ligand as shown in
Figure 1-6B. The Ptch receptor constitutively inhibits the Smo receptor. As a result the 
Smo receptor is trapped in the endocytic vesicles[36]. The downstream transcription 
factor Ci is associated with the scaffold protein Cos2[11, 18, 47, 48]. Costal 2 
additionally recruits PKA, GSK3 and CK1[50]. These kinases phosphorylate the full 
length Ci/Gli transcription factors[11, 18]. The phosphorylated transcription factor serves 
as a signal to recruit the F-box protein Slimb (SLMB). SLMB catalyses C-terminal 
ubiquitination and successive proteolytic degradation of the transcription factor to 
generate a transcriptional repressor[103, 104]. The transcriptional repressor dissociates 
from the HSC, translocates to the nucleus and represses the transcription of the Hh target 
genes[11, 18]. 
 
The Hh signal is also known to be transduced by the Smo receptor via G-
proteins[15, 79, 105]. Smoothened has specificity towards the G?i protein. Recruitment of 
the G?i protein by Smo in response to the Hh ligand decreases the intracellular 
concentrations of cyclic adenosine monophosphate (cAMP)[18]. Decreased cAMP leads 
to the inactivation of the protein kinase: PKA. The protein kinase, PKA, functions to 
phosphorylate and degrade the transcription factor to terminate Hh signalling. Thus 
inactivation of protein kinase A activates Hh signalling[18]. 
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Figure 1-6. The Hedgehog Signal Transduction Cascade.
(A) In the absence of the Hh ligand, the Ptch receptor inhibits Smo; consequently Smo is 
trapped in the endocytic vesicles. The downstream Hh signalling complex (HSC) renders 
the transcription factor Ci inactive, which, although translocates to the nucleus, fails to 
induce the transcription of the Hh target genes. (B) In the presence of the Hh ligand, Ptch 
loses its constitutive repression on Smo; Smo translocates to the cell membrane in 
Drosophila or primary cilium in vertebrates. Thereby the HSC maintains Ci in its full 
length form which translocates to the nucleus to induce the expression of the Hh target 
genes.
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Smoothened signalling is reported to be regulated by cytosolic ?-arrestin proteins 
and G-protein-coupled receptor kinase, GRK[78]. The GRK proteins phosphorylate the 
C-terminal serine/threonine residues of the Smo receptor which serves as a signal to 
recruit ?-arrestin[106]. Beta-arrestin bound to the Smo receptor leads to receptor 
desensitization and clathrin-mediated receptor internalization[78]. It has also been 
reported that ?-arrestins together with the Kif proteins may aid the ciliary transportation 
of the Smo receptor to initiate downstream Hh signalling[107, 108].  
 
 
1.4. Implications of the Hedgehog Pathway in Cancer 
 
In adults Hh signalling is associated with maintenance of tissue homeostasis, 
cellular repair and regeneration, and continence of stem cells[2]. Abnormal Hh signalling 
in adults has been associated with tumorogenesis and cancer and was first reported in 
patients suffering from Gorlin’s syndrome[10]. Gorlin’s syndrome is caused due to a 
loss-of- function mutation in one of the patched genes and the phenotypes include BCC, 
MB and RMS[109, 110]. 
 
Depending on the mechanism of action the cancers associated with 
malfunctioning of the Hh pathway can be categorized under three major types[111, 112]. 
The first type (type I) is Hh ligand independent and results from inactivating mutations in 
Ptch (85%) or activating mutations in Smo (10%)[74, 113]. In the second type (Type II) 
of the Hh pathway cancers such as tumors of the lung, digestive tract and breast are not 
associated with oncogenic mutations in the pathway components rather they act in a 
ligand-dependent autocrine manner[10, 114]. The third type (Type III) of the Hh 
pathway- associated cancers are ligand dependent and act in a paracrine manner to 
activate signalling in the tumor microenvironment[115]. Ectopic Hh signalling in cancer 
may be associated with either the initiation of the tumor as in the case of BCC and MB, 
or the growth of the tumor as observed in the cancers of the digestive tract[10]. In a 
certain group of cancers such as lymphoma, although abnormal Hh signalling has been 
suggested, the exact role of Hh signalling has not been defined. 
 
 
1.4.1. Basal Cell Carcinoma  
 
Basal cell carcinoma (BCC) is the most common type of skin cancer in the United 
States. Ectopic Hh signalling plays a pivotal role in BCC and was first reported due to a 
mutation in the Ptch 1 gene located on chromosome 9[7, 109, 116]. In sporadic BCC 90% 
of cases are due to loss-of-function mutations in one of the ptch alleles, and in 10% of 
cases are due to gain- of-function mutations in smo gene[74, 110, 117]. Harmful UV 
radiations may have been the cause of the mutations.  
 
In most cases BCC is not associated with metastasis, however  if the tumor 
metastasizes it can be deadly[118]. BCC can be treated either by the surgical removal of 
the tumor or by the use of targeted therapeutics[118]. The natural product steroidal 
alkaloid cyclopamine was first used as a topical application, and since then several other 
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cyclopamine derivatives have been developed to enhance potency[119]. The Smo 
inhibitor GDC-0449 developed by Genentech-Curis is the first FDA-approved drug used 
for the treatment of BCC and acts on local as well as metastasized tumors[120].  
 
 
1.4.2. Medulloblastoma
 
Medulloblastoma (MB) is a common childhood tumor of cerebellar origin[121]. 
Each year 400 children are diagnosed with MB in the United States, making it the most 
common pediatric brain tumor. Four distinct molecular sub-types of MB have been 
described on the basis of transcriptional profiles and aberrant Hh signalling has been 
reported in one of the subtypes, categorized as the Hh subtype of MB[122]. The first 
evidence of ectopic Hh signalling in MB was established when mutations in the ptch gene 
were identified in patients with Gorlin’s syndrome[123].  
 
Radio-therapy and chemical therapeutics have been commonly used for the 
treatment of MB; however such treatment is often associated with severe side effects 
including intellectual deterioration. The Smo antagonist GDC-0449 caused rapid 
regression of tumor and reduction of symptoms in MB patients; however, the 
effectiveness was limited due to the relapse of the tumor with a D473H resistant mutation 
in the sixth transmembrane helix of the Smo receptor[97, 124]. Therefore, second 
generation drugs are needed for the treatment of the Hh subtype of MB. These drugs 
should be effective against the resistant mutants and associated with minimal side-effects. 
1.4.3. Rhabdomyosarcoma
Rhabdomyosarcoma (RMS) is the most common type of soft tissue sarcoma in 
children, accounting for 10% of solid pediatric malignancies[10]. RMS is mostly 
sporadic but is sometimes associated with Gorlin’s syndrome[125]. Uncontrolled Hh 
signalling such as occurs after the loss of Ptch may lead to RMS[125]. Overexpression of 
Hh signalling also correlates with tumor proliferation in RMS. The metastatic property of 
the RMS cells can be suppressed by treatment with Hh pathway inhibitors[10]. 
 
 
1.4.4. Targeting the Hedgehog Pathway to Treat Cancers 
 
Aberrant Hh signalling has been reported in a wide variety of cancer conditions 
and thus this pathway has emerged as a lucrative target for the development of drugs[7-
10]. Abnormal Hh signalling reported in cancer may or may not be associated with 
oncogenic mutations[10]. For example, the type II and type III of the Hh-driven cancers 
do not harbor oncogenic mutations in any of its components. They are Hh ligand 
dependent and therefore can be treated by Hh antagonists[112]. In type I Hh tumors such 
as BCC, MB and RMS, which are reported to possess oncogenic mutations in Ptch or 
Smo, they can be treated with therapeutics acting at the level or downstream of the 
oncogenic mutations.  
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Theoretically each step of the Hh signal transduction cascade can be targeted to 
inhibit ectopic signalling; however Smo has emerged as the best defined target for drug 
development[126, 127]. Cyclopamine was the first identified small molecule which acts 
as an antagonist of Hh signalling by binding to the Smo receptor[84, 85, 119]. 
Subsequently a plethora of cyclopamine derivatives with enhanced bioavailability and 
potency have been reported to function as Hh pathway antagonists[128]. GDC-0449 is 
the only FDA-approved drug for the treatment of BCC[88, 89, 91]. Unfortunately 
resistance to this drug has already been reported and therefore the need arises to develop 
second generation drugs[97]. Smo inhibitors such as sonidegib (LDE225, Novartis), 
BMS-833923 and saridegib are also effective in the treatment of BCC and may be 
effective against the resistant mutants[126]. Smo inhibitors are also being tested on a 
variety of ligand-dependent tumors.  
 
Targeting the Hh signalling pathway to treat cancers has been ongoing for years. 
Almost every step in the signal transduction has been targeted to inhibit ectopic 
signalling. Although Smo has emerged as the major drug target of the pathway, other 
candidates are also being analyzed as potential targets for the development of 
therapeutics. The monoclonal antibody 5E1 prevents the binding of Hh to Ptch and has 
demonstrated decent preclinical activity[112].  Hedgehog interacting protein (HHIP) 
mimics, SUFU mimics and Gli inhibitors like the GANT group of small molecules also 
function to ablate ectopic Hh signalling and are in various phases of development[129].  
1.4.5. Promoting the Smoothened Cysteine Rich Domain as a Novel Target for Drug 
Development
 
Clearly Smo plays an important role in the Hh signal transduction cascade and 
therefore has emerged as a target for the development of drugs to inhibit ectopic Hh 
signalling associated with cancer conditions[126]. It is not surprising that Smo has been 
widely used as a target for drug discovery because GPCRs represent the core of modern 
medicine and Smo is a member of the FzD class of GPCRs[16, 62, 63]. Most of the 
characterized drugs such as GDC-0449 bind in the cavity of the 7TM domains[64]; 
however due to the occurrence of resistant mutations on treatment with such Smo 
inhibitors the need arises to develop new drugs[97]. The novel drugs may or may not be 
targeted towards the same binding site.  
 
In such regards we hypothesized that the extracellular Smo CRD may function as 
a novel site for the development of next generation drugs effective against resistant 
mutants. The Smo CRD is homologous to the FzD CRD which binds to the endogenous 
Wnt ligand and activates downstream Wnt signalling[65, 66].  We speculated that like the 
FzD CRD the Smo CRD also possesses a well-defined structure and may play a role in 
binding to small molecules. Therefore to test our hypothesis we initiated structure-
function studies of the Smo receptor, focusing primarily of the extracellular CRD. The 
following chapters discuss our findings with an emphasis on the structure of the Smo 
CRD and its role in binding small molecules to regulate downstream Hh signalling.  
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CHAPTER 2. METHODS
 
 
2.1. Introduction 
 
Nuclear Magnetic Resonance (NMR) as the name indicates describes the 
‘resonating’ behavior of certain ‘nucleus’ (possessing a property called spin) when placed 
in an external ‘magnetic’ field. NMR spectroscopy utilizes the phenomena of NMR to 
study physical and chemical properties of biomolecules. In the present day scenario NMR 
has a wide range of applications; it can be used to determine the structure of molecules, 
probe for interactions between various molecules and provide insights into the dynamic 
or the kinetic behavior of the molecules. The molecules resolved by NMR may be small 
organic molecules, natural products, peptides or proteins of several tens of kilo-daltons in 
molecular weight[130]. Using NMR the molecules can be studied in solution mimicking 
the physiological environment as well as in solid state. In this dissertation we will focus 
on solution NMR spectroscopy. 
 
High resolution solution NMR spectroscopy provides insights into the structure of 
biomolecules at atomic resolution. The theoretical principle of NMR was first proposed 
by Pauli in 1924. He stated that certain atomic nuclei possess the property of spin and 
magnetic moment and when such nuclei are placed in an external magnetic field it leads 
to splitting of their energy levels. Historically the phenomenon of NMR was first 
described by Isidor Rabi in the year 1938. He measured the NMR in molecular beams 
and was awarded the Nobel Prize in Physics for his work in 1944. The groups of Felix 
Bloch from Stanford University and Edward Mills Purcell from the Harvard University 
advanced the technique of NMR for use in solids and liquids and jointly shared the Nobel 
Prize in 1952. Richard R. Ernst developed the Fourier transform (FT) NMR spectroscopy 
and received the Nobel Prize in 1991 for his phenomenal discovery. Kurt Wuthrich 
expanded the technique of NMR spectroscopy for determining the three dimensional 
structure of biomolecules such as proteins in solution and was bestowed with the Nobel 
Prize in 2002. Paul Lauterbur and Peter Mansfield were awarded the Nobel Prize for 
extending the use of NMR for biomedical imaging defined as Magnetic Resonance 
Imaging (MRI).    
 
The technique of NMR provides molecular information at atomic resolution. The 
advantage of NMR over other complementary methods such as X-ray crystallography 
and mass spectrometry is that the samples used in NMR experiments is not destroyed and 
can be recovered after the measurement. Using NMR the molecules can be studied in 
solution mimicking the physiological environment as well as in solid state. Additionally 
NMR can also be used to study biological fluids such as blood and urine. In recent times 
the technique of NMR is also being utilized to analyze the quality of commercial 
commodities such as wine. In this dissertation solution NMR methodology was used to 
determine the structure of a protein domain and therefore will be discussed in detail.  
 
Despite, the widespread use of the NMR methodology, there are some inherent 
limitations associated with this technique. The resolution derived from NMR experiments 
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is often considered to be lower than that derived from X-ray crystallography methods. 
Additionally there is a limitation to the size of the molecule that can be studied by 
solution NMR. As the size of the molecule increases it experiences a slower tumbling 
rate in the magnetic field leading to faster decay of signals which become difficult to 
detect. The data recorded in an NMR experiment is a mixed average of numerous 
individual signals from the biomolecular sample.  Therefore with an increase in the size 
of the molecule the NMR signals overlap making unambiguous resonance assignments 
challenging[130, 131]. Consequently NMR derived data are convoluted and seek time 
and effort to interpret. Accordingly, the time taken to resolve a three dimensional 
structure by NMR is typically longer than the time taken to elucidate the structure by X-
ray crystallography. The major benefit of NMR is that it provides information on 
biomolecules in solution as opposed to experimentally packed crystal conditions as is the 
case with X-ray crystallography methods.  
 
 
2.2. The Physics and Mathematics behind Nuclear Magnetic Resonance  
 
The samples studied by NMR are composed of molecules. The molecules in turn 
are composed of atoms. The atoms are comprised of electrons, protons and neutrons. The 
electrons occupy the electronic orbitals surrounding the nucleus of an atom whereas the 
protons and the neutrons are present in the nucleus of an atom. The subatomic particles 
comprising the electrons, protons and the neutrons are considered spinning on their axes. 
Spin is one of the fundamental properties of matter, appears in multiples of ½ and may be 
positive or negative. Two or more particles with opposite spins may pair up to negate the 
observable effect of spin. In atoms the number of protons and neutrons may be even or 
odd. In case of atoms like 12C and 16O the number of protons and neutrons are both even 
such that they pair against each other and the nucleus of the atom have no net spin. Such 
nucleus cannot be detected by NMR. In case of atoms like 1H, 15N and 13C the number of 
neutrons and/or the number of protons are odd such that the nucleus of the atom 
possesses a net half-integer spin which can be measured by NMR. 
 
Atomic particles possessing the property of spin behave like small magnets with a 
north and south-pole and are described as spin vectors. The nuclei with the two spin 
states possess a magnetic moment (?), which can be expressed as shown in  
Equation 2-1.
?  
?? ? ?????       Equation 2-1 
 
Where h is the Planck’s constant (h=6.626x10-34 Js), and ??is the gyromagnetic ratio of 
the particular nuclei. 
 
Thus the magnitude of the magnetic momentum depends on the value of the 
gyromagnetic ratio. Since different nuclei have different gyromagnetic ratio they 
experience different magnetic moment. Magnetic moment is a vector quantity and defines 
the strength as well as the orientation of the nuclear magnet. ?
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In the absence of any external magnetic field the small spin vectors with specific 
nuclear moments are randomly distributed negating each other’s effect as represented in 
Figure 2-1. Consequently the net magnetic field is zero; however when placed in an 
external magnetic field of strength B0 the spin vector aligns with the external field. The 
spin vectors may be aligned in the direction of the external magnetic field (N?) or against 
the direction of the external magnetic field (N?) giving rise to two different energy states. 
There is always an excess of nuclei in ? (aligned with the external magnetic field, B0) 
spin states than in the ? (aligned against the external magnetic field, B0) spin states, as 
elucidated in Figure 2-1. The ratio between the populations in the two spin states (N? and 
N?) can be described by the Boltzmann’s equation as shown in Equation 2-2. 
 
????? ? ??????
     Equation 2-2
 
Where ?E is the energy difference between the two spin states, T is the temperature 
(degree kelvin) and k (k=1.3805x10-23) is the Boltzmann’s constant.  
 
When placed in an external magnetic field of strength B0 a particle with net spin 
can absorb a photon of frequency ???Equation 2-3 depicts the relationship between the 
frequency of the photon, the gyromagnetic ratio and the external magnetic field. 
?
? ? ???? ? ? ? ? ? Equation 2-3?
 
Where ??is the gyromagnetic ratio of the particle and B0?is the field strength of the 
external magnetic field.  
 
Upon irradiation with the radio frequency (RF) radiation, energy is absorbed; 
causing the transition between ? and ? spin states. The spin vectors can undergo a 
transition between the two energy states by absorbing a photon of energy E as described 
in Equation 2-4. 
 
? ? ???      Equation 2-4 
 
Therefore combining Equation 2-3 and Equation 2-4, Equation 2-5 is generated. 
 
? ? ????? ? ? ? ? ? Equation 2-5 
?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
As stated earlier h is the Planck’s constant (h=6.626x10-34 Js) and ? is the resonance 
frequency also known as the Larmor frequency of the spin. 
 
Thus the amount of energy absorbed by a nucleus depends on several factors such 
as the strength of the external magnetic field. Stronger magnets induce larger ?/? 
population differences as shown in Figure 2-2. The other factor that affects the ?/? 
population differences is the gyromagnetic ratio of the nucleus in observation. Nucleus 
with greater gyromagnetic ratio absorbs and or emits more energy leading to intense 
absorbance signals.  
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Figure 2-1. Behavior of nuclear spins in the absence and presence of an external 
magnetic field.
(A) In the absence of an external magnetic field the nuclear spins are randomly 
distributed and the resultant local magnetic field is zero. (B) In the presence of an 
external magnetic field the nuclear spins orient either in the direction of the magnetic 
field (?) or against the direction of the magnetic field (?). The population of the spins 
aligned in the direction of the magnetic field is usually in excess of the nuclear spins 
aligned against the external magnetic field.
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Figure 2-2. Magnetic field strength and NMR sensitivity.
Irradiation with RF radiation causes the nuclear spins to absorb energy and transit 
between the ? and ? spin states. Stronger magnets induce larger ?/? population 
differences.
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When the spins are irradiated by an orthogonal RF field, B1, close to the Larmor 
frequency of the nucleus under observation they are flipped down to the plane 
perpendicular to B0. The flipped vector precesses around the B1 field while it relaxes back 
to its original position. During the process of relaxation the spinning vector generates 
electromagnetic radiation which induces a current in the coils located in the perpendicular 
plane. Plotting the induced current as a function of time generates a wave which decays 
with time. This is known as the free induction decay (FID). This time domain data can be 
converted to frequency domain data by FT. 
 
The NMR data recorded is a set of peaks and each peak corresponds to a specific 
frequency. The resultant frequency depends on the strength of the external magnetic field. 
Since the external magnetic field varies with different spectrometers it would be difficult 
to compare NMR data obtained from different spectrometers. Therefore an internal 
reference such as tetramethylsilane is used to normalize the frequencies. The normalized 
frequency is defined as the chemical shift (?). The formula for calculating the chemical 
shift is listed in Equation 2-6. 
 
??????? ? ?? ? ?????????? ? ???   Equation 2-6 
 
Where ??is the frequency of the nuclei under observation and ?ref  is the frequency of the 
reference.  
 
Thus as chemical shift (?) is a ratio of both frequencies; the magnetic field 
dependence cancels out. This ratio specifies the position of the peak in a magnetic field 
independent way. The measurement of chemical shifts and assigning the chemical shifts 
to the specific nuclei within the molecular structure of the biomolecule forms the 
foundation of NMR spectroscopic methods.  
 
 
2.3. The Nuclear Magnetic Resonance Instrumentation 
 
 The measurement of NMR spectroscopic data requires an NMR spectrometer. 
The NMR spectrometers are named based on the resonance frequency of the protons in 
the magnetic field generated by the given magnet. For example an NMR spectrometer 
named as 800MHz causes the protons in the sample to resonate at a frequency of 
800MHz. The major components of the NMR spectrometer and their function are briefly 
described as follows. A schematic representation of the major components of the NMR 
spectrometer is illustrated in Figure 2-3.  
 
 
2.3.1. Magnet 
 
 The NMR magnet is the most important and the most expensive part of the NMR 
spectrometer. The superconducting NMR magnets are capable of producing magnetic 
field strengths ranging from 6 to 23.5 Tesla. 
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Figure 2-3. Components of an NMR spectrometer.  
The major components of the NMR hardware are illustrated.
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The superconducting NMR magnet is an electromagnet (a magnet wherein the 
magnetic field is produced by electric current) made of superconducting wires. According 
to the principles of physics the superconducting wires have a resistance almost equal to 
zero at temperatures close to absolute zero (0 K). Such extreme temperatures are 
maintained by immersing the super conducting wires in liquid helium. The 
superconducting wires are a few miles in length and made of brittle niobium, tantalum, 
titanium and tin (NbTaTi)3Sn material encapsulated in copper for strength. To 
accommodate the lengthy wire it is packed into a helical solenoid. The coil and the liquid 
helium are contained in large insulated Dewar. The Dewar in turn is placed in liquid 
nitrogen which acts as a buffer between the atmospheric air temperatures and the 
temperature of liquid helium. 
 
 
2.3.2. Lock System 
 
The lock system can be imagined as a separate spectrometer located within the 
main spectrometer. This spectrometer is customarily tuned to the frequency of a certain 
nuclei (typically deuterium that is added to the sample during sample preparation, 10% 
volume/volume).The lock system constantly invigilates the frequency of the deuterium 
nuclei. If an observable drift is reported in the deuterium frequency it is considered as a 
drift in the external magnetic field. This drift is then corrected by another coil in the main 
magnetic field. Thus the lock helps to monitor and correct any drift in the external 
magnetic field. 
2.3.3. Shim Coils 
 
The shim coils in a NMR spectrometer are responsible for maintaining a 
homogenous magnetic field. The inhomogeneities in the magnetic field may be caused by 
the design of the magnet, the materials used in the probe and ferromagnetic materials 
surrounding the magnet. The shim coils are capable of producing a local magnetic field 
that can oppose and cancel out the inhomogeneities in the external field. Since the 
external variations in the magnetic field may or may not be linear, the shim coils should 
be capable of producing a variety of local magnetic fields across all directions that is in 
the x, y and z axes. The magnetic field created by the shim coils depend on the calculated 
amount of current passed through each coil. The shim coils can be controlled by the user 
computer interface. 
 
 
2.3.4. Sample Probe 
 
The sample probe is the collective name used to describe the sample spinner, the 
temperature control circuit and the RF coils. The sample spinner rotates the NMR tube 
about its axis. When the sample is spun in the z axis the inhomogeneities in the x and y 
axes are averaged out resulting in narrower NMR line-width.  
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One of the major benefits associated with NMR spectroscopy is that the NMR 
data can be measured at a wide range of temperature. A thermocouple and electronic 
circuit monitors and maintains the sample temperature. Air or nitrogen which has been 
heated or cooled is passed over the sample to adjust the temperature as required.  
 
The RF coils are responsible for producing the orthogonal B1 magnetic field 
necessary to rotate the spins in the sample by 900 or 1800. Additionally the RF coils are 
also responsible for detecting the transverse magnetization of the sample spins as it 
precesses in the XY plane. The RF coils can resonate and has a bandwidth or specific 
range of frequencies at which it can resonate. The RF coils need to be tuned for the 
specific sample before the start of the experiment. Each sample has a different 
conductivity and dielectric constant which affect the resonance frequency of the RF coils. 
If the resonance frequency changes such that it does not match the resonance frequency 
of the nuclei under observation, the RF coil will decline to set up the effective B1 field as 
well as fail to detect the signals from the sample. This in turn would lead to poor signal to 
noise ratio. Thus tuning the RF coils to the specific sample before the start of the NMR 
experiment is necessary. 
 
2.3.5. Control Console and the Terminal Computer
 
The control console regulates the RF pulses through the RF transmitter and 
synthesizer. The signals detected from the sample by the RF coils are analog signals 
which are amplified by the RF amplifier and converted to digital signals by the analog 
digital converter (ADC). The digital signal is relayed to the terminal computer in the 
form of the FID. The FID represents the time domain data which is converted by the 
terminal computer to the frequency domain data by the mathematical FT. The terminal 
computer controls the spectrometer through RF pulse programs. The terminal computer 
also serves to display and store the detected digitized signals. 
 
 
2.4. Setting up a Nuclear Magnetic Resonance Experiment 
The following description summarizes the basic steps in setting up an NMR 
experiment. 
 
? A pure biomolecular sample which in this case is the protein of interest is 
prepared in an appropriate aqueous buffer solution with 10% D2O 
(volume/volume). The sample is carefully added to the NMR tube avoiding the 
introduction of air bubbles. The cap is secured on the NMR tube. 
 
? The NMR tube is positioned in the spinner so that the sample is centered on the 
probe coil. The gauge can be used to check the center and symmetry of the sample 
before introducing into the spinner. 
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? One of the benefits associated with NMR spectroscopy is NMR signals can be 
measured across a wide range of temperatures. Accordingly once the sample is 
placed in the center of the probe, the temperature can be adjusted using the 
command edte. 
 
? The super conducting magnets used in high resolution NMR are prone to drift. To 
compensate for this drift and hold the magnetic field in a stable position it is 
needed to lock the magnetic field using an internal standard which in this case is 
deuterium oxide (D2O). Typing the lock command displays a wide choice of 
internal standards, in our case we choose 90% H2O+10% D2O. Locking ensures 
temporal stability of the magnetic field. The lock power should be adjusted to 
maximum without saturation i.e. the increase in the signal must be linear with the 
increase of the power. The lock gain should be adjusted to maximize the lock 
signal. The lock phase is adjusted to obtain maximal signal at a given lock power 
and gain.  
 
? The probe has a resonant circuit for each observed and decoupled nucleus. So 
there is a circuit for 1H and for X, where X may be 15N, 13C, 19F, 31P. Each of 
these circuits is most sensitive at a particular frequency. Tuning is the process of 
adjusting the frequency until it coincides with the frequency of the pulses 
transmitted to the circuit. Matching is the process of adjusting the impedance 
(blockage/resistance) of the resonance circuit to the impedance of the resonance 
line connected to it. Thus at the start of each NMR experiment the frequency 
under observation which in this case is 1H, 15N and 13C should be tuned and 
matched using the command atmm (or atma for automatic tuning and matching). 
The order of tuning the frequencies is 15N, 13C and 1H. Practically on typing this 
command a curve is displayed on the screen, the minimum of the curve must be as 
low (matching) and as well as on the line (tuning) as possible.  
 
? The next step in setting up an NMR experiment is shimming to ensure 
homogeneity of the magnetic field. The sample is surrounded with a set of shim 
coils. Each shim coil is capable of producing a small magnetic field with a 
particular spatial orientation and this can be utilized to cancel out the 
inhomogeneities in the main magnetic fields. The shim coils are labelled x, y and 
z corresponding to the spatial direction of the respective magnetic fields they 
generate. The orientation of the main magnetic field is vertical in the z direction 
and the axial z shim coils modify the field profile along the axis of the main field. 
The radial coils are in the x and y directions. The shim settings control the current 
through the shim coils which in turn controls the magnetic field gradients in the 
different directions. Since the z direction is parallel to the direction of the probe, 
the height of the sample in the NMR tube affects the z shims dramatically. For 
practical purposes a sample height of 5cm was maintained in all experiments and 
shimming was performed using the command topshim. 
 
? Once the basic steps pertaining to all NMR experiments are performed the 
specific experiment (e.g. 1H-15N Heteronuclear Single Quantum Coherence 
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(HSQC), 1H-13C HSQC etc.) can be setup using the rpar command. This 
command provides a list of all the NMR experiments with a standard parameter 
set that is saved on the spectrometer. Note although an experiment is recalled 
from the manufacturer’s list several parameters need to be modified depending on 
the specific protein of interest as described below. 
 
? The proton offset is calibrated. The experiment without presaturation is phased to 
result in an absorptive signal. The offset is varied first in bigger than in smaller 
steps, until a minimum is reached. The experiment is started with command zg 
and processed with the command efp. This can also be achieved by acquiring in 
gs mode and making sure to get rid of high intensity slow component of the FID 
signal which is representative of water. 
 
? Next the 900 proton hard pulse p1 is calibrated. The p1 is adjusted to result in the 
smallest signal possible. This can also be performed using the command pulsecal.  
 
? The one dimensional (1D) experiment is selected from the set of NMR 
experiments. The getprosol command is performed with the determined proton 
hard pulse.  
 
? The receiver gain can be set automatically using the command rga. 
 
? The number of scans, spectral width, number of points to be collected in the 
indirect dimension, etc. need be determined based on the specific experiment and 
protein concentration of the sample. The experiment is started with the command 
zg. The FID is measured which is Fourier transformed using the command efp for 
a 1D experiment or xfb for a 2D experiment. 
2.5. Protein Structure Determination by Nuclear Magnetic Resonance 
2.5.1. Synopsis 
 
Proteins are macromolecules of biological importance. The monomeric unit of the 
protein polymer is defined as an amino acid. There are twenty different amino acids 
which combine in different permutation and combinations to form the protein 
macromolecule. The individual amino acids in the protein are chemically held together 
by a peptide bond giving rise to the primary structure of the protein. The polypeptide in 
turn adopts local secondary conformations such as ?- helices and ?-sheets stabilized by 
hydrogen bonds. The polypeptide chain with its secondary structure folds in space giving 
rise to the tertiary structure of the protein. The tertiary structure of the protein is crucial 
and governs the function of the protein. Proteins are biologically significant 
macromolecules and play an important role in health and disease. Therefore it is an 
absolute necessary to study protein structure and function.  
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The method of NMR spectroscopy can be utilized to determine the three 
dimensional (3D) structure of proteins. In NMR a series of 1D, 2D and 3D experiments 
are performed in order to collect resonance/frequency information of the individual 
nuclei which make up the amino acids which form the building block of the protein 
molecules. The recorded NMR spectrum is a conglomeration of the superimposition of 
the NMR spectrum of the individual amino acids. 
 
As stated earlier, the resonance frequency is converted to chemical shift data by 
referencing using an internal standard such as tetramethylsilane. The chemical shift 
measured by NMR is a reflection of the chemical environment of the nuclei. Some of the 
factors affecting the chemical shift of the nuclei are electron density and electronegativity 
of neighboring atoms. The chemical shift data need to be assigned to the specific nuclei 
within the molecular structure of the protein before any structural information can be 
obtained. The process of assigning each nuclear frequency within the molecular structure 
of the protein is known as NMR assignments and forms an important prerequisite for 
NMR based structure determination.  
 
Essentially protein structures are made of hydrogen, nitrogen and carbon atoms. 
The respective NMR detectable isotopes of these atoms are 1H, 15N and 13C. The natural 
abundance of 1H is 99.9%, 15N is 0.4% and 13C is 1.1%. The natural abundance of proton 
is sufficient to be detected by NMR but the natural abundance of 15N and 13C is low and 
therefore isotope labeling of the protein is required. Typically for the structure 
determination of small proteins or protein domains it is 15N and 13C labelled by 
expressing the protein in minimal media containing isotope labelled nutrients. For 
determining the structure of larger proteins the protein could be triple labelled (2H, 15N 
and 13C). 
 
For best results and spectral compliances the different NMR experiments are 
performed under the same conditions of temperature and buffer. Regularly the protein 
sample used for acquiring multi-dimensional spectra and subsequent structure calculation 
by NMR methods should have a concentration close to one millimolar; however due to 
the challenging protein expression and purification methods associated with the protein 
described in this dissertation, the protein concentration attained was one fourth of one 
millimolar. Invariably, longer acquisition times and the use of high magnetic field and 
cryogenic probes helped overcome the problems associated with lower protein 
concentrations.  
 
 
2.5.2. Nuclear Magnetic Resonance Experiments 
 
Routinely the first spectrum recorded on the protein is the 1D proton spectrum. In 
a 1D proton spectrum thousands of protons resonate in a narrow spectral region. These 
protons need to be assigned within the chemical structure of the protein before obtaining 
any structural information. NMR assignments are made by establishing connectivity 
between protons and on the basis of the chemical properties of the amino acids. 
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In the 2D NMR spectrum two frequency dimensions are measured that allow 
resonances to be separated on the basis of their connectivity through bonds and through 
space. For example the 2D Correlation Spectroscopy (COSY) establishes connections or 
correlations between protons connected by three chemical bonds within a particular 
amino acid and the Total Correlation Spectroscopy (TOCSY) establishes connection 
between three or more chemical bonds within a particular amino acid. The Nuclear 
Overhauser effect correlation spectroscopy (NOESY) type of experiments determines 
correlation between protons through space and not through bonds. The 2D NOESY 
experiment shows a signal if the internuclear distance between the participating proton 
atoms is less than 5 Å. These protons may or may not be from the same amino acid. 
Protons which are far apart in the primary structure of the protein may fold close to one 
another in the tertiary structure of the protein and thus give rise to NOESY signal.  
 
Each particular amino acid has a specific pattern in a COSY/TOCSY spectrum. 
Although the amino acid types can be identified in the correlation spectrums they cannot 
be assigned to specific amino acids within the protein sequence because the connectivity 
between the amino acids have not yet been established. The connectivity can be 
established using the 2D NOESY experiments. This methodology of homonuclear 
sequence specific resonance assignment is valuable for small proteins and when 15N and 
13C labelled protein is not available; however, this method is challenging for proteins of 
bigger size wherein the process of heteronuclear backbone assignment is performed. The 
protein structure determined in this dissertation has a molecular weight of approximately 
fifteen kilodaltons, was expressed in bacteria as an isotope (15N and 13C) labelled protein 
and the NMR backbone assignments were performed using the heteronuclear backbone 
assignment strategy using the software Computer Aided Resonance Assignment (CARA) 
and is described briefly in the sections below[131]. 
 
2.5.3. Heteronuclear Backbone Assignment 
 
For sequential assignment of the amide backbone a combination of 2D 1H -15N 
HSQC and 3D backbone assignment experiments such as HNCA, HNCACAB and 
CBCA(CO)NH were used. These experiments can be imagined as an extension of the 
COSY type of experiments wherein the correlations are established between different 
nuclei types. In the 2D 1H -15N HSQC experiment the correlation is established between 
the 1H and 15N nuclei. Amide proton resonances are well separated due to the dispersion 
by 15N chemical shifts. Each amide group within a protein contributes to a single 
resonance peak, except for proline. The amino groups of the asparagine and glutamine 
side chains give rise to paired resonances depicting the same nitrogen shift but different 
proton shift. Thus, in theory each amino acid except prolines in the protein should 
contribute to a peak in the 2D 1H -15N HSQC spectrum.  
 
The 3D NMR experiments are performed to completely assign the backbone of 
the protein. The 3D NMR experiments are built from 2D NMR experiments by 
introducing an additional measurement in the third dimension as explained in  
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Figure 2-4[132]. The 3D HNCA spectrum shows two peaks in the carbon (third) 
dimension for each amide peak representing an amino acid. The stronger peak represents 
the corresponding C? resonance and the weaker peak represents the C? resonance of the 
preceding residue. In the 3D HNCACB spectrum four peaks are observed. The stronger 
peak in phase represents the self C? resonance and weaker peak in phase represents the 
preceding C? resonance. The other two observable peaks are out of phase, the stronger 
one represents the corresponding C? resonance and the weaker one represents the C? 
resonance of the preceding amino acid. In the 3D CBCA(CO)NH spectrum two peaks are 
observed corresponding to the C? and C? resonances of the preceding amino acid.  
 
By comparing the spins in the different spectra the peaks or spins of the self-
resonances can be separated from the adjacent resonances.  Thus from the simultaneous 
use of multiple 3D backbone assignment experiments, for each amide peak in the 2D 1H-
15N HSQC spectrum the C? and C? of the self and the preceding amino acid can be 
identified and linked. Linking each amide peak to its predecessor helps in building a 
fragment. In theory the entire protein domain can be linked by this method from the N-
terminus to the C-terminus. But in real situations the positioning of the proline residues 
disrupts the process of continuous linking giving rise to smaller fragments. This fragment 
is then assigned to the unique stretch of amino acids in the primary sequence (which is 
already known) of the protein. The heteronuclear assignment strategy primarily relies on 
the fact that the amino acids have a characteristic C? and C? chemical shift distribution. 
Particularly some of the amino acids such as glycine, alanine, serine and threonine have 
unique C? and C? chemical shifts which can be identified without any additional 
information. These amino acids serve to anchor the assignment within the primary 
structure of the protein. The longer the size of the linked fragment the higher is the 
chances of securing it to a unique stretch of amino acids in the protein primary sequence. 
The method described above is the manual method of protein backbone assignment. The 
process of manual assignment is generally tedious and time consuming. 
 
The software CARA has an automated backbone assignment module described as 
‘Autolink’ incorporated in the software[131]. The automatic linking algorithm uses the 
chemical shift information of the self and the preceding residues to calculate a probable 
assignment. The algorithm functions to increase the number of the linked residues, 
considers the secondary structure and consequently scores the assignment[131]. The 
Autolink module is fairly accurate; however it is mandatory to verify all automated 
assignments. In this dissertation the process of automated and manual assignments were 
used in combination. The automated assignments were verified manually and the gaps 
left in the automated assignments were filled by the process of manual assignment. 
 
 
2.5.4. Amino Acid Side Chain Assignment Strategy
 
Each amino acid is characterized by a unique side chain. Some amino acids have 
a simple and short side chain such as alanine whereas others such as leucine and lysine 
are characterized by long side chains. 
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Figure 2-4. Visualizing three dimensional NMR spectrum and generation of strips.  
(A) The 2D 1H-15N HSQC spectrum. The x and the y axes are 1H and 15N respectively.
(B) and (C) The 2D 1H-15N HSQC spectrum is extended in the third dimension which is 
the 13C dimension. (D) and (E) The different planes of the 3D spectrum are represented. 
In this case the 1H dimension forms the x-axis, the 13C dimension forms the y-axis and 
the 15N dimension is in the z-plane. (F) and (G) Each represents a particular position in 
the 1H and 15N dimensions but spans the entire width of the 13C dimension. Thus each 
position generates a strip. (H) Each peak in the 1H-15N HSQC generates a strip 
encompassing the 13C dimension. Source: Higman P. Protein NMR. In. Bristol UK; 
November 2012. 
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The side chain protons include the likes of methyl protons and aromatic protons. 
Regularly side chain assignments are performed after the backbone assignment. Unlike 
the process of backbone assignment wherein automated assignments may be performed 
side chain assignments entirely rely on manual methods. Therefore the process of side 
chain assignments is exhausting and requires time and effort.  
 
In the 2D 1H-13C HSQC spectrum the correlation is established between the 1H 
and the 13C nuclei. Thus all the protons in the protein attached to a carbon atom in 
principle should be observed in the 2D 1H-13C spectrum. The goal of the side chain 
assignment is to attribute each peak to the corresponding side chain proton in the protein. 
The 3D HBHA(CBCACO)NH and the (H)CCH-TOCSY experiments together with the 
3D NOESY-HSQC experiments help in the assignment of the amino acid side chains. 
The 3D TOCSY provides correlation between all the methyl and methylene protons 
within a single amino acid. It is similar to the 2D-TOCSY as described earlier but is 
additionally resolved in the carbon dimension.  
 
On completion of the backbone and side chain resonance assignments an atom list 
can be generated. The atom list enlists each amino acid in the protein and summarizes 
each of its hydrogen, nitrogen and carbon chemical shift. 
 
 
2.5.5. Nuclear Overhauser Effect Correlation Spectroscopy Assignments and 
Distance Constraints 
 
As stated earlier the NOESY experiments establish correlations through space. 
When the nuclei of two protons are spatially close to one another chemical exchange 
takes place meaning the nucleus exchanges between two or more different environment 
conditions. The chemical exchange between the proximal protons gives rise to the NOE 
“cross peak” in all the NOESY experiments. The intensity of the NOE “cross peak” is 
inversely related to the distance between the two participating nuclei as shown in 
Equation 2-7. 
 
?? ?
??
        Equation 2-7 
 
Where V is the volume of the NOESY cross peak and d is the spatial distance 
between the two atoms. The NOE peak intensity is inversely proportional to the 6th power 
dependence of the distance; therefore the distances measured by NOE are always less 
than 5 Å. The regular secondary structures of ?-helices and ?-sheets give rise to regular 
NOE pattern which helps in confirming the secondary structure of the protein. The 
NOESY cross peaks are assigned based on the correlations which have been established 
through the orchestrated analysis of TOCSY and NOESY spectra. 
 
The intensity or the volumes of the NOESY cross peaks in a 15N resolved 1H-1H 
NOESY experiment is related to the distance between the participating protons. The 
NMR method of protein structure determination relies heavily on a dense network of 
such distance restraints. Some of the NOE peaks correspond to the protons within the 
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same amino acid; they are described as intra-residue NOEs. These residues do not 
provide important information regarding the protein secondary or tertiary structure. The 
other observable NOEs are for protons in different amino acids. These are described as 
inter-residue NOEs. The inter-residue NOEs in turn can be classified as sequential, 
medium or long range NOEs. The sequential NOEs are observed between the protons of 
the adjacent amino acids, the medium range NOEs are observed between protons of the 
amino acids which are less than equal to four amino acids apart. The sequential and 
medium range NOEs play a key role in defining the secondary structure of the protein. 
Alpha helices and ?-sheets give rise to characteristic NOE pattern defining the local 
structure of the protein. The long range NOEs are observed between protons of the amino 
acids that are far apart in the primary sequence, at least four amino acids apart. The long 
range inter-residue NOEs are crucial for defining the tertiary structure of the protein. 
Thousands of NOEs are typically required to resolve a protein structure by NMR 
methods. 
 
The practical challenge accompanied with this method is the associated 
degeneracy of the chemical shifts of some of the atoms. This means that some of the 
atoms may have the same chemical shift and thus the distance constraint measurements 
can become ambiguous. This can be controlled at least in part by the use of the 13C- 
NOESY experiments. In which case the 1H -1H cross peaks are now dispersed along the 
13C dimension reducing the chance of overlapping.  
 
The intensities or volumes of the NOE cross peaks (V) can be converted into 
upper distance limits by using the following formula as shown in Equation 2-8. 
 
? ? ?
??
       Equation 2-8 
 
Where V is the volume of the NOESY peak, c is the calibration constant and d is 
the spatial distance between the two atoms. The calibration constant c is initially 
determined from NOEs between protons at fixed distance. Thus on completion of the 
NOE assignments a constraint list is generated which contains the upper distance limits 
of spatially neighboring atom pairs. The lower limit of the distance restraints is provided 
by the van der Waals radius between the two protons. The variation of the distance 
between the two protons between the lower limit (van der Waals forces ~ 2Å) and the 
upper limit (obtained from the NOEs ~ 5Å) allows a relatively large conformational 
space for the participating protons to arrange themselves relative to one another. In the 
structure calculation software, CYANA, the module CALIBA utilizes this principle and 
converts NOE peak intensities to distance constraints[133]. The NOE assignments may 
be performed manually or using a software program. In this dissertation the NOE 
assignments were performed using the program UNIO[134]. UNIO requires the 15N and 
13C resolved 1H-1H NOESY spectrum and the chemical shift list as an input for the 
automated NOE assignment. The chemical shift assignment list should be at the least 
90% complete and the NOESY spectra should be calibrated to the proton list. As stated 
earlier all automated assignments were verified manually. 
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2.5.6. Structure Calculation and Refinement 
The method of NMR based structure calculation utilizes experimentally derived 
constraints such as the distance restraints generated from NOESY experiments and angle 
constraints that can be generated from the chemical shift assignments to generate a 
structure that agrees with all the constraints and maintains a global minimum energy. 
Software programs such as CYANA utilize this information to resolve the tertiary 
structure of biomolecules from NMR derived data[133]. 
 
The dihedral angle constraints are used as input for structure calculation using 
CYANA. The dihedral angle constraint can be calculated by using the program 
TALOS+[135]. The TALOS+ program utilizes the chemical shift assignments (H?, C?, 
C?, CO and N) and the protein primary sequence as an input. It then compares the 
chemical shifts against a database of chemical shifts associated with high resolution 
structures. Comparison is based on triplet sequence of amino acids present in the database 
of the chemical shifts associated with high resolution structures. The program then 
generates the potential backbone dihedral angle (phi (?) and psi (?)) constraints[135]. 
This method relies on the fact that the secondary chemical shifts are correlated to the 
protein secondary structure. The use of the torsion angle restraints greatly reduces the 
conformational space to sample.  
 
The software CYANA is based on the principle of simulated annealing molecular 
dynamics in torsion angle space[133]. In simple terms this means that the atoms are 
imitated to move under heating conditions and consequently cooled to a minimum energy 
level. During this process the only degrees of freedom of movement allowed is across the 
backbone torsion angles of the amino acids in the protein structure. In addition each of 
the generated structure should comply with the distance restraints that are used as an 
input for structure calculation.  
 
In this method the protein primary structure is folded such that the atoms fulfill 
the observed distance constraints. The program uses the same restraints to calculate a 
bunch of structures or conformers. Typically hundred conformers are generated and the 
twenty conformers with the lowest energy or target function are selected. As explained 
earlier, in NMR the distances between the protons cannot be determined definitively, 
what is obtained instead is a range for the distance defined by upper and lower limits. 
Consequently these restraints are utilized to calculate an ensemble of structures rather 
than one single structure.  
 
The initial structures are generated from a random conformation which is 
optimized by simulated annealing molecular dynamics in torsion angle space. Following 
this convention one hundred structures are generated. The quality of the structures 
generated can be assessed by monitoring some key factors. Firstly, the convergence rate 
between the generated structures should be high, i.e. the root mean square deviation 
between the structures should be minimum. Secondly, the number of distance restraints 
violated should be low. Thirdly, the final energy or the target function should be lowest. 
During the final stages of resolving the structure, the protein structures can be refined by 
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adding additional constraints such as hydrogen bonds constraints across the protein 
secondary structure and disulfide bond constraints if appropriate. The hydrogen bonds 
can be estimated by measuring slow exchanging amide protons in deuterium oxide. 
 
In reality NMR based structure calculation is an iterative process between NOE 
assignments and evaluation and structure calculation. The structure is considered final 
when each of the resonance peaks in the NMR spectrum has been attributed to the 
corresponding nuclei within the protein structure. The quality of the determined structure 
is directly dependent on the completeness and correctness of the resonance assignments. 
The root mean square deviation between the twenty structures with the lowest energy is 
less than an Angstrom and the energy of the structures have reached a global minimum. 
2.5.7. Structure Validation 
 
One of the important methods of validating the resolved protein structure is by 
contemplating the Ramachandran plot and was originally developed by G.N 
Ramachandran, C. Ramakrishnan, and V. Sasisekharan[136, 137]. In the protein 
backbone the main chain N-C? and C?-C bonds are relatively free to rotate. These bonds 
respectively form the phi and psi dihedral angles. The Ramachandran plot displays the 
backbone dihedral angle pairs (?,?) of the polypeptide chain in a given protein structure 
and is subdivided into primarily three regions and typically colour coded as red, yellow 
and white. Essentially the red region corresponds to the “highly favorable region” and 
encompasses the residues demonstrating no steric clashes. The yellow regions 
corresponds to the “additionally allowed region” and include the residues wherein the van 
der Waals radii are shorter than usual, this in turn allows the atoms to come close 
together but are still acceptable. The white disallowed region corresponds to 
conformations wherein the atoms in the polypeptide come closer than the sum of their 
van der Waals radii. This in turn would lead to steric clashes and are therefore disallowed 
for all amino acids except glycine because glycine does not possess a side chain. 
Needless to say that a well resolved structure should include maximum amino acids in the 
highly favorable region of the Ramachandran plot and theoretically none in the 
disallowed region[137].  
 
Thus the Ramachandran plot is an important tool for validating the protein 
structure. Steric hindrance from amino acid side chains allows only certain angles for a 
folded protein. Deviation from the allowed values are called outliers, if the 
Ramachandran plot depicts an outlier it is usually because of a wrong assignment and 
therefore can be corrected. An extremely small percentage of the amino acids may still 
have torsion angles in the disallowed region because they may form part of a flexible 
loop. In the present dissertation the Ramachandran plot was used during the final steps of 
structure calculation to correct wrong assignments and reduce violations and global 
energy. The main steps of protein structure determination by NMR are summarized in 
Figure 2-5. 
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Figure 2-5. Flowchart for NMR based protein structure determination.  
The major steps for determining the solution structure from NMR data are shown.
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2.6. Nuclear Magnetic Resonance as a Tool to Study Protein-ligand Interactions 
 
Apart from determining atomic resolution biomolecular structures, NMR being a 
powerful and sophisticated technique has widespread applications in scientific research, 
medicinal chemistry and pharmaceutical industry. The technique of NMR provides 
important information on biomolecular dynamics, protein folding, metabolite and 
chemical analysis and intermolecular interactions. In the pharmaceutical industry the 
technique of NMR is routinely used to support structure-based drug discovery[138]. 
NMR has also been employed to study drug intoxication[139]. In analytical chemistry 
NMR is used as a quality control technique for determining the purity of a sample. 
Interestingly NMR is also being used to profile commercial commodities like wine[140]. 
Amongst the various uses of NMR, in this dissertation NMR was widely used to study 
protein-ligand interactions and therefore will be discussed in detail.    
 
 
2.6.1. 1D Nuclear Magnetic Resonance Experiments to Screen and Identify Potential 
Ligands for Proteins 
Recurrently proteins interact with ligands of endogenous or synthetic origin and 
upon such interaction the structure of both the ligand as well as the protein are perturbed. 
The structural perturbations both on the ligand as well as the protein surface can be 
detected by NMR. The 1D proton spectrum of the ligand can be recorded in the absence 
and presence of an increasing concentration of the protein. Each peak in the 1D spectrum 
of the ligand corresponds to the protons of the ligand. The identity of each peak can be 
established by assigning the atoms of the ligand using the homonuclear assignment 
strategy. If the ligand interacts with the protein, the protons participating in the protein-
ligand interaction witnesses a change in the chemical environment. Therefore the peaks 
shift. The magnitude of the peak shift is dependent on the strength of the protein-ligand 
interaction. Thus, even a simple 1D NMR experiment can be used to obtain important 
information about protein-ligand interactions.  
 
Additional methods based on the principle of intermolecular NOE transfer are 
also used to detect protein-ligand interaction. If the protein-ligand interaction is 
undergoing fast exchange specific NMR methods based on the principle of transferred 
NOE can be used to study the behavior of the ligand in the protein-ligand complex. These 
experiments are described as saturation transfer difference (STD) NMR experiments and 
do not require isotope labeling of the protein or the ligand. A well separated protein 
signal is selectively irradiated with an RF pulse. The saturation then spreads to all the 
protons of the protein by spin diffusion. Intermolecular NOE transfers the saturation to 
the ligand protons at the binding interface[141]. This method is widely used to screen for 
drugs and identify a positive hit from a mixture through positive NOE signals. 
Additionally epitope mapping enables the identification of the part of the ligand that is in 
contact with the protein. The principle of the STD experiment is illustrated in  
Figure 2-6A. 
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Figure 2-6. Transferred NOE experiments to determine protein-ligand interactions.  
(A) The principal of the Saturation Transfer Difference (STD) NMR experiment (B) The 
principal of the Water LOGSY NMR experiment. 
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Water-Ligand Observation with Gradient Spectroscopy (Water-LOGSY) is a 
widely used NMR experiment for the detection of protein-ligand interaction. Like the 
STD experiments, Water-LOGSY experiments are also based on the principle of 
intermolecular NOE transfer. Magnetization is transferred via intermolecular NOEs and 
spin diffusion. In this case, the bulk water is irradiated selectively with the RF pulse. The 
magnetization transfers to other protons of the protein by NOEs and from the protein-
protons to the ligand-protons by spin diffusion. The NOE between the water and the 
protein have an opposite sign from the NOE between the water and the small molecules. 
The ligand concentration is twenty times higher than the protein concentration therefore 
the protein signals are not observed in this experiment. Positive and negative signals in 
the water-LOGSY experiments distinguish between the interacting and the non-
interacting molecules[142]. The principle of Water-LOGSY is explained in Figure 2-6B. 
In this dissertation the technique of Water-LOGSY was widely used to screen and 
identify small molecules that interact with the protein of interest. 
2.6.2. Chemical Shift Mapping to Determine the Ligand Binding Surface on the 
Protein
 
Chemical shift perturbation (CSP) mapping is a simple and unique technique to 
monitor protein-ligand interactions[143]. Regularly the unlabelled ligand is titrated to the 
15N-labelled protein and a 1H-15N HSQC is recorded at each titration point. In a 1H-15N 
HSQC spectrum each peak corresponds to an amide pair of the protein backbone. 
Following the technique of heteronuclear backbone assignment strategy as described 
above, each peak in the spectrum can be assigned to the specific amino acid of the 
protein[131]. If the ligand interacts with the protein, there will be a change in the 
chemical environment of the participating amino acid of the protein which will lead to a 
shift in the peak position in the 1H-15N HSQC spectrum. The shift of the peaks can be 
measured at each titration point, as the protein is titrated with an increasing concentration 
of the ligand. The peaks depicting the maximum CSP are likely to form the ligand 
binding surface of the protein. Thus if the backbone assignment and the tertiary structure 
of the protein are known, CSPs can be used to map the ligand binding surface on the 
protein. 
 
The CSP of each residue can be plotted against the concentration of the ligand to 
generate a titration curve. The titration curve can be fitted to obtain the dissociation 
constant, Kd. Thus the method of CSP is extremely useful and unique because using this 
method information about the binding surface of the protein as well as the binding 
affinity of the ligand can be obtained simultaneously[143]. Additionally the measurement 
of CSPs by NMR is generally fast. Typically for a sample of protein concentration of 
one-half of a millimolar NMR acquisition time is approximately 30 minutes. In the 
present dissertation for titration analysis with different ligands the concentration of the 
proteins varied widely, furthermore some of the ligands tested in the present dissertation 
were such that led to a drop in the intensity of the NMR signals. Therefore, the 
acquisition time for different CSP measurements in this dissertation varied widely 
ranging from 45 minutes to overnight measurements.   
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The experimental conditions during the CSP measurement should be kept 
constant. The external conditions of temperature and buffer should be maintained 
uniformly. Typically the same buffer is used is for the protein and the ligand. A small 
change in pH or salt concentration may alter protein signals and complicate analysis. 
Additionally if the ligand is soluble only in organic solvents such as dimethyl sulfoxide a 
control experiment should be performed with the solvent to rule out the solvent effect. 
 
2.6.3. Binding Kinetics to Determine the Dynamics of Protein-ligand Interaction 
 
In addition to determining the ligand-binding surface on the protein, NMR 
provides important information about the kinetics of binding. The protein-ligand 
interactions can be categorized as fast exchange, intermediate exchange or slow exchange 
in the NMR timescale as summarized in Figure 2-7. In case of weak binding, the ligand 
associates and dissociates from the protein rapidly in sub-milliseconds. The lifetime of 
the complex is short. This form of exchange is described as fast exchange. The protein 
exists in equilibrium between the free and the ligand-bound form. The peaks 
corresponding to the free form of the protein are distinct from the ligand bound form; 
however since the free and the ligand bound protein states are undergoing fast chemical 
exchange the peaks average and one single peak is observed at a position between the 
two component peaks. If the protein-ligand interaction is strong the ligand remains bound 
to the protein. The time taken for the ligand to dissociate from the protein is more than 
one second. Therefore two distinct peaks should be observed simultaneously in NMR. 
The ratio of the two states in equilibrium determines the ratio of the peak integral. This 
phenomenon is described as slow exchange in NMR and is suggestive of tight binding. 
Protein-ligand interactions with intermediate dissociation rate exhibit a broad peak at the 
average position and are described as intermediate exchange in the NMR timescale. In 
the present dissertation all the observed protein-ligand interactions can be described as 
fast exchange on the NMR time scale and are representative of weak binding. 
2.6.4. Dissociation Constant to Determine the Binding Affinity 
NMR can also be used to determine the binding affinity or the dissociation 
constant (Kd) of the protein-ligand complex. In case of weak binding or fast exchange, 
titration of the protein with an increasing concentration of the ligand generates a series of 
moving peaks until the peak reaches an ultimate point corresponding to saturation of the 
protein by the ligand[143]. The titration curve is generated by plotting the observed CSP 
against the ligand concentration as shown in Figure 2-8A. The CSP for each residue in 
the protein on interaction with the ligand can be calculated as shown in Equation 2-9. 
 
    Equation 2-9 
 
Where, ???is the composite chemical shift difference in parts per million (ppm),   
??H is the chemical shift difference in the proton dimension and ??N is the chemical 
shift difference in the nitrogen dimension. 
22 )5/()( NH ??? ?????
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Figure 2-7. Representation of the different binding kinetics.
The different binding kinetics of the protein-ligand interactions can be categorized as fast 
exchange, intermediate exchange or slow exchange in the NMR timescale. 
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Figure 2-8. Example of chemical shift perturbation plot. 
(A) In fast exchange the peak continues to move until saturation is reached on titration 
with higher concentrations of the ligand. (B) The composite chemical shift perturbation 
can be plotted against increasing ligand concentration to obtain the titration curve. The 
titration curve reaches a plateau as saturation is reached with higher concentrations of the 
ligand. The dissociation constant can be calculated from the titration curve by a nonlinear 
least-squares analysis. 
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The titration curve reaches a plateau as saturation is reached with higher 
concentrations of the ligand as shown in Figure 2-8B. The dissociation constant can be 
calculated from the titration curve by a nonlinear least-squares analysis using  
Equation 2-10. 
 
? ? ][2/]][[4)][]([)][]([ 2max PLPKPLKPL dd ????????? ??  Equation 2-10 
 
where [L] is the concentration of the ligand, [P] is the concentration of the protein, ???is 
the observed chemical shift change and ??max is the normalized chemical shift change at 
saturation. 
  
The Kd values determined by NMR are often received with scepticism because 
NMR derived Kd values are typically higher suggestive of weaker binding when 
compared to Kd values determined by other orthogonal methods such as Surface Plasmon 
Resonance (SPR) or Isothermal Calorimetry (ITC). The probable cause of the error in Kd 
measurements by NMR could be attributed to the averaging effect during NMR 
experiments. The Kd values determined by NMR are therefore treated as the upper limit 
of interaction. Nevertheless, the Kd values obtained for different ligands by NMR can be 
compared. The NMR methodology has an additional advantage when compared to other 
methods because using this method the specific residues involved in the protein-ligand 
interaction can be determined.  
2.6.5. Protein-ligand Complex Structure Determination by Nuclear Magnetic 
Resonance
The complex structure of the protein with its ligand which may be of 
physiological origin or may be a synthetic drug by far provides the maximum information 
about protein-ligand interaction. The interaction between the protein and the cognate 
ligand forms the basis of cellular signal transduction mechanisms. The complex structure 
of the ligand with the protein receptor provides a better understanding of the molecular 
details of signalling pathways. Furthermore, the ligand binding site on the receptors is 
frequently targeted for drug development to combat ectopic signalling associated with 
disease conditions. Therefore it is important to determine protein-ligand complex 
structures. The predominant method for determining the protein-ligand complex structure 
is X-ray crystallography; however sometimes it is challenging to attain the ideal 
crystallization conditions for the protein and the ligand especially if the interaction is 
weak. In such cases NMR provides an excellent alternative method for determining the 
complex structure of the protein and the ligand.  
 
There are two methods of complex structure determination by NMR. Firstly, the 
complete complex structure can be determined based on intermolecular NOEs between 
the protein and the ligand. For complete complex structure determination by NMR, 
measuring the intermolecular NOEs between the protein and the ligand is an important 
prerequisite. If the exchange is slow indicating strong interaction 15N/13C- filtered 
NOESY experiments are often used to measure the intermolecular NOEs. If the exchange 
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is fast suggesting weak interaction a transfer NOE experiment is used to measure the 
intermolecular NOEs. Additionally Residual Dipolar Coupling (RDC) experiments may 
be performed to determine the orientation of the ligand with respect to the protein[144]. 
 
Secondly, NMR constraints can be used to dock or model the ligand on the 
protein using software programs such as High Ambiguity Driven Biomolecular Docking 
(HADDOCK)[145]. HADDOCK uses mutagenesis as well as biophysical and 
biochemical data to model the structure of the ligand on the receptor protein. Prior to 
docking the structure of the individual components, i.e. the ligand and the receptor should 
be determined. Additionally there should be no major change in conformation upon 
protein- ligand interaction. The binding surface can be determined by the above described 
CSP strategy or by mutagenesis. The binding surface input information such as the CSPs 
are defined is as Ambiguous Interaction Restraints (AIRs) in HADDOCK. The binding 
surface residues can be categorized as active or passive residues. The active residues 
include the amino acids which depict the maximum CSP with a solvent accessibility 
greater than 50%. The passive residues include the other amino acids which depicted 
smaller CSP or are near the active residues with solvent accessibility greater than 50%. 
 
The software HADDOCK integrates the known structural information of the 
individual components with the binding surface information to generate the complex 
structure of the receptor and the ligand. In most docking protocols one of the binding 
partners is rotated or translated with respect to the other to generate different binding 
poses. Each pose is scored using an empirical scoring function. Empirical scoring 
functions use several terms such as polar interactions, hydrogen bonding, entropy and 
aromatic interactions which are critical for defining protein-ligand interactions. The 
problem associated with such docking protocols is that the conformational sampling 
space becomes very large with increase in the size of the target. The software 
HADDOCK proves to be advantageous over other docking protocols because along with 
the above described scoring function it also incorporates experimental binding 
information such as CSP data and mutagenesis data to maximize the efficiency and 
accuracy of docking[145].  
 
  
 46 
CHAPTER 3. NUCLEAR MAGNETIC RESONANCE ASSIGNMENTS AND 
SOLUTION STRUCTURE OF THE SMOOTHENED CYSTEINE RICH 
DOMAIN*
 
 
3.1. Introduction 
 
Smoothened is the signal transducer of the Hh pathway and is a canonical 
member of the FzD class of GPCRs[13-16, 62, 63]. Accordingly Smo retains seven 
membrane spanning helical domains linked through extracellular and intracellular loops. 
Despite the perpetual interest in the Smo receptor there was no structural evidence on this 
protein till last year. In 2013, the GPCR network elucidated the first crystal structure of 
the 7TM domains of Smo along with the conformation of the extra-cellular loops (ECL) 
and an extracellular linker domain (ECLD), both of which were demonstrated to be 
stabilized by disulfide bonds between conserved cysteine residues[64, 77]; however, the 
major portion of the Smo extracellular domain (ECD) is the cysteine rich domain (CRD), 
and this domain was not included in the reported crystal structure of the Smo receptor.  
 
The CRDs of the FzD family GPCRs possesses modest homology and the 
cysteines in this domain are conserved as shown in Figure 3-1[65, 146]. While the CRD 
of FzD plays an essential role in Wnt ligand binding and receptor dimerization, the role 
of the Smo CRD is not clear; however, it has been shown that the Smo CRD is 
indispensable for Hh signalling in Drosophila and required for high levels of signalling in 
vertebrates[65, 66, 80, 81]. Drosophila and vertebrate Smo lacking the CRD fail to cycle 
to the plasma membrane and primary cilium respectively to induce maximum 
signalling[80, 81]. Furthermore, in Drosophila CRD deletion mutants fail to dimerize, 
suggesting that the CRD may govern Smo dimerization[68].  
 
Based upon its functional importance, and the observation that the related FzD 
CRD binds to Wnt, it has been speculated that the Smo CRD may facilitate binding of an 
as yet unidentified endogenous small molecule that modulates Smo signalling activity in 
the presence of Hh[80]. To test this hypothesis and gain structural and functional 
understanding of this domain, we determined the structure of the Drosophila Smo CRD 
by solution NMR spectroscopy. Our findings show that Smo CRD is a structured domain 
predominated by alpha helical secondary structures stabilized by disulfide bonds and 
maintains the tertiary fold similar to the FzD CRD[147]. 
 
 
                                                 
 
*Chapter 3 adapted with permission. Rana R, Carroll CE, Lee H-J, Bao J, Marada S, 
Grace CRR, et al. Structural insights into the role of the Smoothened cysteine-rich 
domain in Hedgehog signalling. Nat Commun 2013,4. 
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Figure 3-1. Primary sequence alignment of Smo CRD. 
The primary sequence alignment of the Smo CRD and the FzD CRD. (D: Drosophila, H: 
human, M: mouse, C: chicken). The residues conserved in the Smo family are shown in 
blue whereas the residues colored in red are conserved both in the Smo and the FzD 
family. The purple lines indicate the disulfide bond pattern. The residues highlighted in 
yellow correspond to the “site 1” and the residues highlighted in green correspond to the 
“site 2” binding site in FzD-Wnt interaction. The secondary structure elements are 
represented above and below the primary sequence. 
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3.2. Experimental Procedures 
3.2.1. Vector Construction 
The Drosophila Smo CRD (V85-K202) was amplified from pET-SmoN[14]. The 
forward and the reverse primers used were 5’- ATA TAT CAT ATG GTC CGA CGT 
GCC CGT TGC- 3’ and 5’- ATA TAC TCG AGT TAT TTC GTC GGA AAG AGT G- 
3’ respectively. The PCR amplified product was cloned in pET-28a (+) and validated by 
nucleotide sequencing. The human Smo CRD (G65-G177) was amplified from the smo 
cDNA purchased from Origene. The forward and the reverse primers used were  5’-TAT 
ATC ATA TGG GCC GGG CTG CCC CCT GC -3’ and 5’- ATA TAT CTC GAG TTA 
GCC TTC AGG GAA GCG -3’ respectively. The PCR amplified product was cloned in 
pET-28a (+) and validated by nucleotide sequencing.  
3.2.2. Protein Expression and Purification 
For the expression of both the Drosophila and human recombinant protein 
pET28a-smoCRD was transformed into BL21 (DE3) cells. The cells were grown in 
MOPS (3-(N-morpholino) propane sulfonic acid) minimal media supplemented with 15N 
ammonium chloride (1gm/liter) and 13C glucose (2gm/liter) as the sole source of nitrogen 
and carbon respectively. The media was supplemented with vitamin (10ml/liter of 10X 
Kao) and kanamycin (0.03gm/liter).  
 
Cells were grown at 370C to an optical density (OD600) of 0.6 and expression was 
induced with 1mM IPTG (isopropyl ?-D-1-thiogalactopyranoside), followed by overnight 
culturing at 370C. Cells were resuspended in 20mM potassium phosphate, 500mM NaCl, 
1% triton, pH 7.8, and lysed by sonication on ice. The protein of interest accumulated in 
the bacterial inclusion bodies, which were solubilized in 8M Urea and 10mM ?-
mercaptoethanol. The denatured protein solution was added drop-wise in an aqueous 
solution containing 1.25M NaCl, 50mM Tris, 1mM GSH, 2mM GSSG, 0.015% CHAPS, 
1% glycerol, pH 9. Subsequently the diluted protein was concentrated using Amicon 
stirred cell concentrators and/or Pellicon XL devices (Millipore). 
 
The concentrated protein was dialyzed in 5% acetic acid (volume/volume) and 
purified by reverse phase HPLC using a C18 column (Hitachi) followed by further 
purification by gel filtration (AKTA) on a Hiload 16/60 Superdex 200 preparative grade 
column (GE Healthcare). For the purpose of biophysical characterization the protein was 
dialyzed in 10 mM acetic-acid buffer, pH 5. 
 
 
3.2.3. Circular Dichroism Spectroscopy 
To gain understanding of the secondary structure of the Drosophila and human 
Smo CRD we recorded their Circular Dichroism (CD) spectra. The protein samples were 
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prepared in 10mM acetic-acid buffer, pH 5. The CD spectra were measured scanning in 
the far-UV wavelength of 240-190nm at 250C with a 0.02cm path-length cell using an 
Aviv 62DS spectrometer (Aviv, Lakewood, NJ). A scan rate of 10nm/min was employed.  
3.2.4. NMR Spectroscopy 
A 250 ?M pure monomeric sample of the recombinant Drosophila (V85–K202)
or 200 ?M pure monomeric sample of the recombinant human (G65-G177) Smo CRD 
was prepared in 10 mM deuterated acetic-acid buffer and 10% deuterium-oxide 
(volume/volume) for NMR experiments. All spectra were recorded using either 1H, 15N 
labelled or 1H, 15N, and 13C labelled protein on Bruker Avance 800 MHz or 600 MHz 
NMR spectrometers equipped with 1H/15N /13C detect, triple resonance cryogenic probes 
at 25°C.  
 
All spectra were processed using Topspin (Bruker Biospin) 3.0 NMR software 
and analysed using the program, CARA[131]. The backbone chemical shift assignment 
were obtained using the standard triple- resonance assignment strategy using the 2D 1H-
15N HSQC and 3D HNCA, HNCACB, CBCA(CO)NH, HN(CA)CO and HNCO NMR 
experiments. The aliphatic side chain resonance assignments were obtained using 
HBHA(CBCACO)NH and (H)CCH-TOCSY. Distance constraints for the structure 
calculation were derived from 15N; 13C resolved 1H-1H NOESY with a mixing time of 
100 ms.  
3.3. Results and Discussion 
3.3.1. Circular Dichroism Spectra 
The CD spectra are widely used for the analysis of protein secondary structure. 
The shape, intensity and position of maxima and minima recorded for the Drosophila and 
human Smo CRD state that the Smo CRD fold is dominated by helices as shown in 
Figure 3-2.  
3.3.2. One Dimensional Proton NMR Spectra
The 1D-1H spectra of both Drosophila and human Smo CRD show that the 
proteins are folded. The 1D spectrum of the Drosophila Smo CRD is illustrated in Figure 
3-3. The peaks are sharp and narrow. They are well dispersed covering a large range of 
chemical shifts (-0.5-10 ppm). The amide region encompasses chemical shifts spreading 
across 4 ppm, suggestive of a folded protein. Peaks are observed far out near negative 
chemical shifts suggestive of methyl groups. All these features are characteristic of 
folded protein spectra. 
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Figure 3-2. The CD spectra of the Smo CRD.  
(A) The CD spectrum of the Drosophila Smo CRD at 250C in 10mM acetic-acid buffer, 
pH 5. (B) The CD spectrum of the human Smo CRD at 250 C in 10mM acetic-acid buffer, 
pH 5. 
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Figure 3-3. The 1D proton spectrum of Drosophila Smo CRD.  
The 1D proton spectrum of Smo CRD shows widespread signals in the amide region that 
is indicative of folded protein. The signals arising from the different chemical 
environment in the protein are labelled on the spectrum. 
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3.3.3. Two Dimensional 1H-15N and 1H-13C Heteronuclear Single Quantum 
Coherence Spectra and Nuclear Magnetic Resonance Assignments 
In the 2D 1H-15N HSQC experiment the correlation between each amide proton 
and the connected amide nitrogen atom is measured. Except for proline, each amino acid 
in the protein has one amide pair in the backbone, which in principal should be detected 
in a 2D 1H-15N HSQC experiment. Additionally the amide side chains of the asparagine 
and glutamine amino acids are also observed. The dispersion of the amide peaks for both 
the Drosophila and human Smo CRD in the 2D HSQC suggests that the Smo CRD is 
folded. The 2D 1H-15N HSQC spectrum of the Drosophila Smo CRD is shown in Figure
3-4A. 
 
Resonance assignments were performed using the standard triple resonance 
strategy for 13C, 15N labelled proteins[148]. In the 2D 1H-15N HSQC spectrums, all the 
amide resonances of the 118 residues of the Drosophila Smo CRD (V85-K202) could be 
observed except D116. D116 is in the loop region preceding the first helix and hence 
could be undergoing motions in the intermediate time scale resulting in peak broadening 
for the backbone amide; nevertheless, all the side chain resonances of this residue were 
observed. The atom assignments of the Drosophila Smo CRD are listed in Appendix A. 
In the 2D 1H-15N HSQC spectra of human Smo CRD (G65-G177), all the amide 
resonances of the 113 residues were assigned except two residues, L73 and R74. The 
atom assignments of the human Smo CRD are listed in Appendix B. 
 
In the 2D 1H-13C HSQC experiments the correlation between the aliphatic carbon 
and its attached proton is measured. The 2D 1H-13C HSQC spectrum of the Drosophila 
Smo CRD is shown in Figure 3-4B. Assigning the peaks in the 2D 1H-13C HSQC 
spectrum is also known as side chain assignment. Side chain assignments are a 
prerequisite for structure determination by NMR and were performed for the Drosophila 
Smo CRD. Approximately 94% of the peaks were assigned using HBHA(CBCACO)NH 
and (H)CCH-TOCSY NMR experiments. 
 
 
3.3.4. Nuclear Overhauser Effect Assignments Structure Calculation and 
Refinement
The NOE or the distance constraint experiments were performed once the 
backbone and side chain assignments were completed. The NOE restraints were derived 
from15N; 13C resolved 1H-1H NOESY with a mixing time of 100 ms. In the protein 
tertiary structure, due to protein folding, amino acids that may be far apart in the primary 
sequence are brought in close proximity. The NOE NMR experiments establish 
connectivity between two protons if they are within a distance of 5Å, irrespective of 
whether they are connected through bonds or just close together in space. The NOE 
experiments are very crucial for determining the 3D structure of the protein by NMR 
methods. An NOE strip plot for a helical domain of Drosophila Smo CRD encompassing 
residues N128-A132 is shown in Figure 3-5. The chemical structure of the representative 
amino acids with the detailed labelling of the atoms is shown in Figure 3-6.    
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Figure 3-4. The 2D spectra of the Drosophila Smo CRD.  
(A) The 1H-15N HSQC spectrum of the Drosophila Smo CRD. The wide dispersion of the 
amide peaks in the Smo CRD is suggestive that the purified protein is folded (B) The 1H-
13C HSQC spectrum of the Drosophila Smo CRD.
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Figure 3-5. The NOE strip plot representing helical region of Drosophila Smo CRD.  
The NOE strip plot was obtained from 15N resolved 1H-1H NOESY spectrum. The strip 
represents five amino acids encompassing residues N128-A132. The peaks corresponding 
to the self and neighboring amino acids are labelled. The unlabelled peaks correspond to 
long range NOEs. In the lower inset the sequential connectivity of the amide protons 
characteristic of a helical region is shown in black lines. 
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Figure 3-6. Chemical structure depicting the atoms in an amino acid. 
The structures of the amino acids represented in the NOE strip are illustrated.  
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An automated program UNIO was used for the NOE assignment and all these 
assignments were manually checked and modified[134]. Integrated NOE peaks were 
calibrated and converted to distance constraints using the program CALIBA[133]. The 
NOE restraints and 139 dihedral angle constraints were used as input for structure 
calculation using the program CYANA[133]. The dihedral angles were generated by the 
program TALOS+ which uses six kinds (HN, HA, CA, CB, CO, N) of chemical shift 
values for a given residue as input to give the ? and ? angles[135]. A total of 100 
conformers are initially generated and 20 conformers with the lowest energy are used to 
represent the 3-D NMR structure. Structure calculation using NMR methods is an 
iterative process. With the addition of an increasing number of correct NOEs, the root 
mean square deviation between the twenty structures with the lowest energy decreases as 
is shown in Figure 3-7. During the final structure calculation a total of 1421 meaningful 
NOE distance constraints were used. The structure was further refined by adding 22 
hydrogen bond constraints and 4 disulfide bond constraints. The stereoview of the 20 
structures with the lowest energy are shown in Figure 3-8. The ensemble of the final 
structures were checked and validated by PROCHECK. Structure figures for 
representation were generated using the software Pymol. 
 
 
3.3.5. Solution Structure of the Drosophila Smo CRD 
 
The determined solution structure of the Drosophila Smo CRD is of high 
precision. The statistical details for the NMR structure calculation are summarized in 
Table 3-1.The average pairwise root mean square deviation of the 20 structures from the 
lowest energy structure for the backbone and heavy atoms comprising the four helices 
(V85-E177) is 0.4Å and 1.28Å respectively. The NMR constraints, chemical shift data 
and the structure co-ordinates of the Drosophila Smo CRD have been deposited in the 
Protein Data Bank (PDB) and Research Collaborator for Structural Bioinformatics 
(RCSB) with accession codes 2MAH and RCSB103411 respectively.  
 
The structure has no distance violation greater than 0.03 Å and no angle violations 
greater than 1o. The Ramachandran plot of the calculated Smo CRD structure enlisted 
72.5% in the most favourable region, 25.7% in the additionally allowed region, 1.6% in 
the generously allowed region and 0.2% in the disallowed region. The residues in the 
disallowed region of the Ramachandran plot included a stretch of three amino acids 
serine, histidine and methionine, which are part of the histidine tag used to express the 
recombinant protein. The flexible histidine tag is positioned N-terminal to the Smo CRD 
and is not represented in any of the figures presented in this dissertation. 
 
The Smo CRD possesses a well-defined tertiary structure predominated by alpha 
helical secondary structures. The structure with the lowest energy is used to describe the 
secondary structure elements as shown in Figure 3-9A. The globular fold of the Smo 
CRD is predominated by four helical bundles (?1: E120-H135, ?2: C139-A142, ?3: 
F146-K154, ?4: S168-E177). The first helix is longest of the four helices, encompasses 
16 residues and accommodates bulky aromatic residues. The second helix is the shortest 
owing to the positioning of P145.  
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Figure 3-7. Structure refinement of the Drosophila Smo CRD. 
Structures of the Smo CRD at various stages of NOESY assignment, structure calculation 
and refinement. The root mean square deviation between the 20 structures decreases with 
an increasing number of correct NOE distance constraints. The side chains of the 
cysteines forming the disulfide bonds are shown in yellow in the final structure. Each 
structure is an ensemble of the 20 structures with the lowest energy.
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Figure 3-8. Solution structure of the Drosophila Smo CRD.
Stereo-view of the backbone atoms (N, C?, C’) of the ensemble of the 20 structures with 
the lowest energy. 
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Table 3-1. NMR and refinement statistics used for calculating the structure of 
Drosophila Smo CRD.  
 
NMR Distance and Dihedral Constraints Values
Distance Constraints  
    Total NOE                                                       1421 
    Intra-residue                                                      430 
    Inter-residue           
      Sequential (|i – j| = 1)                                      422 
      Medium-range (|i – j| < 4)                               248 
      Long-range (|i – j| > 5)                                    321 
Hydrogen Bonds                                                   22 
Total Dihedral Angle Restraints  
    ?                                                                        71 
    ?                                                                        68
Structure Statistics  
Violations (mean and s.d.)                    
Distance Constraints (Å)                           0.0176±0.0019 
Dihedral Angle Constraints (º)                   0.7607±0.0849 
Max. Dihedral Angle Violation (º)             0.9547±0.0849 
Max. Distance Constraint Violation (Å)    0.0238±0.0152 
Average Pairwise r.m.s. Deviation (Å)  
(Val85-Lys202)    
    Heavy                                                            
    Backbone                                                       
Average Pairwise r.m.s. Deviation (Å)  
 (Val85-Glu177)   
    Heavy                                                            
    Backbone                                                       
 
 
1.28±0.19 
0.7±0.15 
 
 
1.08±0.19 
0.4±0.15 
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Figure 3-9. Structure of the Drosophila Smo CRD and comparison with the mouse 
FzD8 CRD. 
(A) Ribbon representation of the Smo CRD. The alpha helices are labelled in order of 
their appearance in the primary structure. The disulfide bonds are indicated in yellow. (B)
Superimposition of the Smo CRD with the FzD CRD. The Smo CRD is represented in 
cyan and the FzD CRD is coloured red. The helices in both proteins are represented as 
cylinders and the beta strands are represented as arrowheads.
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The rigid backbone of the proline residue and the bulky hydrophobic side chain 
causes a break in the second helix. The third helix originates consecutive to P145 and 
includes 9 residues. The fourth helix is positioned between P167 and P178 and terminates 
in a 310 helix. Although the Smo CRD is predominantly helical, it includes short stretches 
of N-terminal anti-parallel beta strands. 
 
The Smo CRD contains eight conserved cysteines. NMR analysis depicted that 
the cysteine C-alpha chemical shifts and the cysteine C-beta chemical shifts are 
suggestive that all of the cysteines in the Smo CRD are oxidized[149]. The eight 
conserved cysteines form four disulfide bonds. The cysteine disulfide bond pairs were 
determined based on intermolecular NOEs observed between the ?-protons of the 
cysteine residues and is as follows: C90-C155, C100-C148, C139-C179 and C172-C194. 
In addition to the eight conserved cysteines in the Smo CRD, the Smo extracellular 
domain contains five additional cysteines at Drosophila positions 84, 203, 218, 238, 242. 
In the 3D structure of the Drosophila Smo CRD the N- and C- termini are in close 
proximity, implying that C84 and C203 may form a disulfide bond. C218, 238 and 242 
are predicted to be present in the ECLD connecting the Smo CRD to the first 
transmembrane domain. The cysteines in the Smo CRD play an important role in 
stabilizing the tertiary structure of this domain. 
 
3.4. Discussion 
The structure of the Smo CRD is predominated by alpha helices with distant 
relationship to the four-helix bundle. The tertiary structure of the Drosophila Smo CRD 
is similar to the tertiary structure of the FzD8 CRD as shown in Figure 3-9B[65, 66]. 
Despite a minimal similarity in the primary sequence the cysteines in the FzD and Smo 
CRD are conserved except for C107 in the FzD CRD, which is not conserved in the Smo 
CRD. The C107 in the FzD8 CRD forms a disulfide bond with C148[65, 66]. This 
represents the fifth disulfide bond in the FzD receptors, which is different in case of the 
Smo receptors. The FzD CRD contains ten conserved cysteines, which form five 
disulfide bonds[65, 66]. The Drosophila Smo CRD structure determined in this 
dissertation includes eight conserved cysteines, which form four disulfide bonds. The 
four disulfide bonds of Smo CRD determined here are also conserved in the FzD 
CRD[65, 66]. Drosophila C84 and C203 are located respectively at the N- and C-
terminus of the structure determined in this study and may form a disulfide bond. Thus 
the CRDs of both the Smo and the FzD receptors may be stabilized by five disulfide 
bonds stabilizing the CRD to form the tight bundle of four helices. 
 
Recently, the structure of the zebrafish Smo CRD was determined by 
crystallographic methods[150]. The construct (V29-Y212) used in the zebrafish study 
included all the thirteen cysteines present in the Smo ectodomain. The first ten cysteines 
form the canonical CRD and the last three cysteines form part of the extracellular linker 
connecting the extracellular domain structures and the first transmembrane domain. 
Although the zebrafish construct included all thirteen extracellular cysteine residues, the 
electron density was observed for the region including the ten cysteine residues 
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encompassing residues F41-Q158[150]. The structure of the human Smo extracellular 
linker was elucidated in an independent study focussing on the human Smo 7TM 
domains[64]. This structure showed that the first two cysteines of the linker form a 
disulfide bond and the last cysteine of the linker forms a disulfide bond with a cysteine in 
the ECL1 stabilizing the extracellular structures in proximity to the 7TM structures[64]. 
The tertiary structure of the determined Drosophila Smo CRD and the zebrafish Smo 
CRD is similar and the root mean square deviation between the two structures is 2.04 Å. 
The four disulfide bonds of the Drosophila Smo CRD are conserved in the zebrafish Smo 
CRD[150]. Additionally a fifth disulfide bond is formed by a conserved N-and C-
terminal cysteine residue[150]. 
 
Thus the structure of the CRD has been conserved both in the FzD and Smo 
receptors and also across vertebrates (zebrafish Smo) and invertebrates (Drosophila 
Smo), suggesting that this domain may play an important evolutionarily conserved role. 
Given the fact that the FzD CRD plays a role in ligand binding we evaluated the ligand 
binding properties of the Smo CRD as described in the subsequent chapters.  
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CHAPTER 4. GLUCOCORTICOIDS MODULATE HEDGEHOG 
SIGNALLING†
 
 
4.1. Introduction 
 
Glucocorticoids function as steroid hormones and are characterized by the 
classical steroid structure of four cycloalkane rings attached to each other[151]. The 
glucocorticoid nomenclature is derived from “glucose + cortex + steroids” because these 
groups of organic molecules play an important role in ‘glucose’ metabolism; are 
synthesized in the ‘adrenal cortex’ and retain the structure of the ‘steroids’[152]. 
Glucocorticoids are known to function by binding to the glucocorticoid receptor and play 
an important role in regulating immune response, metabolism, cell growth and 
proliferation, development and reproduction[153]. The anti-inflammatory properties of 
the glucocorticoids have led to their widespread use as therapeutics[154]. Glucocorticoids 
have also been used in the treatment of cancer mainly to combat the cancer-associated 
inflammation.  
 
Recent reports have identified a variety of glucocorticoids which regulate Hh 
signalling by acting at the level of the Smo receptor[93]. The identified glucocorticoids 
were categorized as activatory or inhibitory glucocorticoids depending on their effect on 
Smo sub-cellular localization and transcription of Hh target genes. The activatory 
glucocorticoids such as fluocinolone acetonide (FA) and triamcinolone acetonide (TA) 
facilitated Smo ciliary translocation and increased downstream Hh signalling[93]. In 
contrast the inhibitory glucocorticoids such as Budesonide (Bud) and ciclesonide (Cic) 
inhibited Smo ciliary translocation and suppressed downstream Hh signalling[93]. 
Additionally, the inhibitory glucocorticoids acted on wild-type as well as Smo mutants: 
SmoM2 and SmoD473H[93]. SmoM2 is a constitutively active form of Smo, first 
identified in BCC patients and is resistant to treatment with available Smo 
antagonists[74]. The D473H Smo mutant was identified in a MB patient being treated 
with the Smo antagonist GDC-0449 and was associated with tumor recurrence[97]. 
Furthermore, the inhibitory glucocorticoids were shown to modulate Smo function by 
binding to a site distinct from the orthosteric site present in the cavity of the 7TM core, 
previously demonstrated to bind the inhibitory small molecule cyclopamine[84, 85, 93]. 
 
In accordance we hypothesized that the Smo extracellular CRD may act as an 
allosteric binding site for glucocorticoids like Bud and additional Smo modulators. To 
test this hypothesis we analyzed the interaction between the glucocorticoid Bud and the 
Drosophila and human Smo CRD by NMR CSP experiments [143, 155]. Our results 
demonstrate that Bud binds to both Drosophila and human Smo CRD, albeit with 
different binding affinities[147].  
                                                 
 
† Chapter 4 adapted with permission. Rana R, Carroll CE, Lee H-J, Bao J, Marada S, 
Grace CRR, et al. Structural insights into the role of the Smoothened cysteine-rich 
domain in Hedgehog signalling. Nat Commun 2013,4. 
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Furthermore, we generated the modelled structure of Drosophila Smo CRD in 
complex with the inhibitory glucocorticoid Bud, which showed that Bud docks in a 
conserved hydrophobic pocket in Smo CRD. 
 
4.2. Experimental Procedures 
4.2.1. Protein Expression and Purification 
15N labelled Drosophila and human Smo CRD was expressed and purified as 
described in section 3.2.2. 
4.2.2. Nuclear Magnetic Resonance Chemical Shift Perturbation Analysis 
 
Chemical shift perturbation experiments were carried out using 15N labelled 
Drosophila or human Smo CRD prepared in 10 mM deuterated acetic-acid buffer and 
10% deuterium-oxide (volume/volume). 1H-15N HSQC spectra of the Smo CRD were 
recorded in the absence and presence of an increasing concentration of the glucocorticoid 
Bud at 250C using Bruker Avance 600 MHz spectrometer equipped with 1H/15N /13C 
detect, TCI triple resonance cryogenic probes. All data were processed using Topspin 
(Bruker Biospin) 3.0 NMR software and analysed using the program CARA[131] . 
 
A stock solution of 50 mM Bud (Sigma) was made in deuterated dimethyl 
sulfoxide for use in NMR titration experiments. The concentration of dimethyl sulfoxide 
in the NMR titration experiment was maintained at or below 1%. A control experiment 
was performed by titrating 1% dimethyl sulfoxide to Drosophila Smo CRD and no CSPs 
were observed. 
The dissociation constant (Kd) values were calculated by a nonlinear least-squares 
analysis in the program Origin, using the Equation 4-1 
 
? ? ][2/]][[4)][]([)][]([ 2max PLPKPLKPL dd ????????? ??   Equation 4-1 
 
where [L] is the concentration of the glucocorticoid ligand, [P] is the concentration of the 
protein, ?? is the observed chemical shift change and ??max is the normalized chemical 
shift change at saturation, calculated using Equation 4-2 
 
      Equation 4-2 
 
Where, ?? is the chemical shift in p.p.m. 
 
 
22 )5/()( NH ??? ?????
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4.2.3. Structural Modelling of Drosophila Smoothened Cysteine Rich Domain in 
Complex with Budesonide 
The complex structure of the Drosophila Smo CRD and Bud was generated using 
the software High Ambiguity Driven protein-protein Docking (HADDOCK)[145]. The 
simulated annealing protocol in the program CNS was used to calculate the complex 
structure of the protein and the small molecule[145]. Topology and parameter files for 
Bud were generated using xplo2d and the charge parameters of Bud were calculated by 
using the antechamber module in the AMBER10 software package[156]. We used 
ambiguous restraints resulting from the CSPs of 1H-15N Smo CRD on titration with Bud 
as input for the program  HADDOCK[145]. To define the active and passive residues, the 
relative accessible surface area was calculated by the program NACCESS[157]. One 
thousand initial structures of the Drosophila Smo CRD in complex with Bud were 
generated. The structure with the lowest energy was selected and this was consistent with 
the CSPs observed in Smo CRD on titration with Bud. 
 
 
4.2.4. Bio-Layer Interferometry Assay 
 
The Bio-Layer Interferometry (BLI) assay (Octet RED instrument from FortéBio) 
was used to measure the interactions of the Drosophila and human Smo CRD with the 
glucocorticoid Bud. The purified protein was prepared in 0.1 M potassium phosphate 
buffer, pH 6.5 and was subsequently biotinylated. For the process of biotinylation 100 μl 
of 0.2 mM Smo CRD was incubated with 200 μl of 1.0 mg/ml EZ-Link NHS-LC-Biotin 
(Thermo Sci.) for 15 hours on a rocking platform at room temperature. Excess unreacted 
biotin was removed by dialysis in 0.1 M potassium phosphate buffer pH 6.5.  
 
Super streptavidin (SSA) sensors were used to immobilize the biotinylated target 
protein on the optical sensors. Prior to the start of the assay the SSA sensors were pre-wet 
in 0.1M potassium phosphate buffer pH 6.5 with 0.01 % Trion-X100 for 10 minutes. For 
the binding affinity assay 3-5 μM biotinylated protein was immobilized on the SSA 
sensor by incubating for 30 minutes. Subsequently the free streptavidin sites were 
quenched by incubating with 0.5 mM biocytin (Thermo Sci.) for 10 minutes. Excess 
protein and biocytin were removed by washing with 0.1M potassium phosphate, pH 6.5 
for 10 minutes.  
 
To determine the binding affinity of the Drosophila and the human Smo CRD for 
Bud, kinetic experiments were carried out using three different concentrations of Bud 
(62, 41, and 31 ?M). The association step for 50s was followed by the dissociation step 
for 100s. The assay buffer used was 0.1 M potassium phosphate, pH 6.5 with 0.5% 
dimethyl sulfoxide. Biocytin-loaded SSA sensor without loading biotinylated protein was 
used as a control to correct the systematic optical artefacts and baseline drifts. All steps 
were performed at 30 0C with 1000 rpm rotary shaking. The processed data were fitted 
locally with the integrated fitting function using the 1:1 binding model in FortéBio 
analysis software. The Kd values were calculated from curve fitting. 
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4.2.5. Cell-based Luciferase Reporter Assays 
 
Cell-based Hh activity reporter assays were performed in mammalian Shh Light II 
cells[83, 86]. Shh Light II cells are derived from NIH-3T3 cells and co-transfected with 
Gli-responsive firefly luciferase reporter[58]. The stable clonal cell line was selected 
using the aminoglycoside antibiotic Geneticin (G418). The resulting cell line was 
transfected with pRL-TK constitutive Renilla-luciferase expression vector (Promega) and 
pVgRXR vector (Invitrogen) which codes for the ecdysone receptor and the glycopeptide 
antibiotic Zeocin resistance marker. Antibiotic resistance and cell cloning was used to 
generate Shh Light II cells. Presently the Shh Light 2 cell lines have been patented and 
we received the cells as a generous gift from the Ogden lab at St. Jude Children’s 
Research Hospital.  
 
For treatment with the drug Bud, Shh Light II cells were cultured to confluency in 
a 96-well plate and then treated with various concentrations of Bud in DMEM containing 
0.5% (volume/volume) bovine calf serum. Bud was added to cellular media from 
concentrated stocks in dimethyl sulfoxide. After 48 hours, renilla and firefly luciferase 
levels were measured using Dual Luciferase Reporter Assay kit (Promega). Hh pathway 
activity was expressed as the ratio of firefly to renilla luciferase. 
 
Experiments were performed three times in duplicate and error bars represent the 
standard error of the mean. 
 
4.3. Results and Discussion 
4.3.1. Drosophila Smo CRD Binds to the Synthetic Glucocorticoid Budesonide 
Glucocorticoids have been reported to play a role in regulating Smo ciliary 
localization and downstream Hh signalling[93]. Budesonide has been described to 
function as an inhibitory glucocorticoid and stated to bind to a site different from the 
canonical binding site in the cavity of the Smo 7TM domains[93]. Therefore, we decided 
to test whether the Drosophila Smo CRD might bind to Bud. We used NMR CSPs to 
identify the residues that are involved in binding since this method allows us to determine 
precisely the amino acid residues involved in the interaction[143, 155]. 
 
 In the 2D 1H-15N HSQC spectra of the Drosophila Smo CRD in the absence and 
presence of an increasing concentration of the ligand Bud, CSPs induced by the binding 
of Bud were clearly observed indicating Bud bound to the CRD as shown in           
Figure 4-1A. The normalized maximum CSP for each residue of Drosophila Smo CRD 
in the presence of Bud is shown in Figure 4-1B. The interaction between the Smo CRD 
and Bud are guided by three phenylalanine residues, F188 depicted the maximum CSP, 
followed by F187. Although F191 demonstrated a smaller CSP when compared to F187 
and F188 the CSPs on F191 were saturated on titration with an increasing concentration 
of Bud indicating tighter binding affinity.  
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Figure 4-1. The Drosophila Smo CRD binds to the inhibitory glucocorticoid Bud.
(A) 1H-15N HSQC spectra depicting CSPs of Smo CRD on titration with an increasing 
concentration of the ligand Bud. The chemical structure of Bud is shown above the 
spectra. (B) The normalized maximum CSPs of Smo CRD upon addition of Bud are 
plotted versus residue numbers. The red line indicates CSPs greater than 0.01 ppm. The 
residues labelled in black form the Bud-binding pocket on Smo CRD as analyzed from 
the HADDOCK docking experiments. The mouse FzD8-Wnt interacting “site 1” and 
“site 2” residues are shown in orange and green respectively.  The corresponding 
secondary structure elements of the Drosophila Smo CRD are represented below the plot. 
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Phenylalanine 191 is conserved in the vertebrate Smo family and F188 is 
substituted by a tryptophan residue in the vertebrate Smo. The conservation of the Bud 
binding residues in the Smo family suggests that this pocket may have an important role 
in binding an as yet unidentified allosteric regulator of Drosophila Smo. 
 
4.3.2. High Ambiguity Driven Biomolecular Docking of the Drosophila Smoothened 
Cysteine Rich Domain in Complex with Budesonide 
The inhibitory glucocorticoid Bud binds in a hydrophobic pocket in the Smo 
CRD, however the details of the interaction remain obscure without a complex structure. 
We have solved the NMR solution structure of the Drosophila Smo CRD and precisely 
mapped the binding site of the glucocorticoid by NMR CSP titration data. Next we 
wanted to determine the structure of the Smo CRD in complex with Bud. Budesonide is a 
hydrophobic molecule and has limited solubility in an aqueous buffer. Therefore Bud 
cannot be added in excess amounts to the Smo CRD protein solution. This makes it 
difficult to obtain unambiguous distance restraints from NMR NOESY experiments 
required to determine the complex structure by NMR. Therefore we generated the 
complex structure of Smo CRD with Bud using the program HADDOCK[158] . 
 
The CSPs induced in Smo CRD on titration with Bud were used as input for 
complex structure calculation using HADDOCK[145]. The residues that have significant 
CSPs are further shown in the back-bone “ribbon” representation of the Smo CRD, 
wherein the thickness of the ribbon is proportional to the magnitude of CSP observed in 
Smo CRD on Bud binding. The backbone “ribbon” representation of Smo CRD along 
with the positioning of Bud is shown in Figure 4-2A. The results show that the residues 
of Smo CRD that have the largest CSPs induced by the bound Bud are located in the first 
helix and the C-terminal 310 helical domain. 
 
The CSP data on the Drosophila Smo CRD were used as ambiguous restraints for 
modelling the structure of the protein-ligand complex. The active residues included the 
amino acids which depicted the maximum CSP with a solvent accessibility greater than 
50%. The passive residues include the other amino acids which depicted smaller CSPs 
and are near the active residues with solvent accessibility greater than 50%. One thousand 
binding poses were generated and the structure with the lowest energy in agreement with 
the CSP data was selected for representation. The surface of the binding pocket is shown 
in Figure 4-2B. The modelled structure showed that Bud docks into a hydrophobic 
pocket formed by the residues A132, H135, F187, F188 and F191 on the Smo CRD. The 
aromatic steroid rings of Bud interact with the aromatic phenylalanine rings on Smo CRD 
as shown in Figure 4-2C. The aliphatic carbon chain on Bud interacts with H135 and the 
aliphatic carbon chain of Bud with a free hydroxyl group interacts with A132. Thus Bud 
docks in the groove formed by the third and fourth helix and the 310 helical domains as it 
folds back on the fourth helix. The details of the input and output parameters for 
HADDOCK determined Drosophila Smo CRD-Bud complex structure determination are 
summarized in Table 4-1. 
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Figure 4-2. The complex structure of Drosophila Smo CRD and the glucocorticoid 
Bud.  
(A) “Ribbon” representation of the Smo CRD. The backbone thickness of the ribbon is 
directly proportional to the weighted sum (in ppm) of the 1H and 15N CSPs upon binding 
to the ligand Bud. (B) Surface representation of the residues that interact with Bud. The 
aromatic residues are shown in yellow and the positively charged H135 is shown in blue. 
(C) The aromatic side chains of the Bud contacting Smo CRD residues are shown.   
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Table 4-1. The HADDOCK input and output parameters for docking Bud on 
Drosophila Smo CRD. 
 
Parameters Residue Number 
Active Residues D129, A132, F187, F188 and F191 
Passive Residues Y131, K134, K138, N184 and T186 
Fully Flexible Region F187-L192 
Binding Energy -2694 ± 37 kcal/mol 
Buried Surface Area 575 ± 13 Å2 
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4.3.3. Human Smoothened Cysteine Rich Domain Binds to the Synthetic 
Glucocorticoid Budesonide
The effect of glucocorticoids on Smo subcellular localization and subsequential 
Hh signalling has been studied in vertebrates[93]. In the vertebrate system it has been 
stated that Bud binds to Smo at a site distinct from the cavity located in the Smo 7TM 
domains[93]. Therefore we tested the binding of Bud to human Smo CRD. 
 
The NMR titration experiments were performed to determine the specific residues 
involved in ligand binding. The 2D 1H-15N HSQC spectra of human Smo CRD in the 
absence and presence of an increasing concentration of Bud showed that Bud binds to 
human Smo CRD as shown in Figure 4-3A. The normalized CSP for each residue of 
human Smo CRD in the presence of Bud is shown in Figure 4-3B.  Comparing with 
Drosophila Smo CRD, Bud binds to human CRD in a similar region; however, there are 
some clear differences.  For example, a smaller number of residues in human Smo CRD 
had CSPs induced by the binding of Bud, and the absolute values of CSPs observed in 
human Smo CRD are smaller. Furthermore, the CSP observed at the first point of titration 
is more than those observed at subsequent points of titration suggesting that at higher 
concentrations of Bud the interaction between the human Smo CRD and Bud is saturated.  
 
The secondary and tertiary structure of the human Smo CRD can be predicted 
based on the structure of the Drosophila Smo CRD. Accordingly most of the observed 
CSPs localized in the flexible C-terminal loop. Arginine 161 demonstrated the maximum 
CSP. Some of the other residues depicting CSPs in the flexible C-terminus included 
E158, R159, G162 and W163.The other vicinity depicting distinct CSPs clustered in the 
region corresponding to the first helix encompassing residues L108, W109, G111 and 
L112. Although the two regions demonstrating CSPs are located faraway in the primary 
sequence of the protein, based on the structure of the Drosophila Smo CRD these regions 
should be held in close proximity in the tertiary structure of the protein. 
4.3.4. Binding Affinity of the Glucocorticoid Budesonide for Smoothened Cysteine 
Rich Domain 
The binding affinity of the glucocorticoid Bud for Drosophila and human Smo 
CRD was determined from NMR titration plots and BLI experiments. The residues which 
manifested the maximum CSPs on titration with Bud and formed the hydrophobic 
binding surface as inferred from HADDOCK modelling studies were selected to 
determine the binding affinity or Kd from NMR titration experiments. Namely the 
residues included were: F187, F188, F191, L127 and A132 as reported in Figure 4-4 and 
Figure 4-5. The binding affinities of each of these residues were calculated and are 
mentioned in the figures. The binding affinity of the Drosophila Smo CRD for Bud 
determined from NMR experiments ranged from lower hundred to thousand micromolar, 
indicating that Bud binding induced backbone conformational stabilization in Drosophila 
CRD[143].  
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Figure 4-3. The human Smo CRD binds to the inhibitory glucocorticoid Bud.  
(A) 1H-15N HSQC spectra depicting CSPs of human Smo CRD on titration with an 
increasing concentration of the ligand Bud. The chemical structure of Bud is shown 
above the spectra. (B) CSPs of human Smo CRD upon addition of Bud are plotted versus 
residue numbers. Dotted red line indicates CSPs greater than 0.01 ppm. Leucine 108, 
W109, G111, L112 and R161 are homologous to the mouse Smo residues that interact 
with 20-OHC. Glycine 162 is homologous to Drosophila F187 and W163 is homologous 
to Drosophila Smo F188 that interacts with Bud. All these residues map to the “site 1” of 
mouse FzD8-Wnt interaction. “Site 1” and “site 2” residues of mouse FzD8-Wnt 
interaction are shown in orange and green respectively. The secondary structure elements 
as in Drosophila Smo CRD structure are shown below the plot. 
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Figure 4-4. Binding affinity measurement of Drosophila Smo CRD and Bud for 
residues F187, F188 and F191.
Enlarged 1H-15N HSQC spectra of F187, F188, and F191 during the titration of 
Drosophila Smo CRD and the ligand Bud. The spectra are colour coded according to the 
protein: Bud ratio. The chemical shift change is plotted against the concentration of Bud 
and the corresponding Kd values are shown.
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Figure 4-5. Binding affinity measurement of Drosophila Smo CRD and Bud for 
residues L127 and A132.  
Enlarged 1H-15N HSQC spectra of L127 and A132 during the titration of Drosophila Smo 
CRD and the ligand Bud. The spectra are colour coded according to the protein: Bud 
ratio. The chemical shift change is plotted against the concentration of Bud and the 
corresponding Kd values are shown. 
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For determining the NMR based binding affinity of Bud for human Smo CRD the 
residues included were W109, L112 and R161. The binding affinities measured from 
these residues in human Smo CRD clustered around 45 μM as shown in Figure 4-6. 
Judged from NMR titration data, it appeared that Bud binds to human Smo CRD with 
higher affinity.  
 
Although NMR is a useful method for determining specific protein-ligand 
interactions in solution, it is not the ideal method for calculating binding affinity[159, 
160].The associated systemic error in calculating Kd values from NMR is likely caused 
by the averaging effect during NMR experiments[159]. The Kd values calculated by this 
method can only be treated as the upper limit for interaction. Therefore we validated the 
binding affinity measurements using additional BLI experiments. 
 
We determined the binding affinity of Bud for Drosophila Smo CRD using BLI 
methods. Three different concentrations of Bud were tested: 62, 41 and 31μM and the Kd 
values were determined for each concentration with the integrated fitting function by a 
1:1 binding model. The 62 μM concentration of Bud was repeated once, whereas the 41 
μM concentration of Bud was repeated thrice and the 31 μM concentration of Bud was 
repeated twice. The Kd value obtained by curve fitting at 62 μM Bud was 89 μM. The Kd 
values obtained for three different repeats at 41 μM Bud were 74 μM, 59 μM and 318 
μM. The Kd values obtained for the two different repeats at 31 μM Bud were 93 μM and 
85 μM. Thus the average Kd value of Drosophila Smo CRD for Bud was calculated to be 
120 ± 98 μM as reported in Figure 4-7. 
 
To determine the binding affinity of Bud for human Smo CRD three different 
concentration of Bud were tested 62, 41 and 31μM. The respective Kd values obtained by 
curve fitting were 74 μM (62 μM Bud), 37 μM (41 μM Bud), 44 μM (41 μM Bud,) and 
54 μM (31 μM Bud). The average Kd value of human Smo CRD for Bud was 52 ± 16 μM 
as noted in Figure 4-7. Both NMR and BLI data suggest that Bud binds to human Smo 
CRD with a higher affinity than Drosophila Smo CRD. 
 
 
4.3.5. Effect of Budesonide on in-vitro Hh Signalling 
 
Budesonide has been described to function as a negative regulator of Smo ciliary 
localization and downstream Hh signalling[93]. To reinvestigate the effect of the 
glucocorticoid Bud on in-vitro Hh signalling we performed cell-based luciferase assays. 
To determine whether Bud would attenuate signalling by the Smo receptor, Shh Light II 
cells were treated with increasing concentrations of Bud ranging from 0 to 25 μM. 
Hedgehog signalling was induced by adding the small molecule SAG(Enzo) which acts 
as a positive modulator of Hh signalling[83]. There was approximately a 50% inhibition 
of SAG induced Gli-luciferase activity on treatment with Bud as shown in Figure 4-8. 
Therefore we speculate that Bud acts as a weak synthetic mimic of an endogenous ligand 
for the Smo CRD, displacing it from this binding pocket. 
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Figure 4-6. Binding affinity measurement of human Smo CRD and Bud.  
Enlarged 1H-15N HSQC spectra of W109, L112, and R161 during the titration of human 
Smo CRD and the ligand Bud. The spectra are colour coded according to the protein: Bud 
ratio. These are the same residues which interact with 20-OHC in vertebrate Smo. The 
chemical shift change is plotted against the concentration of Bud and the corresponding 
Kd values are shown.  
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Figure 4-7. BLI binding assays show that Bud binds to Drosophila Smo CRD with a 
lower affinity than human Smo CRD.  
The average Kd value of Drosophila Smo CRD for Bud was 120 ± 98 μM.  The average 
Kd value of human Smo CRD for Bud was 52 ± 16 μM. 
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Figure 4-8. Bud attenuates SAG induced reporter gene activity. 
Shh Light II cells were treated with increasing concentrations of Bud. Bud triggered a 40-
50% reduction in SAG induced Gli luciferase activity.  Experiments were performed 
three times in duplicate. Error bars indicate standard error of the mean (s.e.m) 
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4.4. Discussion 
4.4.1. Cysteine Rich Domains and Hydrophobic Ligands
 
The Smo extracellular CRD is homologous to the extracellular CRD of the FzD 
receptors[65, 66, 146]. The FzD receptors function as the signal transducer in the Wnt 
signalling pathway[63, 65, 66].  The Wnt signal transduction cascade is an evolutionary 
conserved developmental pathway controlling cell growth and proliferation and abnormal 
Wnt signalling has been associated with cancer conditions[63]. The FzD receptors bind to 
the endogenous Wnt ligand through the N-terminal CRD[65, 66].  
 
In the recently elucidated crystal structure of the Wnt8 ligand in complex with the 
FzD8 CRD, the Wnt molecule has been described as a “hand” and the palmitate 
modification on one of the cysteine residues of Wnt has been described as the “thumb” of 
the “hand” which protrudes out to bind in a hydrophobic groove in the FzD8 CRD[66]. 
This forms the first site of interaction between the FzD receptor and the Wnt ligand[66]. 
The second Wnt-FzD interaction site is mediated by protein-protein interactions. The 
second interacting surface on Wnt has been described as the “index finger” of the hand 
which grasps FzD CRD on a surface opposite to the first interaction site[66].  
 
The first interaction site is dominated by hydrophobic interactions between the 
palmitate modification on Wnt and hydrophobic amino acid residues of the FzD 
CRD[66]. The nine residues of FzD CRD reported to interact with the palmitate 
modification are not strictly conserved in the Smo receptors; however Smo also possesses 
a similar hydrophobic surface in the equivalent position. In the present study, we show 
that the hydrophobic aromatic residues of Smo residing in a homologous region as the 
palmitate binding site on FzD CRD interact with the glucocorticoid Bud. This states that 
the Bud binding site identified in this study is similar to the lipid binding site of the FzD 
receptors[66]. This observation is not unexpected because it has been hypothesized that 
both Smo and FzD CRD have evolved from a common ancestor recognizing hydrophobic 
molecules[146, 161]. 
 
Glucocorticoids binding to the Smo CRD suggest that like the FzD CRD, the Smo 
CRD also possesses ligand binding capabilities; however Bud is a synthetic molecule 
which perhaps shares a similar chemical scaffold as that of the natural ligand of the Smo 
receptor, assuming that Smo indeed binds to a physiological ligand. In such respect 
contemporary research has shown that the hydrophobic pocket in the vertebrate Smo 
CRD binds to oxysterol derivatives[92, 95, 96].  
4.4.2. Same yet Different Drosophila and Human Smoothened Cysteine Rich 
Domain
Despite a minimal primary sequence identity between the Drosophila and the 
human Smo CRD, the cysteines in this domain are conserved across species[146]. The 
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tertiary structure of the Drosophila Smo CRD determined in this study showed that the 
global fold of this domain is similar to the mouse FzD8 CRD structure[65, 66]. 
Additionally, the root mean square deviation of the Drosophila Smo CRD with the 
recently elucidated structure of the zebrafish Smo CRD is 2.04 Å suggesting that the 
structural fold of CRDs have been conserved across species[150]. 
 
Both the Drosophila and the human Smo CRD interact with the glucocorticoid 
Bud suggesting that the ligand binding properties of the CRD have been conserved across 
species. Likewise the vertebrate Smo CRD has been reported to interact with oxysterols 
like 20-hydroxyl cholesterol and oxysterol derivatives like azasterols, 7-keto-25-hydroxyl 
cholesterol and 7-keto-27-hydroxyl cholesterol[92, 95, 96]. In such studies the 
Drosophila Smo CRD has been reported insensitive to regulation by oxysterols[96]. The 
fact that the oxysterols may not bind to the Drosophila Smo CRD does not preclude the 
fact that the Drosophila Smo CRD may bind to a yet unidentified endogenous ligand. 
This argument is further supported by our observations that the synthetic glucocorticoid 
Bud binds to the Drosophila Smo CRD. 
 
The CSPs observed in the NMR titration experiments both in the case of 
Drosophila and the human protein localized in the same region encompassing the 
residues of the first helix and the C-terminal loop which corresponds to the lipid binding 
site on the FzD CRD. In case of the Drosophila protein the aromatic phenylalanine 
residues played a key role in protein-ligand interaction. Of the three phenylalanines F187, 
F188 and F191 participating in this interaction, F187 is not conserved in the human Smo 
CRD and is instead a glycine residue, G162. The second phenylalanine F188 is W163 
and the third phenylalanine, F191 is conserved in the human Smo CRD. Surprisingly the 
conserved phenylalanine in the human Smo CRD did not depict any observable CSP of 
the back-bone amide. The homologous tryptophan residue W163 depicted CSPs and 
saturation on titration with higher ratios of the glucocorticoid. The equivalent glycine 
residue, G162 also depicted CSPs suggesting that although the exact same residues in the 
Drosophila and the human protein may not be involved in ligand interactions, it is the 
same hydrophobic groove in both species that mediate protein-ligand interaction. In 
addition to the hydrophobic residues in the human Smo CRD, R161 showed significant 
CSPs on titration with the glucocorticoid Bud. In fact R161 of the human Smo CRD 
depicted the maximum CSP on titration with Bud suggesting that charged interactions 
may also play a role in modulating vertebrate Smo CRD ligand interaction. The human 
Smo CRD residues L108, W109, G111, L112 and R161which depicted CSPs on titration 
with Bud are homologous to the mouse Smo residues that interact with the ligand 20-
OHC[95, 96]. 
 
Although both the Drosophila and the human Smo CRD interacted with Bud, a 
noteworthy difference was observed between the two species. In case of the Drosophila 
Smo CRD the maximum value of the observed CSPs was four-five times higher than that 
observed with the human Smo CRD and also the CSPs observed in the human Smo CRD 
were saturated at higher concentrations indicating that the human Smo CRD possessed a 
higher binding affinity than the Drosophila Smo CRD.  
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4.4.3. Ligand Binding Provides a Novel Insight into Hedgehog Signalling
 
Smo is a canonical GPCR and likewise maintains a ligand binding pocket in the 
cavity of the 7TM domains[16, 62-64]. Cyclopamine, a natural product isolated from 
corn lily was the first identified Smo modulator known to dock in the cavity of the 7TM 
domains[84, 85]. Since the discovery of cyclopamine a plethora of small molecules have 
been identified that bind to Smo and regulate Hh signalling[82, 83, 87, 88, 162]. 
Although most of the identified small molecules were described to bind in the cavity of 
the 7TM domains there was no structural evidence till last year. Since the summer of 
May 2013 five structures of the Smo 7TM domains have been reported in complex with 
small molecules namely LY2940680, SANT-1, cyclopamine, SAG and Anta XV[64, 85, 
90]. The complex structures revealed that the small molecules mostly dock into a cavity 
formed by the first, sixth and seventh transmembrane helices and make contacts with the 
residues in the extracellular loop 2[64, 85]. The different small molecules penetrate to 
different extents within the 7TM cavity. The small molecule SANT docks deeper into the 
interior of the 7TM domains whereas the other compounds partly dock in the membrane 
and partly projects outside the membrane layer, suggesting that these small molecules 
may interact with the Smo extracellular structures[64, 85]. 
 
In the present study we show that the inhibitory glucocorticoid Bud binds to both 
the Drosophila and the human Smo CRD. Therefore Smo has at least two distinct binding 
sites, one located in the cavity of the 7TM domains and the other located in the 
extracellular CRD. We speculate that some small molecules may bind to the Smo 7TM 
domains as well as the CRD.   
 
G protein coupled receptor signalling is often associated with ligand binding to 
the extracellular domains which facilitates conformational rearrangements in the 
membrane domains to regulate signalling within the cell[163-165]. Likewise the Smo 
extracellular CRD may act as the binding site for an endogenous lipid molecule. The Smo 
CRD perhaps acts as “fishing bait” which serves to fetch the natural ligand. The bound 
ligand may then initiate conformational rearrangements which in turn would bridge the 
gap between the extracellular and the transmembrane structures to regulate subsequential 
Hh signalling within the cell. 
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CHAPTER 5. PHOSPHOLIPIDS AND HEDGEHOG SIGNALLING 
 
 
5.1. Introduction 
Phospholipids are a class of amphipathic lipids that form a major component of 
cellular membrane structures[166]. The chemical structures of phospholipids are 
comprised of two lipophilic fatty-acid chains esterified to a glycerol or sphingosine 
alcohol backbone and a head group attached to the hydrophilic phosphate group which in 
turn is attached to the alcohol backbone[166]. The fatty-acid side chains form the lipid 
bilayer of the membrane and the phosphate moiety faces the aqueous environment[166]. 
Phospholipids are divided into five major classes depending on the nature of the head 
group attached to the phosphate moiety. The five classes of phospholipids include: 
phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, phosphatidylserine 
and sphingomyelin[166]. In the present dissertation the major focus is on 
phosphatidylinositols and therefore will be discussed briefly. 
 
Phosphatidylinositols are present in all cells and tissue types and are abundant in 
the brain tissues[167]. The phosphatidylinositols form a minor component of the 
membrane structures when compared to phosphatidylcholines and 
phosphatidylethanolamines[168]. The inositol head group of the phosphatidylinositols are 
susceptible to phosphorylation at positions 3, 4 and 5 to produce seven different types of 
phosphatidylinositols[167, 169]. The different phosphatidylinositols are functionally 
distinct and are enriched in different subcellular compartments. The specific lipid kinases 
and lipid phosphatases help in the inter-conversion of the phosphatidylinositols[167, 
169].     
 
Functionally, phosphatidylinositols and their derivatives play an important role in 
regulating cell migration, membrane trafficking and signal transduction[167, 169]. The 
phosphatidylinositols have also been suggested to play a role in regulating Hh signalling 
by acting at the level of the Smo receptor[98, 170]. Genetic experiments have shown that 
the loss of the kinase responsible for the synthesis of PI(4)P results in Hh loss-of-function 
phenotypes whereas loss of the phosphatase responsible for the degradation of PI(4)P 
results in Hh gain-of-function phenotypes[98].  
 
The phosphatidylinositols possesses two fatty-acid side chains. These fatty-acid 
side chains are similar to the palmitate modification on Wnt that form the “site one” 
interaction site of the FzD-Wnt receptor ligand complex[66]. Extrapolating from the 
same we speculated that the fatty-acid side chains of the phosphatidylinositols may bind 
to Smo CRD to regulate Hh signalling. Additionally, as discussed in Chapter 4 we 
believe that certain Smo ligands can simultaneously engage the Smo extracellular and 
membrane spanning domains to regulate signalling. In such regards we hypothesized that 
the fatty-acid side chains of phosphatidylinositols bind to the Smo CRD and the inositol 
head anchors in the cavity of the 7TM domains to regulate signalling. Therefore we 
tested the ability of the different phosphatidylinositols to bind to human Smo CRD. We 
selected the synthetic phosphatidylinositols with fatty-acid side chains of eight carbon 
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atoms (octanoic-acid) so that it is readily soluble in an aqueous buffer and convenient for 
NMR experiments. Pertaining to our hypothesis we observed that the 
phosphatidylinositols irrespective of the number and the position of the phosphate groups 
interact with the human Smo CRD through the fatty-acid side chains. 
 
Additionally we tested the effect of each of these phosphatidylinositols on in-vitro 
Hh signalling. The different phosphatidylinositols had varied effect on Hh signalling, 
suggesting that along with the fatty-acid side chains the inositol head with the phosphate 
modifications also play a role in regulating signalling. The phosphate group at the fourth 
position of the inositol head was particularly important for moderately enhancing SAG 
induced Hh signalling. Thereby, we speculated that the inositol head with the fourth 
position phosphate group is necessary for anchoring in the 7TM domains of the Smo 
receptor and the fatty-acid side chains bind to the Smo CRD. Perhaps the simultaneous 
engagement of extracellular and membrane bound structures by PI(4)P leads to an active 
conformation of Smo conducive for downstream Hh signalling.  
 
 
5.2. Experimental Procedures 
5.2.1. Protein Expression and Purification 
Unlabelled and 15N labelled human Smo CRD was expressed and purified as 
described in section 3.2.2. 
5.2.2. NMR Experiments 
The NMR Water-LOGSY experiments were performed to study the interaction of 
the human Smo receptor and the phosphatidylinositol ligands[142]. Water-LOGSY 
experiments were performed using a 10ms selective 1800 pulse at the water signal 
frequency. The NOE mixing time was 2 seconds. The Water-LOGSY spectrum was 
recorded at 250C with 2048 scans.  
 
Six different phosphatidylinositols with different number and position of the 
phosphate groups were tested, namely: phosphatidyl inositol-4-phosphate (PI(4)P), 
phosphatidyl inositol-3-phosphate (PI(3)P), phosphatidyl inositol-3,4-bisphosphate 
(PI(3,4)P2), phosphatidyl inositol-3,5-bisphosphate (PI(3,5)P2), phosphatidyl inositol-
4,5-bisphosphate (PI(4,5)P2) and phosphatidyl inositol-3,4,5-triphosphate (PI(3,4,5)P3). 
Each of these phosphatidylinositols possesses two octanoic-acid side chains. Inositol-
3,4,5- triphosphate (IP3) lacking the fatty-acid side chain was also tested. The different 
phosphatidylinositols tested in the present study are of synthetic origin and were 
purchased from Avanti Polar Lipids. These phosphatidylinositols are readily soluble in 
aqueous buffer and stock solutions were made by dissolving in 10mM deuterated acetic-
acid buffer, pH 5. 
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The NMR Water-LOGSY spectra were recorded for 200μM of each of the free 
phosphatidylinositol ligands in 10mM deuterated acetic-acid buffer and 10% deuterium-
oxide (volume/volume).  Subsequently 10 μM of the human Smo CRD was added to 
maintain a 1:20 (protein to ligand) ratio and the Water-LOGSY spectrum was recorded. 
The spectra were referenced using the internal standard, 4,4-dimethyl-4-silapentane-1-
sulfonic acid (DSS).  
The NMR CSP experiments were carried out using 15N labelled human Smo CRD 
in 10 mM deuterated acetic-acid buffer and 10% deuterium-oxide (volume/volume). 1H-
15N HSQC spectra of the human Smo CRD were recorded in the absence and presence of 
the ligand phosphatidylinositol, PI(4)P. The 1H-15N HSQC spectrum of the free protein 
was recorded with 32 scans. On addition of the PI(4)P ligand at a ratio  of 1:0.5 (protein: 
ligand) there was an immediate drop in the intensity of the amide signals, therefore the 
1H-15N HSQC spectrum of the human Smo CRD with the PI(4)P ligand was recorded 
with 240scans. 
  
All NMR spectra were recorded at 250C using Bruker Avance 600 MHz 
spectrometer equipped with 1H/15N /13C detect, TCI triple resonance cryogenic probes. 
All data were processed using Topspin (Bruker Biospin) 3.0 NMR software and analysed 
using the program CARA[131]. 
 
5.2.3. Cell-based Reporter Assays 
The cell-based Hh reporter assays were performed as described in section 4.2.5. 
Briefly, the Shh Light II cells were cultured to confluency in a 96-well plate. The cells 
were treated with various concentrations of the phosphatidylinositols ranging from 0-50 
μM, in DMEM containing 0.5% (volume/volume) bovine calf serum. The 
phosphatidylinositols were added to the media from concentrated stocks in Phosphate 
Buffer Solution (PBS). After 48 hours, renilla and firefly luciferase levels were measured 
using Dual Luciferase Reporter Assay kit (Promega). Hh pathway activity was expressed 
as the ratio of firefly to renilla luciferase. Experiments were performed at least three 
times in duplicate and error bars represent the standard error of the mean. 
 
 
5.3. Results and Discussion 
 
5.3.1. Phosphatidylinositols Bind to the Human Smoothened Cysteine Rich Domain 
The results of the NMR Water-LOGSY experiments show that 
phosphatidylinositols irrespective of the number and the position of the phosphate groups 
bind to human Smo CRD. The phosphatidylinositols tested included: PI(4)P, PI(3)P, 
PI(3,4)P2, PI(4,5)P2, PI(3,5)P2 and PI(3,4,5)P3. Each of these synthetic 
phosphatidylinositols possesses an inositol head-group and two fatty-acid side chains, 
each of eight carbon atoms in length. The proton signals arising from the fatty-acid side 
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chains are well-pronounced in the aliphatic region of the 1H-NMR spectrum of the 
phosphatidylinositols. The peak positions of the methyl and the methylene protons are 
well demarcated as shown in Figure 5-1. The six different phosphatidylinositols 
possesses the same fatty-acid side chains and therefore gives rise to the similar proton 
signals in 1H-NMR spectrum. 
 
The Water-LOGSY spectra of the phosphatidylinositols were recorded in the 
absence and the presence of the human Smo CRD. The positive Water-LOGSY signals of 
the ligands, in the presence of human Smo CRD demonstrate that all of the above 
mentioned phosphatidylinositols interact with the human Smo CRD through the fatty-
acid side chains. Phosphatidylinositols with a single phosphate group bind to human Smo 
CRD as shown in Figure 5-1A and Figure 5-1B. The phosphatidylinositols bearing two 
phosphate modifications also interact with human Smo CRD as shown in Figure 5-2A, 
Figure 5-2B and Figure 5-2C. The phosphatidylinositol with three phosphate groups 
also interact with human Smo CRD as shown in Figure 5-3A. Inositol-3,4,5- 
triphosphate (IP3) possesses only the inositol head group with three phosphate 
modifications and lacks the fatty-acid side chains. The signals arising from the protons of 
the inositol head are close to the bulk water signal arising from the aqueous buffer and 
are therefore often hard to detect; however, two isolated proton signals of IP3 could be 
detected as shown in Figure 5-3B. The negative Water-LOGSY signal of the IP3 ligand 
on addition of human Smo CRD, as shown in Figure 5-3B, states that IP3 does not 
interact with human Smo CRD. 
 
 
5.3.2. The Phosphatidylinositol-4-phosphate Induces Backbone Chemical Shift 
Perturbations in Human Smoothened Cysteine Rich Domain 
Genetic experiments have shown that the activation of the Drosophila Smo 
receptor is dependent on the levels of PI(4)P[98, 170]. The loss of the kinase facilitating 
the synthesis of PI(4)P, results in Hh loss-of-function phenotypes whereas the loss of the 
phosphatase responsible for degrading PI(4)P results in Hh gain-of-function 
phenotypes[98, 170]. We have shown that the phosphatidylinositols interact with the 
human Smo CRD by Water-LOGSY experiments, alongside we wanted to identify the 
residues in the human Smo CRD that are important for this interaction, therefore we 
performed the NMR CSP experiments focussing on PI(4)P. 
 
The 2D 1H-15N HSQC spectra of the human Smo CRD was recorded in the 
absence and presence of the ligand, PI(4)P. There was an immediate drop in the intensity 
of the amide signals observed in the 2D 1H-15N HSQC spectrum of the human Smo CRD 
upon addition of PI(4)P ligand at a ratio of 1:0.5 (protein: ligand). Therefore NMR 
titration experiments with an increasing concentration of the PI(4)P ligand could not be 
performed. Nevertheless, in the first titration point distinct CSPs corresponding to the 
amino acids E160 and R161 were observed as shown in Figure 5-4. These residues are 
homologous to the mouse Smo CRD residues which are important for binding to 
oxysterol ligands[95]. Arginine 161 also depicted the maximum CSP on titration with the 
glucocorticoid ligand Bud as described in Chapter 4. 
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Figure 5-1. The phosphatidylinositols with a single phosphate group bind to human 
Smo CRD.  
(A) The NMR Water-LOGSY spectrum shows that PI(4)P binds to human Smo CRD. (B) 
The NMR Water-LOGSY spectrum shows that PI(3)P binds to human Smo CRD. The 
blue spectrum represents the 1D proton spectrum of the ligand. The peaks corresponding 
to the methyl (CH3), the methylene (CH2) and the methylene protons adjacent to the 
ketone side chain (CH2’) are labelled in both spectra. The position of the acetic-acid 
buffer (B) peak and interanal standard DSS is also indicated. The positive ligand peaks 
on addition of the Smo CRD (green) as compared to the negative ligand peaks (red) in the 
absence of Smo CRD indicates that the ligand interacts with the protein. 
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Figure 5-2. The phosphatidylinositols with two phosphate groups bind to human 
Smo CRD.  
(A), (B) and (C) respectively show that PI(3,4)P2, PI(4,5)P2 and PI(3,5)P2 interact with 
Smo CRD. The peaks corresponding to the methyl (CH3), the methylene (CH2) and the 
methylene protons adjacent to the ketone side chain (CH2’) are labelled in all three 
spectra. The position of the acetic-acid buffer (B) peak is also indicated. The positive 
ligand peaks on addition of the Smo CRD (green) as compared to the negative ligand 
peaks (red) in the absence of Smo CRD indicates that the ligand interacts with the 
protein. 
 88 
 
Figure 5-3. The fatty-acid side chain of the phosphatidylinositols is essential for 
interaction with the human Smo CRD.  
(A) PI(3,4,5)P3 interacts with Smo CRD. The peaks corresponding to the methyl (CH3), 
the methylene (CH2) and the methylene protons adjacent to the ketone side chain (CH2’) 
are labelled in the spectra. The position of the acetic-acid buffer (B) peak and interanal 
standard DSS is also indicated. The positive ligand peaks on addition of the Smo CRD 
(green) as compared to the negative ligand peaks (red) in the absence of Smo CRD 
indicates that the ligand interacts with the protein. (B) IP3 lacks the fatty-acid side chain 
and does not interact with the Smo CRD. The signals arising from the protons of IP3 are 
close to the bulk water signal arising from the aqueous buffer and are therefore hard to 
detect; however, two isolated proton signals (H4 and H6) of IP3 could be detected. The 
H4 and H6 protons are attached to the carbon 4 and carbon 6 respectively of the inositol 
ring. The negative ligand peaks in the presence (green) and absence (red) of protein 
indicates that the protein does not interact with the ligand. 
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Figure 5-4. The phosphatidylinositol: PI(4)P, interacts with the human Smo CRD.  
1H-15N HSQC spectra of the human Smo CRD in the absence (blue) and presence (red) of 
the ligand PI(4)P. The ligand PI(4)P causes an immediate drop in the intensity of the 
amide signals. The upper inset depicts the specific chemical shift perturbations observed 
upon addition of PI(4)P. The chemical structure of PI(4)P is shown above the spectra. 
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5.3.3. Phosphatidylinositols Exert Varied Effects on in-vitro Hedgehog Signalling 
 
To examine the effects of the different phosphatidylinositols on in-vitro vertebrate 
Hh signalling we performed cell-based luciferase reporter assays using the vertebrate 
NIH3T3 derived Shh Light 2 cells. The Shh Light 2 cells are stably transfected cell lines 
with Gli responsive firefly luciferase reporter and constitutive renilla luciferase 
expression vector. The Shh Light 2 cells were treated with an increasing concentration of 
the different phosphatidylinositols ranging from 0-50 μM. Namely the different 
phosphatidylinositols tested included: PI(4)P, PI(3)P, PI(3,4)P2, PI(4,5)P2, PI(3,5)P2, 
and PI(3,4,5)P3. The inositol phosphate, IP3 was also tested.   
 
On treatment of the Shh Light 2 cells with PI(4)P, a 30-35% increase in SAG 
induced Hh signalling was observed as shown in Figure 5-5A. The small molecule SAG 
is an activator of Smo and is known to function by binding to the Smo transmembrane 
domains[83, 90]. In the present study SAG is used as a positive control to induce Hh 
signalling. In the absence of SAG, the synthetic PI(4)P activates signalling minimally 
which is basal when compared to SAG induced signalling suggesting that the synthetic 
PI(4)P with two octanoic-acid side chains, does not necessarily function as the 
endogenous ligand for Smo; however it acts in conjunction with SAG to further enhance 
Hh signalling. The other phosphatidylinositol with a single phosphate group, PI(3)P, did 
not affect Hh signalling either in the absence or presence of SAG as shown in  
Figure 5-5B, suggesting that the phosphate group at the fourth position in the inositol 
head group is important for signalling. 
 
To study the effect of the phosphatidylinositols with two phosphate modifications, 
we treated Shh Light 2 cells with increasing concentrations of synthetic PI(4,5)P2, 
PI(3,4)P2 and PI(3,5)P2. The synthetic phosphatidyl inositol PI(4,5)P2, suppresses SAG 
induced Hh signalling by 15-20% as shown in Figure 5-6A. The synthetic 
phosphatidylinositols PI(3,4)P2 and PI(3,5)P2 did not have any observable effect on Hh 
signalling in the absence or presence of SAG as shown in Figure 5-6B and Figure 5-6C. 
Similarly, the phosphatidylinositol with three phosphate modifications, PI(3,4,5)P3 with 
the octanoic-acid side chains and the inositol phosphate, IP3, without the octanoic-acid 
side chains did not have any detectable effect on Hh signalling as shown in Figure 5-7A 
and Figure 5-7B.   
5.4. Discussion 
 
The Smo receptor functions as the signal transducer of the Hh pathway[13, 14]. 
Small molecules modulate Smo activity by anchoring either in the cavity of the 7TM 
domains or the extracellular CRD[64, 83-85, 90, 92, 95, 96, 150]. In Chapter 4 we 
introduced the novel hypothesis that perhaps certain Smo ligands engage both the Smo 
7TM domains as well as the extracellular CRD leading to structural rearrangements in the 
Smo receptor to regulate downstream Hh signalling.  
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Figure 5-5. The effect of the phosphatidylinositols with one phosphate group on Hh 
signalling.  
(A) PI(4)P moderately enhances SAG induced Hh signalling. (B) PI(3) does not effect Hh 
signalling. 
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Figure 5-6. The effect of the phosphatidylinositols with two phosphate groups on Hh 
signalling.  
(A) PI(4,5)P2 minimally decreases SAG induced Hh signalling. (B) and (C) PI(3,4)P2 
and PI(3,5)P2 does not effect Hh signalling. 
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Figure 5-7. The effect of the phosphatidylinositols with three phosphate groups on 
Hh signalling.  
(A) PI(3,4,5)P3 with the octanoic fatty-acid sidechains does not effect Hh signalling. (B)
IP3 comprises the inositol head and lacks the fatty-acid sidechains. IP3 does not effect 
Hh signalling. 
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In such regards we speculated that phosphatidylinositols may be the potential 
Smo ligand which engages both the Smo membrane spanning and extracellular structures 
simultaneously. Such speculations were based on two major supporting factors. Firstly, 
genetic experiments have shown that phosphatidylinositols, specifically PI(4)P play a 
role in regulating Smo activation[98, 170]. Secondly, the FzD receptor which is 
homologous to the Smo receptor binds to its physiological ligand Wnt through a fatty-
acid modification on Wnt[66]. Specifically, the palmitate fatty-acid modification on Wnt 
binds to the extracellular CRD of the FzD receptor[66]. Similarly we hypothesized that 
the fatty-acid sidechain of the phosphatidylinositols binds to the Smo CRD to regulate Hh 
signalling and perhaps the inositol head docks in the cavity of the membrane spanning 
domains. 
 
In the present study we performed all experiments with commercially available 
synthetic phosphatidylinositols bearing two octanoic fatty-acid side chains. Pertaining to 
our hypothesis we observed that phosphatidylinositols irrespective of the number and 
position of the phosphate modifications engage the Smo CRD through the fatty-acid side 
chains. Furthermore, we showed that although the different phosphatidylinositols bind to 
the Smo CRD they have varied effect on in-vitro Hh signalling suggesting that the 
inositol head with different number and position of the phosphate groups regulate Hh 
signalling differently. Accordingly, we demonstrated that the synthetic PI(4)P enhances 
SAG induced Hh signalling by 30-35%, whereas PI(4,5)P2 decreases SAG induced Hh 
signalling by 15-20%. 
 
In conclusion we demonstrated that phosphatidylinositols bind to Smo CRD 
through the fatty-acid side chains and PI(4)P moderately enhances SAG induced Hh 
signalling; however the major reservation of the present study is that the synthetic 
phosphatidylinositols tested here did not have any significant effect on Hh signalling in 
the absence of the signal inducer SAG, suggesting that they may not necessarily function 
as endogenous Smo ligands. However, the observation that the synthetic PI(4)P 
moderately enhances SAG induced Hh signalling suggests that it might acts as a mimic of 
an allosteric activator of Smo. Furthermore, phosphatidylinositols are known to function 
as signalling molecules and regulate membrane trafficking of proteins[167, 169]. 
Similarly PI(4)P may promote the membrane trafficking of Smo receptor and thereby 
render Smo active to induce downstream signalling. 
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CHAPTER 6. IMPLICATIONS AND FUTURE DIRECTIONS 
 
6.1. The Structures of the Smoothened G Protein Coupled Receptor (Structure 
Determination Strategies follow the Rule of Divide and Conquer) 
 
The first seminal finding of the present dissertation is elucidating the structure of 
the extracellular CRD of the Smoothened receptor. The significance of the extracellular 
CRD to the Smo structure and function as well as the importance of the Smo receptor in 
Hh signalling and it’s implication in health and disease has been discussed in Chapter 1. 
As stated earlier Smo is a canonical member of the FzD class of GPCRs and likewise 
retains the characteristic extracellular CRD[16, 63, 65, 146]. Interestingly although the 
structure of the homologous FzD CRD has been known for over a decade now there was 
no structural information on any part of the Smo receptor till the summer of 2013[64-66, 
90]. 
 
Despite continuous interest in studying the function of the Smo receptor, the lack 
of structural information up until recently has largely been attributed to the difficulties 
associated with the expression and purification of membrane proteins and specially 
GPCRs. To address this problem and provide a better understanding of the biology of 
human GPCRs, the GPCR network was formed as a large-scale collaboration to 
understand the structure and function of human GPCRs[171]. The major contribution of 
the GPCR network to the field of Hh signal transduction was the structure determination 
of the Smo 7TM domains[64]. Presently the complex structure of the Smo 7TM domains 
have been resolved with five different molecules and provide insight into the ligand 
binding pocket located within the 7TM domains[64, 85, 90]; however these structures 
lacked both the extracellular CRD and the cytoplasmic domains. Thus compiling the 
results of the present study about the structure of the Smo CRD with the GPCR network 
derived crystal structure of the Smo 7TM domains provides an essentially complete 
picture of the structure of the Smo receptor. The structure of the Smo cytoplasmic 
domains has not yet been determined. The length of the human Smo C-termini is about 
240 residues and predicted to include the eighth helix which may pack parallel to the 
membrane. Resolving the structure of the Smo C-termini will further our understanding 
of how Smo functions to recruit downstream signalling components. The length of the 
Drosophila Smo C-termini is predicted to be 483 residues. The difference in the length of 
Smo C-termini between the two species may lead to different cytosolic engagements to 
regulate downstream Hh signalling.   
 
Contemporary to our elucidation of the structure of the Drosophila Smo CRD, the 
structure of the zebrafish Smo CRD was determined by crystallographic methods[150]. 
The structure of the NMR derived solution structure of the Drosophila Smo CRD is 
similar to the crystal structure of the zebrafish Smo CRD with a root mean square 
deviation of 2.04 Å between the two structures as shown in Figure 6-1. The disulfide 
bond pattern between the two proteins is conserved. The structure of the zebrafish Smo 
CRD includes the N-and C- termini cysteines that were not included in the structure of 
the Drosophila Smo CRD.  
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Figure 6-1. Superimposed structures of the Drosophila and the zebrafish Smo CRD.  
The Drosophila Smo CRD determined by NMR is represented in cyan and the zebrafish 
Smo CRD determined by crystallographic methods is shown in magenta. The sticks 
indicate the disulfide bonds in both structures. 
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These two cysteines form the fifth disulfide bond of the Smo CRD[150]. Smo 
CRD has been implicated to a play a role in receptor dimerization and in the crystal 
structure of the zebrafish Smo CRD there were two Smo molecules in the 
crystallographic asymmetric unit[68, 150]. The interface between the two molecules 
buried a surface area of 490 Å2 and the crystal contact was formed through a Zn ion 
which bonded to three different protein chains[150]. This suggested that the dimer 
observed in the crystal may not be of physiological relevance[150]. Additionally it was 
stated that the purified Smo CRD behaved as a monomer at a concentration of 5 μM; 
however this does not rule out the possibility that the Smo CRD may form a 
physiologically relevant dimer especially at higher concentrations. 
 
 
6.2. Multiple Ligand Binding Sites on Smoothened Receptor Help Propose a Novel 
Mechanism for Hedgehog Signalling  
 
The second important finding of the present study is that the Smo CRD possesses 
hydrophobic ligand binding capabilities. In the present work we showed that both the 
Drosophila and the human Smo CRD binds to the synthetic glucocorticoid Bud, albeit 
with different affinities as described in Chapter 4. Glucocorticoids regulate Hh signalling 
by acting at the level of the Smo receptor[93]. 
 
Recently, it has been shown that oxysterols and oxysterol derivatives also 
modulate Smo signalling by binding to the CRD[95, 96, 150]. It has been proposed that 
the Smo CRD perhaps acts as an allosteric binding site to regulate Hh signalling. The 
recent biochemistry experiments showed that the CRD is essential for binding to 
oxysterols derived on beads[96, 150]. In order to identify the specific residues involved 
in binding, individual or small stretches of amino acids in the Smo CRD were mutated 
and checked for their ability to bind oxysterols[95, 96, 150]. The choice of residues to 
mutate was based upon the complex structure of the FzD receptor and the Wnt 
ligand[66]. The Wnt protein interacts with FzD on two sites. The first site is mediated by 
a palmitate modification on Wnt which engages a hydrophobic groove in the CRD 
whereas the second site is dominated by protein-protein interactions between the receptor 
and the ligand protein[66]. The presumption is that the ligand binding site on Smo CRD 
would include the homologous residues as the palmitate binding site on FzD CRD. This 
approach for determining the key residues in Smo CRD required for ligand binding was 
solely biased on the complex structure of the FzD8 CRD and the Wnt8a ligand which 
revealed the intricate structural details of the interaction[66]. 
 
In the present dissertation we were successful in providing the first direct 
structural evidence of the residues in both Drosophila and human Smo CRD that are 
involved in binding to the hydrophobic glucocorticoid, Bud. NMR titration experiments 
provide an excellent choice of monitoring protein-ligand interaction and identifying 
unique residues involved in the interaction as described in Chapter 2[143, 155, 159, 160]. 
Using this methodology we were able to determine the specific residues both in the 
Drosophila and the human Smo CRD that are essential for ligand binding. The NMR 
based structural results of the present study were further supported by contemporary 
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biochemistry research. Necessarily the residues that depicted the maximum CSPs in the 
human CRD on titration with the glucocorticoid, Bud corresponded to the mouse residues 
which when mutated failed to bind the oxysterol ligands and consequently failed to 
induce downstream Hh signalling[95, 96]. Thus although the glucocorticoid and the 
oxysterol ligands are different the hydrophobic ligand binding pocket which serves to 
dock these molecules are similar in the mouse and the human Smo receptor. Thus in the 
recent times Smo CRD has emerged as the second ligand binding site on Smo[95, 96, 
150]. This further strengthens the argument that the CRDs have evolved from an 
ancestral domain capable of recognizing hydrophobic molecules[146, 161].  
 
The first ligand binding site on Smo was described a decade earlier and was 
identified to be located in the pocket of the 7TM domains[83, 84]. Cyclopamine a plant 
derived alkaloid is the first described small molecule modulator known to dock in the 
cavity of the 7TM domains[84, 85]. Since then a plethora of small molecules have been 
described which compete with cyclopamine for binding to the Smo receptor indicating 
that these synthetic small molecules dock in the cavity located in the 7TM domains[83, 
93]. While some of these small molecules such as SAG and purmorphamine function as 
Smo agonists others such as cyclopamine and the SANT group of small molecules 
function as Smo antagonists[83, 84, 87]. The complex structures of the Smo receptor with 
the different ligands show that the ligands penetrate the binding-cavity to varying 
degree[64, 85, 90].  The antagonist SANT docks deep down in the cavity, whereas, 
cyclopamine stems outside the cavity of the 7TM domains and makes contacts with the 
extracellular loop structures[85].  
 
Most of the described Smo modulators are synthetic. Oxysterols have emerged as 
the likely candidate as an endogenous ligand for Smo provided Smo activity is indeed 
regulated by a physiological ligand[92, 95, 96, 150]; however this is subject to debate as 
the cellular levels of oxysterols are low and there is no concrete evidence that Smo 
activity is indeed regulated by any endogenous ligand. Although the natural ligand of 
Smo is yet unknown, presently what is known clearly is that Smo has at least two definite 
binding sites, one located in the extracellular CRD and the other situated in the 7TM 
domains[64, 85, 150]. The extracellular region of Smo CRD may be flexible as shown in 
Figure 6-2A. Smo ligands may bind in the cavity of the 7TM domains and regulate 
signalling regardless of binding to the CRD. Similarly, small molecules may bind to Smo 
CRD and control Hh signalling irrespective of engaging the cavity in the 7TM domains, 
however; we speculate that perhaps there exists a certain class of small molecules which 
can bind to the Smo CRD and induce a conformational shift bridging the Smo 
extracellular and 7TM domain structures, which in turn would lead to conformational 
rearrangements in the membrane spanning domains to modulate downstream Hh 
signalling as shown in Figure 6-2B. The Smo CRD perhaps acts as “fishing bait”, which 
binds to the Smo ligand and induces conformational rearrangements between the Smo 
CRD and 7TM domains to regulate signalling. 
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Figure 6-2. A novel model for Smo allosteric regulation.  
(A) The Smo CRD may be flexible. The disulfide bonds stabilizing the N-terminal Smo 
extracellular linker domain are shown in red lines. (B) The Smo receptor has more than 
one binding site. Molecules like Bud and oxysterols bind to the Smo CRD (left, red 
rectangle) to regulate signalling. Cyclopamine and GDC-0449 are known to bind in the 
cavity located in the 7TM domains (right, pink inverted triangle) to control Hh signalling. 
We speculate that there is the possibility of a class of molecules (middle, yellow star) 
which would bind to the CRD and cause a conformational change of the Smo 
extracellular structures to bring it closer to the 7TM domains. This in turn would lead to 
structural rearrangements of the Smo 7TM domains to regulate signalling. Reprinted with 
permission. Rana R, Carroll CE, Lee H-J, Bao J, Marada S, Grace CRR, et al. Structural 
insights into the role of the Smoothened cysteine-rich domain in Hedgehog signalling. 
Nat Commun 2013,4. 
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6.3. The Unanswered Question: Does Smoothened Really Have an Endogenous 
Ligand?
 
For years now Smo activity has been demonstrated to be regulated by small 
molecules mostly of synthetic origin[83, 87, 88]. Presently there is also an FDA approved 
drug GDC-0449 for the treatment of BCC that functions by acting at the level of Smo[88, 
89, 91]. Despite such major advancements in the field of Smo there is a dearth of 
knowledge regarding some of the basic aspects of Smo regulation and Hh signalling. One 
of the major unanswered questions is whether Smo activity is regulated by an 
endogenous ligand. The other major gap in the understanding of the Hh signal 
transduction cascade is how Ptch regulates Smo. The answers to both these questions 
may not be mutually exclusive that is Ptch perhaps regulates Smo activity by regulating 
the physiological ligand of Smo. Despite the current disparities regarding whether Smo 
activity is regulated by an endogenous ligand or not, we believe that Smo activity is 
regulated by a physiological ligand. Our presumption has originated from the following 
facts. 
 
Firstly, the Smo CRD is similar to the CRDs related to FzD receptors and the Hh-
interacting proteins[65, 66, 146]. These domains are suggested to have evolved from a 
common ancestral origin which play an important role in binding to hydrophobic 
ligands[146, 161]. Additionally the nearest member of the Smo CRD is the FzD CRD 
which indeed binds to the Wnt ligand through a palmitate modification suggesting that 
the FzD CRD retains the property of binding to hydrophobic ligands[66]. Similarly, the 
Smo CRD may pertain to its evolutionary history and like the other members may bind to 
a yet unidentified hydrophobic ligand.  
 
Secondly, Smo is a GPCR and it is not unlikely for a GPCR to be regulated by 
physiological ligands[16, 62, 63, 163-165]. In canonical GPCR signalling ligand binding 
leads to conformational rearrangements in the membrane spanning domains to activate 
downstream signalling[16, 62, 63, 171]. Thus Smo may function as a typical GPCR and 
function by binding to an endogenous ligand. This is further supported by the fact that 
Smo possess the ability to bind to synthetic molecules to regulate signalling[64, 83, 87]. 
Perhaps these synthetic molecules act as a mimic of the yet unidentified natural ligand of 
the Smo receptor. 
 
Thirdly, accepting the concept that Smo activity is regulated by a natural ligand 
may help answer the enigmatic question of how Ptch regulates Smo. Ptch has a sterol 
sensing domain which may help in the transport of the sterol which could function as the 
natural ligand of Smo[34]. The importance of the sterol sensing domain of Patched is 
emphasized by the fact that missense mutations in this domain of Patched abrogate its 
ability to inhibit the Smo receptor[172]. In the absence of the Hh ligand Ptch is most 
likely maintained in an inactive conformation which interferes with the functioning of the 
sterol sensing domains of the Ptch receptor and hinders the transport of the sterol which 
may function as the Smo ligand. In the presence of the Hh ligand the conformation of the 
Ptch receptor is such that it results in a functional sterol sensing domain. This in turn 
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leads the Smo receptor accessible to its natural ligand to regulate downstream Hh 
signalling. 
 
Despite the facts supporting our presumption, the question still remains as to 
whether Smo activity is indeed regulated by an endogenous ligand. Smo in various 
respects is different from both the FzD receptors and the typical GPCRs and thereby may 
differ from them in its ability to bind to an endogenous ligand. Perhaps rather than a 
physiological ligand regulating Smo activity it is the sub-cellular distribution of Smo that 
regulates its activity. Vertebrate Smo is not functional when it is trapped in the 
endosomal vesicles. Trafficking of Smo to the primary cilium is an important prerequisite 
for Hh signalling[38]. Ptch through its sterol sensing domain perhaps maintains the lipid 
and sterol environment in the membrane conducive for Smo to reside and function.  
 
In Chapter 5 we described that the phosphatidylinositol, PI(4)P enhances SAG 
induced Hh signalling. The fact that PI(4)P in the absence of SAG induces a minimal 
increase in Hh signalling which is basal when compared to SAG induced signalling 
suggests that PI(4)P may not necessarily function as the specific endogenous ligand for 
Smo; however PI(4)P may help in the formation of a lipid associated signalosome 
complex that help trafficking Smo to the primary cilium in vertebrates or plasma 
membrane in Drosophila to activate downstream signalling. This hypothesis is further 
supported by the fact that a similar observation was made in the Wnt pathway wherein 
phospholipids aided the formation of a signalosome complex required for cell surface 
localization of the receptors to regulate signalling[173]. 
6.4. Smoothened as a Template for Drug Discovery 
 
Abnormal Hh signalling has been predominantly associated with BCC, MB, RMS 
and also been implicated in a variety of other cancers such as cancers of the digestive 
tract[7-10, 114]. The Ptch-Smo interaction is the most commonly disrupted step in 
cancers associated with ectopic Hh signalling. Although presently every step of the Hh 
signalling cascade is being studied for the development of anti-cancer therapeutics, the 
Smo GPCR has undoubtedly emerged as the most successful druggable candidate of the 
pathway[88, 89, 111]. 
 
The GPCR families of receptors collectively form the targets of most drugs and it 
is not uncommon that Smo being a GPCR has gained such intense success as a target for 
the development of anti-cancer therapeutics[171]. The teratogenic compound 
cyclopamine was the first identified Hh inhibitor described to dock in the cavity of the 
Smo transmembrane domains[84, 85]. Although cyclopamine was able to slow down 
tumor growth in animal models it was essentially not developed for therapeutic use. The 
soluble and more potent cyclopamine derivative saridegib also known as IPI-926 has 
entered a clinical trial for BCC[174]. Presently the only FDA approved Smo inhibitor is 
GDC-0449 or vismodegib[88, 89, 91]. Vismodegib is marketed as Erivedge and the 
recommended daily dose is 150mg administered orally for the treatment of adults with 
metastatic BCC or locally advanced BCC[174]. 
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When GDC-0449 was administered for the treatment of MB it caused a rapid 
regression of tumor and reduction of symptoms in MB patients but there was relapse of 
the tumor with a D473H resistant mutation in the sixth transmembrane helix of the Smo 
receptor[97]. Additionally alanine scan mutagenesis of the Smo receptor identified novel 
mutations such as E518K that could confer resistance to GDC-0449[124]. Therefore 
second generation drugs that act on GDC-0449 resistant Smo mutants need to be 
developed. In the present work we have shown that the Smo CRD binds to the synthetic 
glucocorticoid, Bud, as elaborated in Chapter 4. Furthermore, Bud acts on wild-type as 
well GDC-0449 resistant Smo mutants[93]. Hence, we speculated that the Smo CRD 
could be evaluated for the development of Bud like molecules with higher potency that 
will represent a novel class of anti-cancer therapeutics.  
 
Presently, the structures of the Smo transmembrane domains have been elucidated 
in complex with different antagonists namely LY2940680, SANT-1, cyclopamine and 
Anta XV[64, 85, 90]. We hypothesize that combining the structural scaffolds of the 
different Smo antagonists will help generate second generation Smo antagonists which 
will perhaps be more potent than the individual parent Smo antagonists. The Smo 
antagonist LY2940680 penetrates the cavity of the 7TM domains of Smo to a lesser 
extent when compared to that of SANT-1 which docks deeper inside the cavity[64]. Thus 
combining these two molecules as depicted in Figure 6-3 may generate a Smo antagonist 
with higher efficacy.  
 
Additionally, we speculate that there is indeed an endogenous ligand for Smo 
which functions by bridging the extracellular Smo CRD and the 7TM domains. Therefore 
synthesizing a drug that possesses the capability to recruit the Smo extracellular as well 
as the transmembrane structures simultaneously in theory may have a higher potency than 
small molecules occupying individual domains. In such respects we observed that the 
fatty-acid sidechain of the phosphatidylinositols binds to the Smo CRD as described in 
chapter 5. Therefore we speculated that another novel class of Smo antagonists can be 
synthesized by adding a fatty-acid sidechain to the known Smo antagonists such as 
cyclopamine and GDC-0449. The designs of such Smo inhibitors are depicted in Figure 
6-4. As presumed if the fatty-acid sidechain of these antagonists bind to Smo CRD and 
the ring scaffolds dock in the cavity of the 7TM domains, these molecules may have a 
better chance of Smo regulation. 
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Figure 6-3. Design of Smoothened inhibitors.  
Existing Smo inhibitors LY2940680 and SANT may be combined chemically to 
synthesize a novel Smo inhibitor. 
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Figure 6-4. Design of Smo inhibitors.
A palmitic acid side chain may be linked chemically to the known Smo inhibitors such as 
GDC-0449 and cyclopamine to synthesize a novel class of Smo regulators.  
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APPENDIX A. DROSOPHILA SMO CRD ATOM ASSIGNMENTS 
 
 
Residue Number Residue Name Atom Chemical Shift 
85 VAL C 175.218 
85 VAL CA 57.885 
85 VAL CB 35.895 
85 VAL CG1 18.515 
85 VAL CG2 20.273 
85 VAL H 7.805 
85 VAL HA 5.297 
85 VAL HB 1.461 
85 VAL QG1 0.422 
85 VAL QG2 -0.26 
85 VAL N 112.794 
86 ARG C 174.128 
86 ARG CA 54.192 
86 ARG CB 34.757 
86 ARG CG 26.085 
86 ARG CD 43.85 
86 ARG H 8.43 
86 ARG HA 4.578 
86 ARG HB2 1.638 
86 ARG HB3 1.534 
86 ARG QG 1.486 
86 ARG QD 2.977 
86 ARG N 117.854 
87 ARG C 176.265 
87 ARG CA 57.824 
87 ARG CB 29.913 
87 ARG CG 28.214 
87 ARG CD 43.181 
87 ARG H 8.569 
87 ARG HA 4.619 
87 ARG QB 1.723 
87 ARG QG 1.517 
87 ARG QD 3.168 
87 ARG HE 7.419 
87 ARG N 124.928 
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Appendix A. Continued. 
 
Residue Number Residue Name Atom Chemical Shift 
87 ARG NE 117.269 
88 ALA C 174.173 
88 ALA CA 51.382 
88 ALA CB 23.05 
88 ALA H 8.082 
88 ALA HA 4.379 
88 ALA QB 1.236 
88 ALA N 127.39 
89 ARG C 177.847 
89 ARG CA 55.271 
89 ARG CB 31.215 
89 ARG CG 26.896 
89 ARG CD 43.086 
89 ARG H 8.133 
89 ARG HA 4.692 
89 ARG HB2 1.8 
89 ARG HB3 1.745 
89 ARG QG 1.587 
89 ARG QD 3.18 
89 ARG HE 7.313 
89 ARG N 116.82 
89 ARG NE 116.871 
90 CYS C 175.288 
90 CYS CA 51.785 
90 CYS CB 38.246 
90 CYS H 9.709 
90 CYS HA 5.732 
90 CYS HB2 3.014 
90 CYS HB3 2.514 
90 CYS N 126.567 
91 TYR CA 54.951 
91 TYR CB 39.807 
91 TYR CD1 134.091 
91 TYR CE1 116.951 
91 TYR H 8.87 
91 TYR HA 5.079 
91 TYR HB2 3.04 
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Residue Number Residue Name Atom Chemical Shift 
91 TYR HB3 2.699 
91 TYR QD 6.785 
91 TYR QE 6.318 
91 TYR N 120.309 
92 PRO CA 61.773 
92 PRO CB 31.173 
92 PRO CG 27.009 
92 PRO CD 50.108 
92 PRO HA 4.836 
92 PRO HB2 2.03 
92 PRO HB3 1.936 
92 PRO HG2 2.185 
92 PRO HG3 1.994 
92 PRO HD2 3.862 
92 PRO HD3 3.712 
93 THR C 173.688 
93 THR CA 61.324 
93 THR CB 70.191 
93 THR CG2 21.227 
93 THR H 7.978 
93 THR HA 4.253 
93 THR HB 4.041 
93 THR QG2 0.885 
93 THR N 115.177 
94 SER C 175.079 
94 SER CA 57.057 
94 SER CB 66.02 
94 SER H 8.451 
94 SER HA 4.702 
94 SER HB2 4.058 
94 SER HB3 3.811 
94 SER N 116.822 
95 ASN C 175.705 
95 ASN CA 55.564 
95 ASN CB 37.637 
95 ASN H 8.802 
95 ASN HA 4.385 
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Residue Number Residue Name Atom Chemical Shift 
95 ASN QB 2.715 
95 ASN HD21 7.564 
95 ASN HD22 6.893 
95 ASN N 118.803 
95 ASN ND2 112.721 
96 ALA C 179.229 
96 ALA CA 53.087 
96 ALA CB 19.563 
96 ALA H 8.004 
96 ALA HA 4.262 
96 ALA QB 1.299 
96 ALA N 118.571 
97 THR C 175.334 
97 THR CA 60.586 
97 THR CB 70.195 
97 THR CG2 21.698 
97 THR H 7.551 
97 THR HA 4.581 
97 THR HB 4.653 
97 THR QG2 0.945 
97 THR N 106.312 
98 ASN C 174.221 
98 ASN CA 52.79 
98 ASN CB 36.768 
98 ASN H 7.897 
98 ASN HA 4.528 
98 ASN HB2 3.194 
98 ASN HB3 2.633 
98 ASN HD21 7.285 
98 ASN HD22 6.414 
98 ASN N 122.599 
98 ASN ND2 106.804 
99 THR C 173.651 
99 THR CA 59.011 
99 THR CB 72.745 
99 THR CG2 20.913 
99 THR H 7.49 
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Residue Number Residue Name Atom Chemical Shift 
99 THR HA 4.979 
99 THR HB 3.486 
99 THR QG2 0.841 
99 THR N 107.151 
100 CYS C 173.688 
100 CYS CA 55.634 
100 CYS CB 45.854 
100 CYS H 8.632 
100 CYS HA 4.095 
100 CYS HB2 2.919 
100 CYS HB3 2.802 
100 CYS N 118.809 
101 PHE C 176.261 
101 PHE CA 59.067 
101 PHE CB 36.576 
101 PHE CD1 132.752 
101 PHE CE1 130.73 
101 PHE CZ 131.44 
101 PHE H 9.018 
101 PHE HA 4.275 
101 PHE HB2 3.301 
101 PHE HB3 3.021 
101 PHE QD 6.883 
101 PHE QE 6.886 
101 PHE HZ 7.334 
101 PHE N 128.19 
102 GLY C 174.173 
102 GLY CA 45.112 
102 GLY H 8.566 
102 GLY HA2 4.239 
102 GLY HA3 3.561 
102 GLY N 104.504 
103 SER C 173.873 
103 SER CA 57.436 
103 SER CB 63.718 
103 SER H 7.533 
103 SER HA 4.529 
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Residue Number Residue Name Atom Chemical Shift 
103 SER QB 3.73 
103 SER N 116.201 
104 LYS C 176.632 
104 LYS CA 56.409 
104 LYS CB 32.169 
104 LYS CG 24.365 
104 LYS CD 28.605 
104 LYS CE 41.628 
104 LYS H 8.768 
104 LYS HA 4.056 
104 LYS QB 1.538 
104 LYS QG 1.198 
104 LYS QD 1.417 
104 LYS QE 2.785 
104 LYS N 127.456 
105 LEU CA 52.01 
105 LEU CB 40.68 
105 LEU CG 26.621 
105 LEU CD1 25.453 
105 LEU CD2 22.219 
105 LEU H 8.304 
105 LEU HA 4.12 
105 LEU HB2 1.323 
105 LEU HB3 0.205 
105 LEU HG 1.239 
105 LEU QD1 0.63 
105 LEU QD2 0.626 
105 LEU N 128.016 
106 PRO CA 62.807 
106 PRO CB 29.625 
106 PRO CG 26.537 
106 PRO CD 49.961 
106 PRO HA 4.453 
106 PRO HB2 2.145 
106 PRO HB3 1.926 
106 PRO HG2 1.95 
106 PRO HG3 1.776 
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Residue Number Residue Name Atom Chemical Shift 
106 PRO HD2 3.53 
106 PRO HD3 3.027 
107 TYR C 175.239 
107 TYR CA 53.718 
107 TYR CB 38.637 
107 TYR CD1 134.566 
107 TYR CE1 117.894 
107 TYR H 6.311 
107 TYR HA 4.689 
107 TYR HB2 3.173 
107 TYR HB3 3.026 
107 TYR QD 6.836 
107 TYR QE 6.525 
107 TYR N 116.871 
108 GLU C 176.282 
108 GLU CA 57.502 
108 GLU CB 31.105 
108 GLU CG 36.1 
108 GLU H 8.591 
108 GLU HA 4.138 
108 GLU QB 1.864 
108 GLU QG 2.135 
108 GLU N 118.221 
109 LEU C 175.42 
109 LEU CA 53.202 
109 LEU CB 43.587 
109 LEU CG 27.153 
109 LEU CD1 25.498 
109 LEU CD2 23.139 
109 LEU H 8.176 
109 LEU HA 4.974 
109 LEU HB2 2.217 
109 LEU HB3 0.963 
109 LEU HG 1.507 
109 LEU QD1 0.713 
109 LEU QD2 0.588 
109 LEU N 119.826 
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Residue Number Residue Name Atom Chemical Shift 
110 SER C 173.833 
110 SER CA 53.006 
110 SER CB 64.691 
110 SER H 7.924 
110 SER HA 5.02 
110 SER HB2 3.208 
110 SER HB3 2.838 
110 SER N 111.561 
111 SER C 175.602 
111 SER CA 57.388 
111 SER CB 66.333 
111 SER H 8.628 
111 SER HA 4.841 
111 SER QB 3.016 
111 SER N 111.459 
112 LEU C 179.571 
112 LEU CA 56.032 
112 LEU CB 41.904 
112 LEU CG 26.938 
112 LEU CD1 25.003 
112 LEU CD2 24.013 
112 LEU H 9.519 
112 LEU HA 4.383 
112 LEU QB 1.551 
112 LEU HG 1.294 
112 LEU QD1 0.413 
112 LEU QD2 0.552 
112 LEU N 128.995 
113 ASP C 176.486 
113 ASP CA 58.352 
113 ASP CB 41.259 
113 ASP H 8.191 
113 ASP HA 4.168 
113 ASP HB2 2.754 
113 ASP HB3 2.418 
113 ASP N 115.013 
114 LEU C 175.556 
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Residue Number Residue Name Atom Chemical Shift 
114 LEU CA 54.483 
114 LEU CB 39.219 
114 LEU CG 26.318 
114 LEU CD1 21.976 
114 LEU H 8.732 
114 LEU HA 4.329 
114 LEU HB2 2.141 
114 LEU HB3 1.47 
114 LEU HG 1.056 
114 LEU QQD 0.645 
114 LEU N 118.298 
115 THR C 172.812 
115 THR CA 58.759 
115 THR CB 71.985 
115 THR CG2 20.435 
115 THR H 7.574 
115 THR HA 2.784 
115 THR HB 2.647 
115 THR QG2 0.328 
115 THR N 106.427 
116 ASP CA 52.757 
116 ASP CB 40.737 
116 ASP HA 4.398 
116 ASP HB2 2.459 
116 ASP HB3 2.076 
117 PHE C 176.169 
117 PHE CA 57.477 
117 PHE CB 39.27 
117 PHE CD1 131.518 
117 PHE CE1 132.594 
117 PHE CZ 131.862 
117 PHE H 7.575 
117 PHE HA 4.498 
117 PHE HB2 3.109 
117 PHE HB3 2.648 
117 PHE QD 7.151 
117 PHE QE 7.407 
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Residue Number Residue Name Atom Chemical Shift 
117 PHE HZ 6.935 
117 PHE N 117.929 
118 HIS C 175.08 
118 HIS CA 56.439 
118 HIS CB 31.104 
118 HIS CD2 119.685 
118 HIS CE1 137.643 
118 HIS H 9.23 
118 HIS HA 4.585 
118 HIS HB2 3.258 
118 HIS HB3 3.071 
118 HIS HD2 7.098 
118 HIS HE1 8.077 
118 HIS N 115.333 
119 THR C 173.696 
119 THR CA 58.725 
119 THR CB 72.851 
119 THR CG2 21.622 
119 THR H 7.343 
119 THR HA 4.528 
119 THR HB 4.387 
119 THR QG2 1.096 
119 THR N 106.891 
120 GLU C 178.417 
120 GLU CA 59.38 
120 GLU CB 29.873 
120 GLU CG 36.482 
120 GLU H 8.841 
120 GLU HA 3.611 
120 GLU HB2 1.797 
120 GLU HB3 1.528 
120 GLU HG2 1.89 
120 GLU HG3 1.617 
120 GLU N 121.798 
121 LYS C 177.745 
121 LYS CA 59.47 
121 LYS CB 32.13 
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Residue Number Residue Name Atom Chemical Shift 
121 LYS CG 24.437 
121 LYS CD 28.386 
121 LYS CE 42.016 
121 LYS H 8.307 
121 LYS HA 3.903 
121 LYS QB 1.751 
121 LYS HG2 1.288 
121 LYS HG3 1.214 
121 LYS QD 1.599 
121 LYS QE 2.897 
121 LYS N 121.091 
122 GLU C 178.051 
122 GLU CA 59.094 
122 GLU CB 30.468 
122 GLU CG 36.919 
122 GLU H 7.537 
122 GLU HA 3.852 
122 GLU QB 1.948 
122 GLU HG2 2.143 
122 GLU HG3 2.039 
122 GLU N 117.79 
123 LEU C 178.07 
123 LEU CA 59.007 
123 LEU CB 42.75 
123 LEU CG 27.001 
123 LEU CD1 24.927 
123 LEU H 7.321 
123 LEU HA 3.211 
123 LEU HB2 1.81 
123 LEU HB3 1.569 
123 LEU HG 1.295 
123 LEU QQD 1.021 
123 LEU N 118.763 
124 ASN C 177.689 
124 ASN CA 57.31 
124 ASN CB 39.288 
124 ASN H 8.335 
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Residue Number Residue Name Atom Chemical Shift 
124 ASN HA 4.127 
124 ASN HB2 2.714 
124 ASN HB3 2.529 
124 ASN HD21 7.498 
124 ASN HD22 6.842 
124 ASN N 116.987 
124 ASN ND2 112.59 
125 ASP C 178.868 
125 ASP CA 57.51 
125 ASP CB 39.596 
125 ASP H 8.376 
125 ASP HA 4.306 
125 ASP HB2 2.629 
125 ASP HB3 2.51 
125 ASP N 120.935 
126 LYS C 179.458 
126 LYS CA 55.698 
126 LYS CB 31.082 
126 LYS CG 24.521 
126 LYS CD 28.082 
126 LYS CE 41.937 
126 LYS H 7.748 
126 LYS HA 4.168 
126 LYS QB 1.78 
126 LYS QG 1.171 
126 LYS QD 1.726 
126 LYS QE 2.938 
126 LYS N 119.626 
127 LEU C 178.732 
127 LEU CA 57.722 
127 LEU CB 41.236 
127 LEU CG 25.852 
127 LEU CD1 25.602 
127 LEU CD2 22.655 
127 LEU H 8.221 
127 LEU HA 3.688 
127 LEU HB2 1.661 
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Residue Number Residue Name Atom Chemical Shift 
127 LEU HB3 1.339 
127 LEU HG 1.13 
127 LEU QD1 0.392 
127 LEU QD2 0.046 
127 LEU N 120.255 
128 ASN C 178.394 
128 ASN CA 55.628 
128 ASN CB 38.269 
128 ASN H 7.482 
128 ASN HA 4.58 
128 ASN HB2 2.914 
128 ASN HB3 2.864 
128 ASN HD21 7.775 
128 ASN HD22 6.846 
128 ASN N 113.63 
128 ASN ND2 113.685 
129 ASP C 179.095 
129 ASP CA 56.623 
129 ASP CB 39.883 
129 ASP H 7.834 
129 ASP HA 4.482 
129 ASP HB2 2.866 
129 ASP HB3 2.455 
129 ASP N 120.683 
130 TYR C 176.554 
130 TYR CA 62.142 
130 TYR CB 37.436 
130 TYR CD1 133.432 
130 TYR CE1 118.373 
130 TYR H 8.132 
130 TYR HA 3.984 
130 TYR HB2 3.38 
130 TYR HB3 3.1 
130 TYR QD 7.33 
130 TYR QE 6.75 
130 TYR N 116.512 
131 TYR C 177.915 
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Residue Number Residue Name Atom Chemical Shift 
131 TYR CA 61.395 
131 TYR CB 37.345 
131 TYR CD1 133.47 
131 TYR CE1 118.363 
131 TYR H 7.558 
131 TYR HA 3.632 
131 TYR QB 2.851 
131 TYR QD 7.174 
131 TYR QE 6.895 
131 TYR N 118.786 
132 ALA C 179.39 
132 ALA CA 54.142 
132 ALA CB 18.404 
132 ALA H 7.453 
132 ALA HA 3.935 
132 ALA QB 1.354 
132 ALA N 120.715 
133 LEU C 177.28 
133 LEU CA 56.634 
133 LEU CB 41.045 
133 LEU CG 28.196 
133 LEU CD1 26.081 
133 LEU CD2 23.773 
133 LEU H 7.764 
133 LEU HA 3.765 
133 LEU HB2 2.069 
133 LEU HB3 1.57 
133 LEU HG 1.63 
133 LEU QD1 0.868 
133 LEU QD2 0.67 
133 LEU N 117.212 
134 LYS C 177.121 
134 LYS CA 58.865 
134 LYS CB 31.247 
134 LYS CG 23.834 
134 LYS CD 28.957 
134 LYS CE 41.183 
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Residue Number Residue Name Atom Chemical Shift 
134 LYS H 7.001 
134 LYS HA 3.039 
134 LYS HB2 0.896 
134 LYS HB3 0.818 
134 LYS HG2 0.127 
134 LYS HG3 0.047 
134 LYS QD 1.077 
134 LYS HE2 2.529 
134 LYS HE3 2.46 
134 LYS N 118.756 
135 HIS C 174.232 
135 HIS CA 57.245 
135 HIS CB 30.221 
135 HIS CD2 120.468 
135 HIS CE1 138.791 
135 HIS H 6.973 
135 HIS HA 4.304 
135 HIS HB2 3.129 
135 HIS HB3 2.868 
135 HIS HD2 7.035 
135 HIS HE1 7.623 
135 HIS N 113.331 
136 VAL CA 59.159 
136 VAL CB 30.604 
136 VAL CG1 22.649 
136 VAL CG2 20.108 
136 VAL H 7.821 
136 VAL HA 4.531 
136 VAL HB 2.15 
136 VAL QG1 0.935 
136 VAL QG2 0.77 
136 VAL N 121.486 
137 PRO CA 66.637 
137 PRO CB 32.212 
137 PRO CG 27.321 
137 PRO CD 51.022 
137 PRO HA 4.07 
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Residue Number Residue Name Atom Chemical Shift 
137 PRO HB2 2.405 
137 PRO HB3 1.977 
137 PRO QG 1.998 
137 PRO HD2 3.75 
137 PRO HD3 3.568 
138 LYS C 180.048 
138 LYS CA 59.398 
138 LYS CB 31.296 
138 LYS CG 24.657 
138 LYS CD 27.876 
138 LYS CE 41.76 
138 LYS H 9.234 
138 LYS HA 4.099 
138 LYS QB 1.877 
138 LYS QG 1.597 
138 LYS QD 1.718 
138 LYS QE 2.931 
138 LYS N 116.832 
139 CYS C 175.012 
139 CYS CA 58.297 
139 CYS CB 38.803 
139 CYS H 7.496 
139 CYS HA 4.32 
139 CYS HB2 3.23 
139 CYS HB3 3.031 
139 CYS N 116.333 
140 TRP C 177.462 
140 TRP CA 58.821 
140 TRP CB 30.425 
140 TRP CD1 126.832 
140 TRP CE3 119.77 
140 TRP CZ2 113.921 
140 TRP CZ3 122.123 
140 TRP CH2 124.328 
140 TRP H 8.254 
140 TRP HA 4.452 
140 TRP HB2 3.234 
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Residue Number Residue Name Atom Chemical Shift 
140 TRP HB3 2.964 
140 TRP HD1 7.061 
140 TRP HE1 9.844 
140 TRP HE3 6.825 
140 TRP HZ2 6.824 
140 TRP HZ3 6.175 
140 TRP HH2 5.215 
140 TRP N 119.987 
140 TRP NE1 128.198 
141 ALA C 178.845 
141 ALA CA 54.188 
141 ALA CB 18.323 
141 ALA H 7.968 
141 ALA HA 3.736 
141 ALA QB 1.324 
141 ALA N 116.093 
142 ALA C 178.414 
142 ALA CA 53.243 
142 ALA CB 19.832 
142 ALA H 6.929 
142 ALA HA 4.147 
142 ALA QB 1.321 
142 ALA N 116.351 
143 ILE C 176.35 
143 ILE CA 62.228 
143 ILE CB 39.375 
143 ILE CG1 31.092 
143 ILE CG2 17.874 
143 ILE CD1 14.59 
143 ILE H 8.695 
143 ILE HA 4.212 
143 ILE HB 2.045 
143 ILE HG12 1.697 
143 ILE QG2 0.958 
143 ILE QD1 1.128 
143 ILE N 115.15 
144 GLN C 173.47 
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Residue Number Residue Name Atom Chemical Shift 
144 GLN CA 61.829 
144 GLN CB 25.973 
144 GLN CG 33.328 
144 GLN H 7.315 
144 GLN HA 3.332 
144 GLN QB 1.555 
144 GLN HG2 1.265 
144 GLN HG3 1.028 
144 GLN HE21 6.316 
144 GLN HE22 5.64 
144 GLN N 122.564 
144 GLN NE2 109.407 
145 PRO CA 65.894 
145 PRO CB 30.481 
145 PRO CG 27.833 
145 PRO CD 49.756 
145 PRO HA 4.076 
145 PRO QB 2.131 
145 PRO HG2 1.913 
145 PRO HD2 3.375 
145 PRO HD3 3.268 
146 PHE C 175.919 
146 PHE CA 59.712 
146 PHE CB 39.329 
146 PHE CD1 132.442 
146 PHE CE1 130.945 
146 PHE CZ 132.38 
146 PHE H 6.892 
146 PHE HA 4.289 
146 PHE HB2 3.23 
146 PHE HB3 2.868 
146 PHE QD 6.865 
146 PHE QE 7.009 
146 PHE HZ 7.309 
146 PHE N 119.137 
147 LEU C 180.297 
147 LEU CA 57.952 
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Residue Number Residue Name Atom Chemical Shift 
147 LEU CB 41.645 
147 LEU CG 26.484 
147 LEU CD1 27.209 
147 LEU CD2 22.994 
147 LEU H 8.589 
147 LEU HA 3.611 
147 LEU HB2 1.918 
147 LEU HB3 1.004 
147 LEU HG 1.643 
147 LEU QD1 0.565 
147 LEU QD2 0.323 
147 LEU N 116.693 
148 CYS C 175.556 
148 CYS CA 57.678 
148 CYS CB 39.396 
148 CYS H 8.001 
148 CYS HA 4.127 
148 CYS HB2 2.898 
148 CYS HB3 2.706 
148 CYS N 115.085 
149 ALA C 177.745 
149 ALA CA 54.306 
149 ALA CB 18.568 
149 ALA H 7.671 
149 ALA HA 3.916 
149 ALA QB 1.354 
149 ALA N 121.743 
150 VAL C 175.806 
150 VAL CA 64.622 
150 VAL CB 32.936 
150 VAL CG1 21.66 
150 VAL CG2 23.716 
150 VAL H 7.46 
150 VAL HA 3.735 
150 VAL HB 1.511 
150 VAL QG1 0.609 
150 VAL QG2 0.296 
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Residue Number Residue Name Atom Chemical Shift 
150 VAL N 115.667 
151 PHE C 176.192 
151 PHE CA 60.42 
151 PHE CB 40.182 
151 PHE CD1 132.71 
151 PHE CE1 129.398 
151 PHE CZ 130.249 
151 PHE H 8.93 
151 PHE HA 4.048 
151 PHE HB2 3.143 
151 PHE HB3 2.704 
151 PHE QD 7.374 
151 PHE QE 7.148 
151 PHE HZ 6.935 
151 PHE N 115.306 
152 LYS C 184.176 
152 LYS CA 53.428 
152 LYS CB 33.274 
152 LYS CG 25.54 
152 LYS CD 29.658 
152 LYS CE 42.81 
152 LYS H 7.802 
152 LYS HA 4.816 
152 LYS QB 1.785 
152 LYS QG 1.226 
152 LYS HD2 1.675 
152 LYS HD3 1.379 
152 LYS HE2 2.815 
152 LYS HE3 2.708 
152 LYS N 115.47 
153 PRO CA 62.477 
153 PRO CB 32.347 
153 PRO CG 27.718 
153 PRO CD 50.34 
153 PRO HA 4.245 
153 PRO QB 1.728 
153 PRO QG 1.547 
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Residue Number Residue Name Atom Chemical Shift 
153 PRO HD2 3.449 
153 PRO HD3 3.147 
154 LYS C 173.356 
154 LYS CA 58.027 
154 LYS CB 31.285 
154 LYS CG 25.275 
154 LYS CD 28.73 
154 LYS CE 40.857 
154 LYS H 8.537 
154 LYS HA 3.039 
154 LYS HB2 0.687 
154 LYS HB3 -0.075 
154 LYS QG 0.411 
154 LYS HD2 0.749 
154 LYS HD3 0.354 
154 LYS HE2 2.183 
154 LYS HE3 2.081 
154 LYS N 122.391 
155 CYS C 171.655 
155 CYS CA 53.804 
155 CYS CB 41.219 
155 CYS H 7.037 
155 CYS HA 5.391 
155 CYS HB2 2.309 
155 CYS HB3 1.792 
155 CYS N 127.562 
156 GLU C 173.371 
156 GLU CA 54.874 
156 GLU CB 34.63 
156 GLU CG 35.918 
156 GLU H 9.401 
156 GLU HA 4.492 
156 GLU HB2 1.894 
156 GLU HB3 1.839 
156 GLU HG2 2.07 
156 GLU HG3 2.026 
156 GLU N 124.483 
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Residue Number Residue Name Atom Chemical Shift 
157 LYS C 176.509 
157 LYS CA 55.856 
157 LYS CB 31.809 
157 LYS CG 24.612 
157 LYS CD 28.476 
157 LYS CE 41.177 
157 LYS H 8.526 
157 LYS HA 4.581 
157 LYS HB2 1.531 
157 LYS HB3 1.391 
157 LYS HG2 1.135 
157 LYS HG3 1.042 
157 LYS QD 1.433 
157 LYS HE2 2.822 
157 LYS HE3 2.767 
157 LYS N 122.694 
158 ILE C 176.337 
158 ILE CA 60.847 
158 ILE CB 39.625 
158 ILE CG1 27.17 
158 ILE CG2 16.511 
158 ILE CD1 12.6 
158 ILE H 9.001 
158 ILE HA 4.049 
158 ILE HB 1.556 
158 ILE HG12 1.365 
158 ILE HG13 1.294 
158 ILE QG2 0.666 
158 ILE QD1 0.58 
158 ILE N 128.382 
159 ASN C 175.496 
159 ASN CA 53.97 
159 ASN CB 37.238 
159 ASN H 9.474 
159 ASN HA 4.212 
159 ASN HB2 2.949 
159 ASN HB3 2.666 
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Residue Number Residue Name Atom Chemical Shift 
159 ASN HD21 7.578 
159 ASN HD22 6.795 
159 ASN N 127.596 
159 ASN ND2 112.813 
160 GLY C 173.651 
160 GLY CA 45.167 
160 GLY H 8.476 
160 GLY HA2 4.094 
160 GLY HA3 3.373 
160 GLY N 101.656 
161 GLU C 174.422 
161 GLU CA 54.294 
161 GLU CB 32.934 
161 GLU CG 35.875 
161 GLU H 7.591 
161 GLU HA 4.587 
161 GLU QB 1.804 
161 GLU HG2 2.105 
161 GLU HG3 1.999 
161 GLU N 120.042 
162 ASP C 176.214 
162 ASP CA 55.408 
162 ASP CB 41.629 
162 ASP H 8.489 
162 ASP HA 4.34 
162 ASP HB2 2.908 
162 ASP HB3 2.555 
162 ASP N 126.603 
163 MET C 172.9 
163 MET CA 53.649 
163 MET CB 35.529 
163 MET CG 32.804 
163 MET CE 18.224 
163 MET H 8.853 
163 MET HA 4.911 
163 MET HB2 1.787 
163 MET HB3 1.278 
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Residue Number Residue Name Atom Chemical Shift 
163 MET HG2 2.468 
163 MET HG3 2.342 
163 MET QE 1.723 
163 MET N 121.977 
164 VAL C 172.991 
164 VAL CA 58.203 
164 VAL CB 34.629 
164 VAL CG1 24.114 
164 VAL CG2 21.05 
164 VAL H 8.964 
164 VAL HA 4.814 
164 VAL HB 1.559 
164 VAL QG1 0.907 
164 VAL QG2 0.685 
164 VAL N 119.963 
165 TYR C 176.464 
165 TYR CA 57.549 
165 TYR CB 38.274 
165 TYR CD1 133.471 
165 TYR CE1 117.567 
165 TYR H 8.137 
165 TYR HA 4.444 
165 TYR HB2 2.789 
165 TYR HB3 2.581 
165 TYR QD 6.75 
165 TYR QE 6.348 
165 TYR N 125.849 
166 LEU CA 52.426 
166 LEU CB 42.038 
166 LEU CG 27.028 
166 LEU CD1 24.515 
166 LEU CD2 24.681 
166 LEU H 8.308 
166 LEU HA 4.683 
166 LEU QB 1.505 
166 LEU HG 1.582 
166 LEU QD1 0.769 
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Residue Number Residue Name Atom Chemical Shift 
166 LEU QD2 0.701 
166 LEU N 123.151 
167 PRO CA 61.704 
167 PRO CB 32.02 
167 PRO CG 27.297 
167 PRO CD 50.256 
167 PRO HA 4.678 
167 PRO HB2 2.237 
167 PRO HB3 2.117 
167 PRO HG2 1.957 
167 PRO HG3 1.875 
167 PRO HD2 3.824 
167 PRO HD3 3.659 
168 SER C 175.473 
168 SER CA 56.324 
168 SER CB 65.193 
168 SER H 7.668 
168 SER HA 4.632 
168 SER HB2 4.265 
168 SER HB3 3.894 
168 SER N 113.955 
169 TYR C 178.116 
169 TYR CA 62.057 
169 TYR CB 37.925 
169 TYR CD1 133.485 
169 TYR CE1 118.18 
169 TYR H 8.492 
169 TYR HA 3.724 
169 TYR HB2 3.294 
169 TYR HB3 2.626 
169 TYR QD 6.95 
169 TYR QE 6.688 
169 TYR N 122.582 
170 GLU C 177.421 
170 GLU CA 58.867 
170 GLU CB 28.969 
170 GLU CG 36.427 
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Residue Number Residue Name Atom Chemical Shift 
170 GLU H 8.503 
170 GLU HA 3.846 
170 GLU HB2 1.932 
170 GLU HB3 1.701 
170 GLU QG 2.15 
170 GLU N 118.362 
171 MET C 176.804 
171 MET CA 58.648 
171 MET CB 33.058 
171 MET CG 32.282 
171 MET CE 16.827 
171 MET H 7.409 
171 MET HA 3.708 
171 MET QB 2.139 
171 MET QG 2.456 
171 MET QE 2.006 
171 MET N 116.221 
172 CYS C 178.047 
172 CYS CA 58.737 
172 CYS CB 35.006 
172 CYS H 6.817 
172 CYS HA 3.857 
172 CYS HB2 2.278 
172 CYS HB3 2.131 
172 CYS N 114.131 
173 ARG C 179.435 
173 ARG CA 59.641 
173 ARG CB 29.273 
173 ARG CG 25.796 
173 ARG CD 43.003 
173 ARG H 8.885 
173 ARG HA 3.376 
173 ARG HB2 1.404 
173 ARG HB3 1.192 
173 ARG QG 1.381 
173 ARG QD 2.872 
173 ARG N 124.629 
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Residue Number Residue Name Atom Chemical Shift 
174 ILE C 175.624 
174 ILE CA 63.811 
174 ILE CB 38.229 
174 ILE CG1 26.623 
174 ILE CG2 17.501 
174 ILE CD1 14.098 
174 ILE H 7.422 
174 ILE HA 3.796 
174 ILE HB 1.853 
174 ILE HG12 1.412 
174 ILE HG13 1.15 
174 ILE QG2 0.846 
174 ILE QD1 0.78 
174 ILE N 113.379 
175 THR C 175.798 
175 THR CA 62.856 
175 THR CB 70.168 
175 THR CG2 22.263 
175 THR H 7.574 
175 THR HA 3.889 
175 THR HB 4.129 
175 THR QG2 1.111 
175 THR N 109.403 
176 MET C 177.174 
176 MET CA 60.235 
176 MET CB 32.338 
176 MET CG 32.327 
176 MET CE 16.098 
176 MET H 7.152 
176 MET HA 3.541 
176 MET QB 2.07 
176 MET QG 2.455 
176 MET QE 1.862 
176 MET N 119.638 
177 GLU CA 60.422 
177 GLU CB 26.103 
177 GLU CG 36.005 
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Residue Number Residue Name Atom Chemical Shift 
177 GLU H 8.58 
177 GLU HA 4.114 
177 GLU HB2 1.952 
177 GLU HB3 1.872 
177 GLU QG 2.105 
177 GLU N 117.224 
178 PRO CA 65.128 
178 PRO CB 31.141 
178 PRO CG 27.893 
178 PRO CD 50.204 
178 PRO HA 4.304 
178 PRO HB2 1.981 
178 PRO HB3 1.437 
178 PRO HG2 1.978 
178 PRO HG3 1.907 
178 PRO HD2 3.597 
178 PRO HD3 3.423 
179 CYS C 174.808 
179 CYS CA 54.06 
179 CYS CB 42.879 
179 CYS H 7.208 
179 CYS HA 4.679 
179 CYS HB2 3.187 
179 CYS HB3 3.071 
179 CYS N 111.879 
180 ARG C 178.21 
180 ARG CA 59.743 
180 ARG CB 29.486 
180 ARG CG 26.057 
180 ARG CD 43.243 
180 ARG H 7.436 
180 ARG HA 3.161 
180 ARG HB2 1.906 
180 ARG HB3 1.642 
180 ARG QG 1.368 
180 ARG QD 3.049 
180 ARG HE 7.016 
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Residue Number Residue Name Atom Chemical Shift 
180 ARG N 123.75 
180 ARG NE 115.983 
181 ILE C 176.577 
181 ILE CA 63.166 
181 ILE CB 37.781 
181 ILE CG1 27.844 
181 ILE CG2 17.306 
181 ILE CD1 13.593 
181 ILE H 8.13 
181 ILE HA 4 
181 ILE HB 1.844 
181 ILE HG12 1.363 
181 ILE HG13 1.214 
181 ILE QG2 0.831 
181 ILE QD1 0.788 
181 ILE N 116.384 
182 LEU C 178.346 
182 LEU CA 54.697 
182 LEU CB 42.872 
182 LEU CG 27.304 
182 LEU CD1 26.603 
182 LEU CD2 22.845 
182 LEU H 7.771 
182 LEU HA 4.54 
182 LEU HB2 1.805 
182 LEU HB3 1.685 
182 LEU HG 1.504 
182 LEU QD1 0.91 
182 LEU QD2 0.826 
182 LEU N 119.738 
183 TYR C 176.169 
183 TYR CA 59.682 
183 TYR CB 37.18 
183 TYR CD1 131.938 
183 TYR CE1 120.703 
183 TYR H 7.886 
183 TYR HA 4.125 
    
 145 
Appendix A. Continued. 
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183 TYR HB2 2.965 
183 TYR HB3 2.903 
183 TYR QD 6.459 
183 TYR QE 7.004 
183 TYR N 121.945 
184 ASN C 175.612 
184 ASN CA 52.67 
184 ASN CB 38.058 
184 ASN H 8.228 
184 ASN HA 4.885 
184 ASN HB2 2.886 
184 ASN HB3 2.805 
184 ASN HD21 7.568 
184 ASN HD22 6.795 
184 ASN N 115.992 
184 ASN ND2 111.975 
185 THR C 175.844 
185 THR CA 61.815 
185 THR CB 72.484 
185 THR CG2 21.264 
185 THR H 7.649 
185 THR HA 4.682 
185 THR HB 4.469 
185 THR QG2 1.288 
185 THR N 109.094 
186 THR C 175.033 
186 THR CA 63.174 
186 THR CB 68.529 
186 THR CG2 21.201 
186 THR H 8.261 
186 THR HA 4.026 
186 THR HB 4.134 
186 THR QG2 0.981 
186 THR N 112.067 
187 PHE C 175.398 
187 PHE CA 59.89 
187 PHE CB 39.668 
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187 PHE CD1 131.517 
187 PHE CE1 131.784 
187 PHE H 7.764 
187 PHE HA 4.153 
187 PHE QB 2.884 
187 PHE QD 6.844 
187 PHE QE 7.025 
187 PHE N 118.139 
188 PHE CA 56.245 
188 PHE CB 38.81 
188 PHE CD1 132.999 
188 PHE CE1 130.252 
188 PHE H 7.67 
188 PHE HA 4.662 
188 PHE HB2 2.789 
188 PHE HB3 2.574 
188 PHE QD 6.754 
188 PHE QE 7.029 
188 PHE N 118.447 
189 PRO CA 62.432 
189 PRO CB 32.67 
189 PRO CG 26.937 
189 PRO CD 50.293 
189 PRO HA 4.398 
189 PRO HB2 2.14 
189 PRO HB3 1.387 
189 PRO QG 1.651 
189 PRO HD2 3.327 
189 PRO HD3 3.128 
190 LYS C 177.977 
190 LYS CA 60.279 
190 LYS CB 31.599 
190 LYS CG 24.915 
190 LYS CD 28.946 
190 LYS CE 42.607 
190 LYS H 8.565 
190 LYS HA 3.58 
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Residue Number Residue Name Atom Chemical Shift 
190 LYS QB 1.753 
190 LYS HG2 1.401 
190 LYS HG3 1.314 
190 LYS QD 1.587 
190 LYS QE 2.836 
190 LYS N 118.753 
191 PHE C 173.946 
191 PHE CA 57.841 
191 PHE CB 36.807 
191 PHE CD1 133.281 
191 PHE CE1 132.398 
191 PHE CZ 131.403 
191 PHE H 6.795 
191 PHE HA 4.481 
191 PHE HB2 3.487 
191 PHE HB3 2.661 
191 PHE QD 7.036 
191 PHE QE 6.9 
191 PHE HZ 7.343 
191 PHE N 110.638 
192 LEU C 175.398 
192 LEU CA 53.169 
192 LEU CB 44.901 
192 LEU CG 24.522 
192 LEU CD1 25.563 
192 LEU CD2 25.567 
192 LEU H 7.204 
192 LEU HA 4.71 
192 LEU HB2 1.792 
192 LEU HB3 1.024 
192 LEU HG 1.826 
192 LEU QD1 0.736 
192 LEU QD2 0.691 
192 LEU N 119.653 
193 ARG C 177.099 
193 ARG CA 55.25 
193 ARG CB 30.355 
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193 ARG CG 27.16 
193 ARG CD 42.817 
193 ARG H 7.09 
193 ARG HA 4.328 
193 ARG QB 1.742 
193 ARG QG 1.587 
193 ARG QD 2.791 
193 ARG N 116.807 
194 CYS C 175.022 
194 CYS CA 54.449 
194 CYS CB 34.958 
194 CYS H 8.21 
194 CYS HA 4.588 
194 CYS HB2 2.881 
194 CYS HB3 2.733 
194 CYS N 117.271 
195 ASN C 175.08 
195 ASN CA 53.188 
195 ASN CB 40.003 
195 ASN H 7.801 
195 ASN HA 4.811 
195 ASN HB2 2.839 
195 ASN HB3 2.67 
195 ASN HD21 7.657 
195 ASN HD22 6.952 
195 ASN N 120.232 
195 ASN ND2 114.087 
196 GLU C 176.447 
196 GLU CA 57.928 
196 GLU CB 29.822 
196 GLU CG 36.338 
196 GLU H 9.086 
196 GLU HA 4.225 
196 GLU QB 1.911 
196 GLU QG 1.924 
196 GLU N 123.435 
197 THR C 174.853 
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197 THR CA 63.694 
197 THR CB 68.841 
197 THR CG2 21.608 
197 THR H 8.067 
197 THR HA 3.964 
197 THR HB 3.951 
197 THR QG2 1.012 
197 THR N 113.403 
198 LEU C 176.215 
198 LEU CA 55.656 
198 LEU CB 42.291 
198 LEU CG 26.85 
198 LEU CD1 24.96 
198 LEU CD2 23.206 
198 LEU H 7.448 
198 LEU HA 3.964 
198 LEU HB2 1.079 
198 LEU HB3 0.643 
198 LEU HG 1.204 
198 LEU QD1 0.761 
198 LEU QD2 0.617 
198 LEU N 121.377 
199 PHE C 179.412 
199 PHE CA 53.495 
199 PHE CB 39.248 
199 PHE CD1 132.342 
199 PHE CE1 130.432 
199 PHE H 7.542 
199 PHE HA 5.202 
199 PHE HB2 3.008 
199 PHE HB3 2.814 
199 PHE QD 7.259 
199 PHE QE 7.161 
199 PHE N 117.704 
200 PRO CA 62.949 
200 PRO CB 32.242 
200 PRO CG 27.435 
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200 PRO CD 50.414 
200 PRO HA 4.528 
200 PRO HB2 2.214 
200 PRO HB3 1.891 
200 PRO HG2 1.852 
200 PRO HG3 1.792 
200 PRO HD2 3.754 
200 PRO HD3 3.492 
201 THR C 174.175 
201 THR CA 61.863 
201 THR CB 69.742 
201 THR CG2 21.498 
201 THR H 8.452 
201 THR HA 4.324 
201 THR HB 4.123 
201 THR QG2 1.076 
201 THR N 114.025 
202 LYS CA 57.661 
202 LYS CB 33.467 
202 LYS CG 24.484 
202 LYS CD 28.887 
202 LYS CE 42.239 
202 LYS H 7.831 
202 LYS HA 4.046 
202 LYS HB2 1.692 
202 LYS HB3 1.605 
202 LYS QG 1.248 
202 LYS QD 1.417 
202 LYS QE 3.185 
202 LYS N 127.089 
 
 
 
 
 
 
. 
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Residue Number Residue Name Atom Chemical Shift 
65 GLY CA 44.866 
65 GLY H 8.568 
65 GLY N 110.631 
66 ARG CA 54.092 
66 ARG CB 33.568 
66 ARG H 8.399 
66 ARG N 118.431 
67 ALA CA 52.56 
67 ALA CB 18.342 
67 ALA H 8.508 
67 ALA N 126.813 
68 ALA CA 50.575 
68 ALA CB 20.85 
68 ALA H 7.964 
68 ALA N 125.589 
70 CYS CA 56.115 
70 CYS CB 42.206 
70 CYS H 8.373 
70 CYS N 126.153 
71 GLU CA 56.12 
71 GLU CB 30.757 
71 GLU H 9.52 
71 GLU N 123.866 
75 TYR CA 56.313 
75 TYR CB 41.653 
75 TYR H 6.985 
75 TYR N 115.809 
76 ASN CA 52.918 
76 ASN CB 38.726 
76 ASN H 8.345 
76 ASN N 116.528 
77 VAL CA 59.527 
77 VAL CB 34.128 
77 VAL H 7.128 
77 VAL N 115.617 
78 CYS CA 54.99 
78 CYS CB 47.639 
78 CYS H 9.088 
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78 CYS N 125.011 
79 LEU CA 54.803 
79 LEU CB 40.469 
79 LEU H 9.576 
79 LEU N 127.547 
80 GLY CA 44.911 
80 GLY H 7.752 
80 GLY N 103.062 
81 SER CA 57.403 
81 SER CB 63.607 
81 SER H 7.977 
81 SER N 117.765 
82 VAL CA 62.918 
82 VAL CB 31.214 
82 VAL H 8.767 
82 VAL N 126.97 
83 LEU CA 51.393 
83 LEU CB 40.838 
83 LEU H 8.209 
83 LEU N 130.061 
85 TYR CA 54.328 
85 TYR CB 38.472 
85 TYR H 6.591 
85 TYR N 116.586 
86 GLY CA 45.745 
86 GLY H 8.171 
86 GLY N 102.141 
87 ALA CA 51.542 
87 ALA CB 22.069 
87 ALA H 8.627 
87 ALA N 125.651 
88 THR CA 58.538 
88 THR CB 71.209 
88 THR H 9.046 
88 THR N 112.456 
89 SER CA 56.615 
89 SER CB 65.857 
89 SER H 8.316 
89 SER N 112.546 
90 THR CA 61.864 
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90 THR CB 67.864 
90 THR H 8.374 
90 THR N 116.183 
91 LEU CA 57.392 
91 LEU CB 43.533 
91 LEU H 7.857 
91 LEU N 120.104 
92 LEU CA 54.971 
92 LEU CB 39.288 
92 LEU H 8.457 
92 LEU N 113.989 
93 ALA CA 49.524 
93 ALA CB 17.887 
93 ALA H 6.923 
93 ALA N 121.028 
94 GLY CA 46.066 
94 GLY H 6.749 
94 GLY N 118.69 
95 ASP CA 52.367 
95 ASP CB 41.471 
95 ASP H 7.187 
95 ASP N 118.08 
96 SER CA 57.935 
96 SER CB 66.627 
96 SER H 7.356 
96 SER N 114.015 
97 ASP CA 53.474 
97 ASP CB 42.061 
97 ASP H 9.119 
97 ASP N 122.753 
98 SER CA 56.16 
98 SER CB 66.723 
98 SER H 7.797 
98 SER N 110.808 
99 GLN CA 60.106 
99 GLN CB 29.619 
99 GLN H 9.56 
99 GLN N 121.247 
100 GLU CA 60.593 
100 GLU CB 28.653 
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100 GLU H 9.075 
100 GLU N 121.483 
101 GLU CA 58.99 
101 GLU CB 29.949 
101 GLU H 8.079 
101 GLU N 122.149 
102 ALA CA 55.045 
102 ALA CB 18.189 
102 ALA H 8.423 
102 ALA N 123.013 
103 HIS CA 60.525 
103 HIS CB 29.259 
103 HIS H 8.35 
103 HIS N 116.352 
104 GLY CA 46.704 
104 GLY H 7.749 
104 GLY N 104.621 
105 LYS CA 57.303 
105 LYS CB 30.476 
105 LYS H 7.835 
105 LYS N 121.153 
106 LEU CA 58.239 
106 LEU CB 42.051 
106 LEU H 8.105 
106 LEU N 121.045 
107 VAL CA 66.258 
107 VAL CB 31.432 
107 VAL H 7.633 
107 VAL N 116.905 
108 LEU CA 57.476 
108 LEU CB 40.605 
108 LEU H 7.284 
108 LEU N 122.085 
109 TRP CA 59.865 
109 TRP CB 30.311 
109 TRP H 8.289 
109 TRP N 120.219 
110 SER CA 61.491 
110 SER CB 62.728 
110 SER H 7.84 
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110 SER N 112.283 
111 GLY CA 46.31 
111 GLY H 8.015 
111 GLY N 111.133 
112 LEU CA 55.889 
112 LEU CB 41.383 
112 LEU H 7.922 
112 LEU N 119.636 
113 ARG CA 58.458 
113 ARG CB 29.153 
113 ARG H 7.057 
113 ARG N 121.204 
114 ASN CA 53.244 
114 ASN CB 37.77 
114 ASN H 7.079 
114 ASN N 113.584 
115 ALA CA 49.184 
115 ALA CB 17.697 
115 ALA H 7.853 
115 ALA N 125.41 
117 ARG CA 58.668 
117 ARG CB 29.348 
117 ARG H 8.845 
117 ARG N 116.909 
118 CYS CA 57.851 
118 CYS CB 38.364 
118 CYS H 7.532 
118 CYS N 115.296 
119 TRP CA 59.286 
119 TRP CB 29.708 
119 TRP H 9.272 
119 TRP N 122.445 
120 ALA CA 54.169 
120 ALA CB 18.806 
120 ALA H 7.601 
120 ALA N 113.919 
121 VAL CA 60.897 
121 VAL CB 32.006 
121 VAL H 7.059 
121 VAL N 104.379 
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122 ILE CA 62.563 
122 ILE CB 36.844 
122 ILE H 9.012 
122 ILE N 123.603 
123 GLN CA 61.609 
123 GLN CB 23.615 
123 GLN H 7.417 
123 GLN N 124.242 
125 LEU CA 57.354 
125 LEU CB 40.939 
125 LEU H 6.297 
125 LEU N 117.729 
126 LEU CA 57.501 
126 LEU CB 40.998 
126 LEU H 8.454 
126 LEU N 116.525 
127 CYS CA 59.057 
127 CYS CB 40.887 
127 CYS H 8.011 
127 CYS N 116.116 
128 ALA CA 54.389 
128 ALA CB 18.63 
128 ALA H 7.43 
128 ALA N 120.222 
129 VAL CA 64.114 
129 VAL CB 32.878 
129 VAL H 7.392 
129 VAL N 114.186 
130 TYR CA 61.808 
130 TYR CB 39.626 
130 TYR H 8.867 
130 TYR N 115.377 
131 MET CA 53.432 
131 MET CB 34.209 
131 MET H 7.561 
131 MET N 114.692 
133 LYS CA 57.887 
133 LYS CB 31.573 
133 LYS H 8.432 
133 LYS N 121.485 
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Residue Number Residue Name Atom Chemical Shift 
134 CYS CA 54.235 
134 CYS CB 36.734 
134 CYS H 7.505 
134 CYS N 128.623 
135 GLU CA 55.98 
135 GLU CB 33.189 
135 GLU H 8.603 
135 GLU N 126.856 
136 ASN CA 54.267 
136 ASN CB 36.849 
136 ASN H 9.374 
136 ASN N 124.032 
137 ASP CA 55.07 
137 ASP CB 38.663 
137 ASP H 7.761 
137 ASP N 111.749 
138 ARG CA 54.987 
138 ARG CB 32.71 
138 ARG H 7.293 
138 ARG N 118.465 
139 VAL CA 59.134 
139 VAL CB 33.74 
139 VAL H 9.109 
139 VAL N 125.421 
140 GLU CA 56.549 
140 GLU CB 30.463 
140 GLU H 8.206 
140 GLU N 126.308 
141 LEU CA 51.69 
141 LEU CB 40.686 
141 LEU H 8.228 
141 LEU N 124.66 
143 SER CA 56.767 
143 SER CB 65.101 
143 SER H 7.938 
143 SER N 113.49 
144 ARG CA 60.111 
144 ARG CB 29.343 
144 ARG H 8.436 
144 ARG N 123.139 
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Residue Number Residue Name Atom Chemical Shift 
145 THR CA 66.274 
145 THR CB 68.46 
145 THR H 8.113 
145 THR N 114.103 
146 LEU CA 57.543 
146 LEU CB 42.032 
146 LEU H 7.4 
146 LEU N 123.411 
147 CYS CA 60.097 
147 CYS CB 37.029 
147 CYS H 6.975 
147 CYS N 114.788 
148 GLN CA 58.404 
148 GLN CB 27.241 
148 GLN H 9.146 
148 GLN N 122.935 
149 ALA CA 53.979 
149 ALA CB 18.176 
149 ALA H 7.834 
149 ALA N 120.735 
150 THR CA 62.771 
150 THR CB 72.025 
150 THR H 7.17 
150 THR N 101.283 
151 ARG CA 58.497 
151 ARG CB 30.728 
151 ARG H 7.362 
151 ARG N 119.293 
152 GLY CA 46.648 
152 GLY H 8.977 
152 GLY N 105.493 
154 CYS CA 52.293 
154 CYS CB 40.849 
154 CYS H 7.359 
154 CYS N 109.833 
155 ALA CA 55.667 
155 ALA CB 17.957 
155 ALA H 7.446 
155 ALA N 126.103 
156 ILE CA 62.983 
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Residue Number Residue Name Atom Chemical Shift 
156 ILE CB 37.631 
156 ILE H 8.319 
156 ILE N 115.894 
157 VAL CA 65.461 
157 VAL CB 31.77 
157 VAL H 7.715 
157 VAL N 121.439 
158 GLU CA 58.554 
158 GLU CB 29.821 
158 GLU H 6.958 
158 GLU N 118.562 
159 ARG CA 57.319 
159 ARG CB 30.724 
159 ARG H 7.484 
159 ARG N 115.69 
160 GLU CA 57.288 
160 GLU CB 30.585 
160 GLU H 7.638 
160 GLU N 117.391 
161 ARG CA 56.929 
161 ARG CB 31.426 
161 ARG H 7.82 
161 ARG N 116.655 
162 GLY CA 43.749 
162 GLY H 7.955 
162 GLY N 108.456 
163 TRP CA 54.034 
163 TRP CB 28.994 
163 TRP H 8.387 
163 TRP N 121.443 
165 ASP CA 57.769 
165 ASP CB 39.321 
165 ASP H 8.931 
165 ASP N 121.675 
166 PHE CA 56.906 
166 PHE CB 36.906 
166 PHE H 7.552 
166 PHE N 112.988 
167 LEU CA 52.917 
167 LEU CB 43.643 
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Residue Number Residue Name Atom Chemical Shift 
167 LEU H 7.532 
167 LEU N 119.315 
168 ARG CA 56.122 
168 ARG CB 30.429 
168 ARG H 7.251 
168 ARG N 118.248 
169 CYS CA 52.541 
169 CYS CB 34.684 
169 CYS H 8.249 
169 CYS N 123.03 
170 THR CA 59.851 
170 THR CB 68.048 
170 THR H 8.411 
170 THR N 115.601 
172 ASP CA 54.686 
172 ASP CB 38.818 
172 ASP H 8.532 
172 ASP N 113.366 
173 ARG CA 56.361 
173 ARG CB 33.227 
173 ARG H 7.159 
173 ARG N 118.602 
174 PHE CA 54.961 
174 PHE CB 39.168 
174 PHE H 7.755 
174 PHE N 114.404 
176 GLU CA 56.3 
176 GLU CB 30.512 
176 GLU H 8.554 
176 GLU N 120.929 
177 GLY CA 46.064 
177 GLY H 8.03 
177 GLY N 117.379 
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